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Dilated Cardiomyopathy (DCM) is characterized by depressed myocardial function and 
dilation of the left ventricle. The incidence rate varies between 0.58 and 0.73 per 100,000 
children, and is more likely to be diagnosed below 1 year of age than at older pediatric 
ages (1, 2). At diagnosis, up to 80% of children display signs and symptoms of heart failure 
ranging from poor feeding and growth failure, to overt failure of the circulation (1, 3, 4). 
A substantial number of children suffer from progressive disease and develop end-stage 
heart failure. DCM is the leading indication for heart transplantation and up to 50% of 
children die or undergo heart transplantation within 5 years after diagnosis (3, 5). On the 
other hand, a recent study on the long-term outcome of children with DCM, reported 
recovery in 33% of patients more than 10 years after diagnosis (6). 
Management of dilated cardiomyopathy in children
As disease severity and outcome vary widely, the starting point for optimizing 
management of children with DCM is adequate risk prediction. This proves to be a great 
clinical challenge. Prerequisite for risk prediction is better understanding of disease 
etiology and closely linked to that, understanding pathophysiology. Also, in-depth study 
of the clinical course and disease parameters from diagnosis and onward is essential to 
obtain useful risk factors for adverse outcome. This has been done in adult heart failure, 
and also in pediatric DCM (3, 6-9). Recognition of the children at the highest risk of adverse 
outcome is critical: these are the children who should be monitored closely and, if medical 
treatment fails, should be listed for heart transplantation at a timely stage, and if needed, 
bridging to transplantation with mechanical support of the circulation is a viable option 
too. Optimizing current medical treatment in terms of heart failure medication and the 
care for patients with end stage heart failure is needed as well. Here, we will concisely 
introduce these three aspects of management of pediatric DCM. 
The importance of understanding disease etiology 
Children with DCM share a common clinical phenotype, but the underlying diagnoses 
varies widely. The Pediatric Cardiomyopathy Registry (PCMR) reported outcomes of 
a total of 1426 children with DCM in 6 diagnostic subgroups: idiopathic DCM (iDCM) 
(66%), myocarditis (16%), neuromuscular disorder (9%), familial DCM (5%), inborn error of 
metabolism (4%) and malformation syndrome (1%). Transplant free survival at 5 years after 
diagnosis was 47% in patients with idiopathic DCM opposed to 73% in children diagnosed 
with myocarditis (3). Data from the PCMR also revealed that at 3 years after presentation, 
52% of children with myocarditis related DCM had achieved echocardiographic 
normalization, whereas only 21% of children with iDCM showed normalization (10). These 
studies clearly demonstrate that etiology is closely related to outcome and emphasize 
the importance of establishing etiology. Furthermore, when disease etiology is known, 
treatment and counseling can be tailored to the individual patient and family.
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Genetics
Since the early 1990s, inherited gene variants have been implicated in the etiology of 
DCM. Recent advances in sequencing and array-based technologies have improved 
our understanding of the genetic basis of DCM. Genes encoding transcription factors, 
cytoskeletal, ion transport, nuclear membrane and mitochondrial proteins are involved 
in isolated DCM, while more than 200 genes are involved in syndromes or inborn errors 
of metabolism of which DCM can be part of the phenotype (11, 12). As in adult-onset 
cardiomyopathy, genetic testing in the pediatric population has now been integrated 
into daily clinical practice. These days, in up to 54% percent of pediatric DCM diagnoses 
a genetic cause can be established (13). Children, especially those under 2 years of age, 
display a different gene profile compared to adult-onset DCM. MYH7, VCL and TPM1 are 
the most frequently affected genes in children < 2 years of age(13-15). TTN, BM20 and 
TNNT2 are the most frequently mutated genes in the age group of 2-18 years of age (16). 
The importance of genetics in the management of pediatric DCM is evident. First of all, 
knowledge of the genetic basis of this disease gives insight into pathophysiology and 
can provide leads to develop targeted therapy. Second, as has recently been shown in 
pediatric hypertrophic cardiomyopathy, genotype-phenotype associations can be used 
as a tool in risk prediction for adverse outcome (17). Third, when a (likely) pathogenic 
variant is found, possible outcomes can be discussed with patients and families can be 
counseled. Conversely, in familial DCM, a negative genetic test could exempt children 
from life-long follow up.
Cellular patho-mechanisms of DCM in children
Medical treatment of children with DCM has unfortunately not led to substantial 
improvement in morbidity and mortality over the last two decades (18). This is in sharp 
contrast with adult DCM, where protocolized medical treatment undoubtedly has 
improved outcome (19, 20). Pediatric DCM might therefore be essentially different than 
adult DCM, and there is an urgent need for new approaches to better understand the 
disease process in children. Recently, multiple studies have demonstrated important 
differences in the molecular characteristics of pediatric and adult DCM hearts (21-25). It is 
hypothesized that myocardial cellular mechanisms are uniquely regulated in children with 
DCM. For instance, Tatman et al studied explanted hearts of children with DCM and found 
unique changes in gene expression that suggest maintenance of an undifferentiated state 
of cardiomyocytes (26). A distinctive profile in the pathophysiology of pediatric DCM is 
plausible and strongly motivates research in this specific area. We expect that this would 
provide new targets for medical treatment and also for future research on mechanisms 
involved in the pediatric failing heart.
How to predict outcome – risk factors for adverse outcome
When trying to identify children with DCM at the highest risk for adverse outcome, 
what do we look for? In general, we aim to construct a prediction tool that evaluates the 
severity of heart failure at diagnosis as well as the changes over time, and that couples 
this information with survival or heart transplantation probabilities. Such a prediction 
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tool would combine medical experience with a fitting statistical model and would enable 
physicians to make better informed decisions and thus improve outcome. In the CARS 
study we prospectively collected data that would enable the evaluation of severity of 
heart failure and to connect it to the hard endpoints of death and heart transplantation.
Risk factors for adverse outcome
Previous research has identified several risk factors for adverse outcome in children 
with DCM. The majority of registry based studies, like the large PCMR and the National 
Australian Childhood Cardiomyopathy Study (NACCS) focused on risk factors that are 
present at the time of diagnosis. Risk factors that were repeatedly found are older age (>6 
years), congestive heart failure, severity of left ventricle dysfunction, and idiopathic and 
familial cardiomyopathy (3, 6, 8, 27). In addition to the risk profile present at diagnosis, the 
evolution over time of these same risk factors may hold prognostic information as well. As 
recently shown by den Boer et al, the change over time of NT-proBNP level in children with 
DCM was predictive for the risk of death, heart transplantation and mechanical support 
of the circulation (9). This concept of prognostic information in temporal evolution of risk 
factors proved to be useful and thus the choice of which risk factors to study builds on 
our previous work in CArdiomyopathy Registry Study (CARS) (9, 28-30). We included the 
following 7 risk factors in the analyses based on proved predictive value in both adult and 
pediatric heart failure. 
1. NT-proBNP. This peptide is an inactive form of the cardiac hormone BNP, which is 
secreted from the myocardium into the circulation, as a response to cardiomyocyte 
stretch. Numerous clinical studies have demonstrated that the level of this peptide 
correlates well with severity of heart failure. In both adults and children, it has also been 
shown an independent predictor of mortality (31-34).
2. The New York University Pediatric Heart Failure Index (NYU PHFI). This heart failure 
score is validated especially for the pediatric population (35). The well-known NYHA 
classification is not applicable as children display different signs and symptoms of heart 
failure compared to adults. Den Boer et al have shown that the NYU PHFI at diagnosis 
and more than 1 year after diagnosis was independently predictive for adverse outcome 
in children with DCM (30).
3. Length Z-score. Length, normalized to Z- scores, is regarded a solid proxy for overall 
health in children and most likely provides a long term reflection of disease severity. 
However, length Z-score and its evolution over time has not extensively been studied in 
children with DCM. In a PCMR study on risk factors for death and heart transplantation 
Alvarez et al showed that height-for-age at diagnosis was associated with death and 
stated that using length Z-score as transplantation indication might substantially 
improve survival (5).
4. LVIDd. A commonly used proxy for severity of heart failure is the end-diastolic 
dimension of the left ventricle (LVIDd) as measured by 2D-echocardiography. The LVIDd 
is easy to obtain and can be normalized to a Boston Z-score, which is based on body 
surface area, age and gender (36). Left ventricular diameter has been associated with 
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outcome in adults and children with heart failure (37, 38). In children with DCM, LVIDd 
had been associated with outcome as well (3, 5, 39). 
5. Global Peak Strain. Speckle tracking echocardiography (STE) has been shown to be a 
reliable measure of regional and global LV systolic function. Longitudinal, circumferential 
and radial movements can be evaluated and subsequently quantified. Global peak 
strain (GPS) can be calculated as the mean of the peak strain of all left ventricular 
segments in a longitudinal 6-segment model, in a standardized manner (40). GPS has 
been associated with the risk of death and heart transplantation in both children and 
adults with heart failure (41-44). In pediatric DCM, STE is increasingly used to evaluate 
left ventricular function (45, 46). Den Boer et al recently demonstrated that in children 
with DCM, left ventricular GPS as measured during follow-up was predictive of death 
and heart transplantation (28).
6. 6MWD%. The 6-minute walk test (6MWT) is a safe, simple and well-accepted prognostic 
tool in adults with heart failure(47). In children, the 6MWT is also feasible and has been 
shown to be predictive for outcome in patients with pulmonary hypertension (48, 49). 
The distance walked in a 6MWT can be expressed as a percentage of predicted, taken 
into account height, gender and age (6MWD%) (50). In a previous study, den Boer et al 
showed that in children with DCM, a single 6MWD% below 63% identified patients with 
the highest risk of dying or heart transplantation (29).
7. Child Behavior Checklist. Compelling evidence from two meta-analyses shows that 
adults with heart failure are at increased risk of anxiety and depression (51, 52). It is 
also well-established that depressive and anxiety symptoms in adults with heart failure 
predict mortality (53-55). Children with DCM have an impaired health related quality 
of life (HRQoL) and children’s physical HRQoL (reported by parents) predicts mortality 
and cardiac transplantation, independent from heart failure severity (30). However, to 
the best of our knowledge, the predictive value of depressive and anxiety symptoms in 
children with DCM has not been studied previously. 
Optimizing treatment of children with DCM
Pharmacotherapy
In general, pharmacotherapy of children with DCM mirrors adult DCM. Angiotensin-
converting enzyme inhibitors (ACEi) and beta-adrenergic receptor blockers (B-blockers) 
clearly have improved mortality and morbidity in adults (19, 20). In children however, it is 
far less evident that these drugs improve prognosis. Up until now, only one randomized 
clinical trial on the effect of heart failure drugs in children with DCM has been performed. 
This trial, published in 2007, assessed the effect the B-blocker carvedilol on heart failure 
outcomes in children with symptomatic systolic heart failure and could not demonstrate 
that carvedilol improved heart failure outcome (56). Also, the shift from digoxin based 
medical therapy to ACEi and B-blockers in the late 1980s and 1990s, does not seem to 
have resulted in sustained improvement of transplant free survival (18). 
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Although its efficacy has not been proven in the pediatric population yet, ACEi and 
B-blockers are commonly prescribed in children with DCM, based on the assumption that 
pathophysiological mechanisms are similar to those in adults (57).
What the safety issues and adequate dosing strategy of these drugs in children with DCM 
would be is not fully known (58, 59). Children are not small adults, also with regard to 
medical therapy. Growth and development pay an important contribution to variation 
in the disposition and effect of most drugs in children and must therefore be taken into 
account (60).
To address the issue of heart failure drugs in children with DCM, we joined a larger 
research project to develop an age-appropriate pediatric enalapril formulation (EU FP7 
LENA project). As a first start, we performed a systematic review of the literature on the 
safety of ACEi in children with heart failure. Knowledge on ACEi related adverse events 
and possible risk factors can support the design of clinical trials with ACEi, but can also be 
used to improve safety in clinical practice.
Mechanical support of the circulation
For children with medically incurable end-stage heart failure, heart transplantation is 
the only long term therapeutic option. As donor availability is limited, children face a 
prolonged time on the waiting list. North American studies report a waiting list mortality 
of 25%, which is the highest in transplantation medicine (61). In order to improve survival 
in patients with end-stage heart failure who fail medical therapy, much effort has been put 
into the development of mechanical support of the circulation. Extracorporeal membrane 
oxygenation (ECMO) has successfully been used to sustain the circulation for several days 
to weeks, but has serious limitations in providing long-term support (62). Ventricular 
assist devices (VADs) are nowadays a well-accepted, long-term therapeutic option in 
adult end-stage heart failure (63). Implementation of VADs in the pediatric population has 
been troublesome due to technical problems and difficulties in medical management. 
However, in recent years, several centers have presented their experience with Berlin 
Heart EXCOR VAD as long term support. They have shown that Berlin Heart EXCOR VAD is a 
reliable and relatively safe device in bridging children to heart transplantation or recovery 
(64-66). Since 1998, our institute serves as a referral hospital in the Netherlands for end-
stage heart failure and heart transplantation in children. The Berlin Heart Excor Pediatric 
Ventricular Assist Device has become available in our hospital since 2007. We aimed to 
describe the outcome of children supported with a VAD in our center in terms of mortality 
and complications. Secondly, we aimed to determine the effect of the introduction of the 
VAD on waiting list mortality.
Heart transplantation 
Since the first heart transplantation in 1967, the field of transplantation medicine 
has evolved enormously. Today, heart transplantation is a widely accepted treatment 
for adults with end-stage heart failure without alternative therapeutic option (67). In 
children, heart transplantation is a well-accepted therapy as well, and the number of 
transplantations yearly reported to the database of the International Society for Heart and 
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Lung Transplantation (ISHLT) gradually increased from around 400 in the 90s to around 
600 in the last 5-10 years (67). 
In 1998, the first child underwent heart transplantation in our center. When critically 
appraising the outcome of our program, a number of factors that determine outcome on 
the waiting list and after heart transplantation have to be taken into account. Firstly, who do 
we list: the underlying diagnosis leading to end-stage heart failure is shown to be related 
to outcome. Children who undergo heart transplantation for congenital heart disease have 
a less positive outlook than children with DCM (68, 69). Also, large volume centers have a 
better post heart transplantation outcome (67, 70-72). We therefore needed to evaluate the 
case mix and the number of yearly heart transplantation in our center. Secondly, when do 
we list: pre-transplantation condition and support, as well as age at transplantation affects 
outcome as well (73). Previously, we reported a low transplantation rate in children with 
DCM in the first year after diagnosis (3%), as compared to the large PCMR registry which 
reported an 18% transplantation rate in the 1st year after diagnosis. Similar data were shown 
by the Australian NACCS (3, 6). Also, median time to listing was considerably longer in our 
cohort, 18 months versus 1.4 months. We did not find differences in clinical characteristics 
of our cohort as compared to other (large) registries and importantly, we did not find an 
increased mortality (74). This low early transplantation rate might reflect a policy that defers 
listing patients for heart transplantation as long as possible, and that pursues stabilizing 
patients on oral heart failure therapy before listing. The question is whether this strategy 
leads to selection of a group of children for heart transplantation with an unfavorable risk 
profile that affects outcome on the waiting list as well as outcome after heart transplantation. 
Taken all these factors into account, we evaluated the outcome of 18 years of pediatric heart 
transplantation and compared our results to published international experience.
CARS cohort and statistical modelling
Study cohort CARS 
The cohort of children we studied is the CARS cohort, which is the result of a unique 
collaboration between pediatric cardiologists of the 8 Dutch university hospitals. We aimed 
to include all children (0-18 year) with DCM in a time frame of 7 years, from October 2010 to 
July 2017. We enrolled children with a previous diagnosis of DCM until 2010, or with newly 
diagnosed DCM from 2010 and onward. DCM was defined as the presence of impaired 
systolic function (fractional shortening (FS) ≤25%) and left ventricular (LV) dilation (LV end-
diastolic dimension (LVEDD)> +2 Z-score for body surface area). Patients with structural 
heart disease were excluded. The research program was organized in such a way that study 
visits coincided with routine outpatient clinic visits or hospital admissions. In the first year 
after diagnosis, children were evaluated by the study team 1 to 4 times per year. After the 
first year, children were evaluated 1 to 2 times per year, dependent on the frequency of 
visits. The primary study endpoint was defined as death or heart transplantation. Secondly, 
we defined recovery as 2 consecutive echocardiograms with normalized LVEDD and FS, the 
date of the first normalized echocardiogram was considered as date of recovery. Thirdly, the 
remaining children were categorized as having “ongoing disease”.
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Statistical modelling
Since the basis of CARS study was repeated measurements of the abovementioned risk 
factors, we needed a statistical model that would allow interpreting in particular the 
repeated measurements. A statistical model that best fitted our data proved to be a so 
called Joint Model. This statistical model is a combination of a Mixed Effect model for 
repeated measurements, and a Cox Regression model for survival data. The Mixed Effect 
model assumes that each subject in the population has his own evolution over time. It 
also accounts for the correlation within the measurements obtained from the individual 
patients and can address dissimilar spaced patient visit times, as is common in clinical 
practice. A Cox model for survival data is routinely used when interest is on event outcome, 
in our studies defined as cardiac death: heart transplantation or death. A Cox regression 
model alone assumes that the level of the risk factor, say NT-proBNP, remains constant 
between one measurement and the next, to suddenly change at the moment of the 
patient visit. For markers that slowly change of time, like NT-proBNP, the Cox model alone 
is therefore too rough an estimate. The joint model thus elegantly couples the survival 
model of time to event data (heart transplantation or death) with a Mixed Effect model for 
the repeated measurements (75). 
AIMS OF THIS THESIS
The aim of this thesis is three-fold: first, to provide better insight into the etiology of 
childhood DCM; second, to evaluate the contribution of temporal evolution of risk factors 
in predicting adverse outcome, and third, to improve treatment of children across the 
clinical spectrum of DCM.
OUTLINE OF THIS THESIS
Chapter 2 describes the current practice and results of genetic evaluation in our national 
cohort of children with DCM, and reports the relation between the presence of (likely) 
pathogenic variants and clinical outcome. In Chapter 3 we explore the cellular phenotype 
in a unique collection of pediatric DCM myocardium samples by combining functional 
measurements in single isolated cardiomyocytes, protein analyses and electron 
microscopy. In Chapter 4 the added value of repeated 6MWT in addition to a single 6MWT 
in predicting outcome is evaluated. Chapter 5 describes the use of serial measurements 
of known risk factors in prediction of outcome. Chapter 6 reviews the safety of ACE-
inhibitors for the treatment of heart failure in children. In Chapter 7 we evaluate the level 
of emotional and behavioral problems and whether depressive and anxiety problems are 
associated with outcome. Chapter 8 describes the outcome of children supported with 
a VAD and the effect of the introduction of VAD on waiting list mortality is evaluated. In 
Chapter 9 we evaluate the outcome of heart transplantation against the background of a 
restrictive early listing strategy.
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ABSTRACT 
OBJECTIVES To describe the current practice and results of genetic evaluation in 
Dutch children with dilated cardiomyopathy (DCM) and evaluate genotype-phenotype 
correlations that may guide prognosis.
METHODS We performed a multicenter prospective observational study in children 
diagnosed with DCM from 2010 to 2017.
RESULTS One hundred forty-four children were included. Initial diagnostic categories 
were idiopathic DCM in 67 children (47%), myocarditis in 23 (16%), neuromuscular in 7 
(5%), familial in 18 (13%), inborn error of metabolism in 4 (3%), malformation syndrome 
in 2 (1%) and ‘other’ in 23 (16%). Median follow-up time was 2.1 years [IQR 1.0-4.3]. 
Hundred-seven patients (74%) underwent genetic testing. We found a likely pathogenic 
(LP) or pathogenic (P) variant in 39 children (36%), most often in MYH7 (n=9). In one 
patient initially diagnosed with myocarditis, a pathogenic LMNA variant was found. 
During the study, 39 patients (27%) reached study endpoint (SE: all-cause death or heart 
transplantation). Transplant-free survival was significantly lower in patients with a LP/P 
variant (P=0.005), and children with a LP/P variant were more likely to reach SE compared 
to children without (hazard ratio 2.8; 95% CI 1.3 to 5.8, P=0.007), while apart from left 
ventricle diastolic dimension, clinical characteristics at diagnosis did not differ between 
the two groups.
CONCLUSION Genetic testing is a valuable tool for predicting prognosis in children 
with DCM, with carriers of a LP/P variant having a worse prognosis overall. Genetic 
testing should be incorporated in clinical work-up of all children with DCM regardless of 
presumed disease etiology.
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INTRODUCTION
Since the early 1990s, gene variants have been implicated in the etiology of dilated 
cardiomyopathy (DCM), which is defined as systolic dysfunction and increased ventricular 
chamber volume. Genetic DCM was initially thought to be a disease primarily caused by 
variants in genes encoding cytoskeletal and sarcomeric proteins (1-3). However, recent 
advances in sequencing and array-based technologies have increased our understanding 
of the genetic basis of DCM. In addition to genes encoding sarcomeric and cytoskeletal 
proteins, genes coding for transcription factors, ion channels, the nuclear membrane and 
mitochondrial proteins are now also known to be involved in isolated DCM. In addition, 
more than 200 genes are known that underlie syndromes or inborn errors of metabolism 
(IEMs) in which DCM can be part of the phenotype (4-6).
As in adult-onset cardiomyopathy, genetic testing has now been integrated into daily 
clinical practice in the pediatric population, and a genetic cause can be identified in up 
to 27-54% of pediatric DCM patients (7-9). MYH7 (5.1%), VCL (3.2%) and TPM1 (2.2%) are 
among the most frequently affected genes in children younger than two years of age, 
while TTN (10.0%), RBM20 (6.7%) and TNNT2 (4.7%) are the most frequently mutated 
genes in the 2-18 year age group(10).
The etiology of pediatric DCM is a strong predictor of long-term outcome. The 5-year 
transplant-free survival rate is 47% in idiopathic DCM, while it is 73% in DCM related 
to myocarditis. In familial DCM, the 5-year survival rate is high (94%), but the 5-year 
transplantation rate is also relatively high (38%). These differences emphasize the 
importance of establishing the genetic etiology in DCM, as it may help further guide 
optimal treatment (11, 12). Studies in adult DCM patients have reported a more severe 
phenotype and earlier onset in patients with a pathogenic genetic variant compared to 
variant-negative patients (13, 14). Furthermore, DCM patients with pathogenic variants in 
LMNA, PLN, RBM20, DES and FLNC are at higher risk for malignant arrhythmias and have a 
worse prognosis than patients with variants in other genes (13-16). Matthew et al. showed 
that the affected gene (e.g. MYH7), a higher variant burden and de novo variant status are 
all factors independently associated with earlier onset and higher frequency of adverse 
outcomes in pediatric hypertrophic cardiomyopathy (17). However, studies reporting on 
the utility of genetic testing for risk stratification in children with DCM are scarce.
The aims of the present study were twofold. First, we aimed to describe the current practice 
and results of genetic evaluation in a large cohort of pediatric DCM patients presenting to 
all tertiary referral hospitals in the Netherlands. Second, we evaluated these patients for 
potential genotype–phenotype correlations that may guide prognosis.
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METHODS
Patients
Data were collected in a multicenter, prospective observational study design. Eight tertiary 
pediatric cardiology centers cooperated in the study. Given the structure of the Dutch 
health service system, these eight centers serve almost 100% of the Dutch population.
Patients (age < 18 years at diagnosis) were included from October 2010 to July 2017. 
In addition, we retrospectively enrolled children diagnosed with DCM before 2010. The 
first member of each family who presented to our services with a diagnosis of DCM was 
designated the proband for this analysis.
DCM was defined as the presence of impaired systolic function (fractional shortening (FS) 
≤25%) and left ventricular (LV) dilation (LV end-diastolic dimension (LVEDD) z-score >2 for 
body surface area) (18, 19). Patients with additional structural heart disease that explained 
their LV dilation were excluded. A diagnostic work-up was performed in all patients, 
as previously described (11, 20). Patients were subsequently classified into an initial 
diagnostic category within the six months following their DCM diagnosis. Diagnostic 
categories consisted of: idiopathic, myocarditis, neuromuscular disease (NMD), familial, 
IEM, malformation syndrome or other. This classification follows the standard of the 
Pediatric Cardiomyopathy Registry (PCMR) (11, 21). Familial DCM is defined as two or more 
affected family members and/or an explanatory genetic finding.
Diagnosis of myocarditis was made based on clinical grounds and viral test results. 
Myocarditis was ‘definite’ if there was histological or immune-histological evidence of 
myocarditis. Myocarditis was ‘probable’ when blood plasma/serum or cerebrospinal 
fluid PCR or culture was positive for enterovirus, adenovirus, parechovirus or human 
parainfluenza virus, or if blood plasma/serum PCR or culture was positive for parvovirus 
B19, HHV6, cytomegalovirus or Epstein-Barr virus accompanied by serological proof of 
a primary infection (seroconversion and/or positive IgM) (20). In the patients diagnosed 
before 2010, data on diagnostic work-up, family history and genetic variant segregation 
analysis were retrospectively collected.
Study endpoint (SE) was defined as all-cause death or heart transplantation (HTx). In 
addition, patient status at the last follow-up visit was recorded as ‘ongoing disease’ or 
‘recovered’. Recovered was defined as two consecutive echocardiograms with normalized 
LVEDD and FS, with the date of the first normalized echocardiogram considered the date 
of recovery. Furthermore, gender, age at diagnosis, New York University Pediatric Heart 
Failure Score (NYUPHFI), NT-proBNP, and standardized echocardiogram (LVEDD, FS) were 
recorded at inclusion. All study data were collected during routine outpatient clinic visits 
or hospital admissions. Subjects were followed until SE was reached, the age of 18 years, 
or the last outpatient visit within the study window. This study was approved by the 
Medical Research Ethical Committee of the Erasmus University Medical Center (MEC 2014-
062) and performed in accordance with the Declaration of Helsinki. All legal parents and 
children ≥12 years of age gave their written informed consent.
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Genetic evaluation and variant classification
The genetic data we collected reflect the genetic evaluation that was common practice at 
that time: single gene testing (e.g. Sanger sequencing of MYH7), targeted next-generation 
sequencing (NGS) of a gene panel (typically 46-61 genes), exome sequencing (ES) with 
analysis of genes related to cardiomyopathy (7) or open exome analysis. Additional genetic 
testing (e.g. SNP-array) was performed in a subset of patients in whom a malformation 
syndrome was suspected. As this was an observational study, patients who had no genetic 
testing or a test that is now considered too limited were not actively referred for genetic 
(re)evaluation.
Patients were considered genetically evaluated when at least one genetic test was 
performed. The pathogenicity of the variants was assessed using Alamut Visual Software 
(Interactive Biosoftware, Rouen, France). All variants were reclassified (December 2019) 
by a molecular geneticist specialized in cardiogenetics (RLdD) according to ACMG criteria 
(22). Variants with a minor allele frequency <0.1% in the Genome Aggregation Database 
(gnomAD) were considered rare. Nonsense and frameshift variants were considered null 
variants if they occurred proximal to the last 50 bases of the penultimate exon. We defined 
two groups: patients with a pathogenic (P) or likely pathogenic (LP) variant (class 4 or 5) 
and patients without a pathogenic variant, including patients with one or more variants 
of unknown significance (VUS, class 3) (23).
Statistical analysis
Categorical variables were reported as numbers and percentages. Continuous variables 
were reported as means with standard deviation (SD) when normally distributed, or as 
medians with interquartile range (IQR) when non-normally distributed. To compare 
clinical characteristics between patients with a LP/P variant and those with negative 
genetic test results, the student’s t-test was used in case of normally distributed variables 
and the Wilcoxon rank test was used when variables were non-normally distributed. A Chi-
square test or two-sided Fisher exact test was performed to examine the relation between 
categorical data.
We used the Kaplan-Meier method to estimate transplant-free survival in the two groups. 
The log-rank test was used to determine whether the difference between the two curves 
was statistically significant. Univariate Cox regression analysis was used to test the 
predictive value of a LP/P variant. Proportional hazard assumptions were tested, and were 
not violated. The hazard ratio and 95% confidence interval (CI) were calculated. Testing 
was performed two-sided, and statistical significance was set at P < 0.05. All analyses were 
performed using IBM SPSS Statistics for Windows, version 24 (IMB Corp, Armonk, NY, USA). 
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RESULTS
Patient characteristics
Hundred forty-four children with DCM were included in the study: 97 children (67%) 
diagnosed during the study period and 47 patients (33%) diagnosed before the start of 
the study in 2010. Median age at diagnosis was 1.5 years [IQR 0.12-9.97], and 63 children 
(44%) were diagnosed before the age of 1 year.
Initial diagnostic categories included idiopathic DCM in 67 children (46%), myocarditis 
in 23 (16%), NMD in 7 (5%), familial DCM in 18 (13%), IEM in four (3%), malformation 
syndrome in two (1%) and ‘other’ in 23 (16%). The ‘other’ category included anthracycline-
related DCM in eight (6%), LV dilation and systolic dysfunction with non-compaction 
cardiomyopathy (NCCM) in six (4%) (as described by van Waning et al.(24)), DCM based 
on tachyarrhythmia in three (2%), LV infarction in two (1%), vasculitis in two (1%) and 
congenital AV-block in one (1%).
The median follow-up time was 2.1 years [IQR 1.0-4.3]. Table 1 describes the clinical 
characteristics of the cohort.
Table 1. Characteristics of children with dilated cardiomyopathy stratified by LP/P variant-positive 
patients and variant-negative patients
Characteristic Total LP/P positive Variant-negative P-value
n=144 n=39 n=68
Gender, female, n (%) 68 (47) 20 (51) 32 (47) 0.49
Age at DCM diagnosis, 
years, median (IQR)
1.5 (0.12 to 10.0) 2.3 (0.1 to 12.4) 1.7 (0.3 to 6.0) 0.94
Heart failure score*, 
NYUPHFI, median (IQR)
9 (7 to 12) 9 (6 to 11) 9 (6 to 13) 0.28
Echocardiographic parameters*, mean (SD) 
LVEDD Z- score 4.8 (3.6) 4.3 (3.8) 5.6 (2.7) 0.04
SF 15.9 (7.0) 17 (7) 15 (7) 0.10
NT pro BNP*, pg/ml, median 
(IQR)
5244 (1893 to 21651) 4253 (895 to 28218) 6932 (1147 to 19028) 0.41
Time diagnosis till last 
follow-up years, median 
(IQR)
3.1 (1.3 to 5.7) 2.3 (0.6 to 5.4) 3.3 (1.3 to 5.8) 0.31
Status at end of study, n (%)
Death/transplantation** 39 (27) 17 (44) 12 (18) 0.002
Ongoing disease 82 (57) 20 (50) 46 (67) 0.04
Recovered 23 (16) 2 (5) 10 (15) 0.10
Genetic evaluation, n (%) 107 (74%)
Variant-negative: VUS or no variant
*at study inclusion 
Student’s T-test in normally distributed data and Wilcoxon rank test in non-normally distributed data.
** Chi Square
DCM, dilated cardiomyopathy; IQR, interquartile range; NYUPHFI, New York University Pediatric 
Heart Failure Index; LVEDD, Left Ventricular End Diastolic Dimension; SF, shortening fraction; NT pro 
BNP, N Terminal-pro brain natriuretic peptide.
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Genetic findings
Hundred-seven of 144 DCM patients (74%) underwent genetic testing, with some 
patients undergoing more than one test. Twenty-three (20%) patients underwent Sanger 
sequencing of one or more genes, 82 (72%) patients had a targeted NGS gene panel, 29 
patients (25%) had ES with analysis of an expanded gene panel related to cardiomyopathy 
and one patient had ES with comprehensive analysis of all known genes. Table 2 describes 
the number of genetically evaluated patients and the number of LP/P variants per 
diagnostic category.
Table 2. Genetic evaluation and outcome per diagnostic category
Initial diagnostic DCM 
category
Number of 
patients at 
start
n (% of all 
patients)
Number of 
patients 
genetically 
evaluated
n (% of dx 
category)
Number of LP/P 
variants
n (% of 
genetically 
evaluated)
Number of patients 
after genetic 
evaluation and 
reclassification
n (% of all patients)
Idiopathic 67 (47) 56 (84) 8 (14) 64 (44)
Myocarditis 23 (16) 7 (30) 1 (14) 22 (15)
NMD 7 (5) 7 (100) 6 (88) 8 (6)
Familial 18 (13) 18 (100) 13 (74) 26 (18)
IEM 4 (3) 4 (100) 4 (100) 4 (3)
Malformation syndrome 2 (1) 2 (100) 2 (100) 2 (2)
Other 23 (16) 13 (56) 5 (38) 18 (12)
DCM, dilated cardiomyopathy; NMD, neuromuscular disease; IEM, inborn error of metabolism; LP, 
Likely Pathogenic; P, Pathogenic
Thirty-nine (36%) patients carried a LP/P variant, including 11 who had one or more 
additional VUSs. Thirty-nine patients (36%) had only one or more VUS, while 29 (27%) 
patients had no variant (Figure 1). No difference was observed in the percentage of 
genetic testing in patients who reached the SE compared to those who did not (29 of 39 
(74%) versus 78 of 105 (75%), P=0.9).
LP/P variants were found in 21 different genes, with MYH7 the largest contributor of 
pathogenic variants (9 LP/P variants (23%)). The second highest contributors were TTN 
and TMP1, each accounting for 8% of positive test results. No variants were identified for a 
number of cardiac genes that are part of standard gene panels (Supplementary Table 1). 
The clinical and genetic characteristics of the 39 patients with a LP/P variant are described 
in Table 3. Two patients with LP/P variants in genes related to a malformation syndrome 
(Alström syndrome) were found. Seven patients had LP/P variants in genes related to 
NMD (Duchenne disease, infantile type I muscle fiber disease and cardiomyopathy, 
centronuclear myopathy). Four had LP/P variants in genes related to IEM (Very Long 
Chain Acyl-CoA dehydrogenase Deficiency, propionic acidemia, Barth syndrome and 
GM1 gangliosidosis). In three patients, we found LP/P variants in two genes: MYH7/RYR2, 
SCN5A/KCNQ1 and TBX20/GLB1. DCM-associated SCN5A variants have been shown to 
have either loss- or gain-of-function effects on cardiac sodium channel activity (25-27). 
In one patient, biallelic ASNA1 variants were found (as described previously (28)). We also 
found six LP/P variants in four patients that we did not deem to be explanatory for the 
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DCM, including two compound heterozygous truncating variants in CEP135, a de novo 
deletion of chromosome 14q22.3q23.1 (Hg19: 57,007,506-61,613,506), two compound 
heterozygous pathogenic missense variants in SLC37A4 and a de novo missense variant 
in MAP3K7. Five of 40 variants (13%) were proven de novo (in three children with LP/P 
variants, no data on segregation of the variants was available).
The diagnostic classifications of 20 patients changed during the study period. LP/P variants 
were found in 8 children (12%) who had initially been diagnosed with idiopathic DCM, and 
their cases were therefore reclassified to familial/genetic DCM. Four of 23 patients who 
were diagnosed with myocarditis underwent genetic evaluation, and a pathogenic LMNA 
variant was found in one patient. The diagnostic category of this patient was therefore 
reclassified as familial/genetic DCM (Table 2). In five patients with LV dilation and systolic 
dysfunction with NCCM classified as ‘other’, a LP/P variant was found (DES, MYH7, NKX2.5, 
PLN, SCN5A, (Table 3)). One patient initially classified as familial was reclassified as NMD 
after genetic evaluation (MYL2).
In addition, variant reclassification altered the definitive diagnosis in five patients (26% 
of all diagnostic reclassifications, Table 3). In these patients with a putative LP/P variant 
leading to allocation into the familial/genetic DCM group, the variant was reclassified 
as a VUS and patients were reclassified as idiopathic DCM. None of the variants initially 
classified as VUS were reclassified as LP/P (Table 2).
Clinical outcome
During the study period, 39 patients (27%) reached SE: 17 patients died (12%) and 22 
patients (15%) underwent HTx. Median time from diagnosis to death was 0.09 years [IQR 
0.03 to 1.1]. Median time to HTx was 2.9 years [IQR 1.1 to 6.1]. At the end of the study, 23 
children (16%) had recovered (35% diagnosed with myocarditis), while 82 children (57%) 
had ongoing disease.
Association of LP/P variants with clinical outcome
17 of 39 children with a LP/P variant reached SE, while 20 had ongoing disease and two 
(with variants in MYH7 and LMNA) recovered.
Children with a LP/P variant were more likely to die or undergo HTx compared to children 
without a pathogenic variant (17 of 39 (44%) versus 12 of 68 (17%), P=0.006). We found 
no differences in clinical characteristics at time of diagnosis between children with a LP/P 
variant and those without, with only the LV diameter higher in children who were variant-
negative (P=0.04, Table 1). Median age at SE tended to be lower in children with a LP/P 
variant, however this difference was not statistically significant (P=0.19). Median age at SE 
was 10.9 years [IQR 0.6 to 16.1] in variant-positive patients, and 5 of 17 (29%) were under 1 
year of age. In variant-negative patients, median age at SE was 13.3 years [IQR 6.9 to 14.6], 
and the age of the youngest patient at SE was 3.5 years.
Of the 17 LP/P variant-positive children reaching SE, 10 (53%) died and 7 (41%) underwent 
HTx. The majority of variant-negative children who reached a SE underwent HTx (8/12; 
67%), while 4 of 12 children died (36%, P=0.26).
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Transplant-free survival was significantly lower in patients with a LP/P variant compared 
to variant-negative patients (P=0.005, Figure 2). This was also true when we excluded the 
eight children who were diagnosed with NMD (P=0.04). Children with a LP/P variant had 
a 2.8-times increased risk of death or HTx (hazard ratio 2.8; 95% CI 1.3 to 5.8, P=0.007). 
Transplant-free survival was higher in MYH7-positive children compared to those with a 
LP/P variant in other genes (P=0.03, KM curve not shown).
In children without LP/P variants, we did not find an association between the presence or 
absence of VUSs and SE: 6/39 reached a SE with one or more VUS versus 6/29 who reached 
a SE without VUS (P=0.4, Figure 1).
The number of patients reaching a SE and the heterogeneity of genetic findings meant 
that we had insufficient statistical power to explore the relationship between single 
affected genes or de novo variants and outcome.
Figure 1. Outcome genetic evaluation
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Figure 2. Kaplan-Meier analysis of 107 genetically evaluated children with DCM, children with a 
LP/P variant versus no variant or VUS
LP/P: class 4 or 5 variant according to the ACMG classification
DISCUSSION
In this cohort of 107 genetically evaluated children with DCM, 39 children (36%) carried a 
LP/P variant in a DCM-related gene, most often in MYH7. Children with DCM who carried a 
LP/P variant had a 2.8-times increased risk for death or HTx compared to children without 
such a variant, but clinical characteristics at time of diagnosis (apart from LVEDD) did not 
differ between the two groups. In addition, children with a LP/P variant were more likely 
to die or undergo HTx at an earlier age. These findings highlight the importance of early 
genetic testing in children with DCM, as the determination of a genetic etiology can be 
valuable for predicting clinical outcome.
Yield of genetic testing in children with DCM
In adults with DCM, the yield of genetic testing varies between 16-37%(29). There are 
only a few studies on current genetic testing in pediatric DCM. These studies differ in 
inclusion criteria (isolated DCM versus non-isolated DCM), the extent of genetic testing, 
and variant filtering and interpretation. Pugh et al. reported an overall yield of 37% in 
766 individuals with DCM (including 286 patients younger than 18 years) using gene 
panels that included between 5 to 46 genes, with titin (TTN) being the largest contributor 
(up to 14%). Unfortunately, these authors did not specify the yield in the pediatric age 
group (10). Kühnish et al. found 8 LP/P variants in 34 pediatric patients with DCM (24%) 
using a panel‐based NGS approach targeting 89 genes, which identified variants in 
TTN (1), TNNT2 (2), TNNI3 (1), MYH7 (1), MYBPC3 (1) and ACTC1 (1)(30). In a recent study 
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by Herkert et al., combining copy number variant analysis with stepwise trio-based ES 
yielded a diagnosis in more than 50% (28/44 families) of pediatric DCM patients. They 
also identified patients with familial and non-familial DCM and patients with extra-
cardiac features or possible myocarditis (7). In a study by Long et al., ES in 18 families 
with DCM (including three syndromic cases) yielded a genetic diagnosis in 33% when 
filtering for 55 known DCM genes. When they expanded their analysis by filtering the 
exome for compound heterozygous and de novo variants, they diagnosed four additional 
patients, including carriers of rare and syndromic genes (ALMS1 and PRDM16) and two 
potential novel genes (RRAGC and TAF1A), resulting in a final yield of 50%. Vasilescu et 
al. reported a genetic diagnosis in 10 of 37 pediatric DCM patients (27%), of which three 
were in novel or less-established disease genes (PPA2, TAB2 and NRAP) and two were in 
mitochondrial DNA. They also showed an increase in a genetic diagnosis with later onset 
of cardiomyopathy: age <1 year - 34% positive DNA diagnosis, age 1 to 5 years - 38% and 
age >6 years - 60%. They further showed that infants manifesting before 1 year of age 
had the poorest prognosis, especially when their cardiomyopathy was associated with a 
metabolic or syndromic origin, which is in line with previous studies (9). Finally, in a study 
in neonates with heart failure, ES was diagnostic in 10/15 (68%), although only 20% had a 
clinical diagnosis of DCM (31).
The yield of genetic testing in pediatric DCM is higher than that in adult-onset non-
ischemic DCM, varying between 27 to 54% (7, 8, 10, 32, 33). In addition, the spectrum of 
genes involved in pediatric DCM differs from that seen in adult (non-ischemic) DCM (34, 
35). Pugh et al. showed that the genes implicated in DCM vary with age. In adults and 
children 2-18 years of age, the majority of variants were located in TTN and DSP. In children 
under 2 years of age, MYH7 was predominantly mutated and no TTN variants were found 
(10). This matches our findings as 7/9 children in our cohort with LP/P MYH7 variants were 
under the age of 1 year at diagnosis, confirming that these variants frequently underlie 
DCM with infant presentation.
Our yield of 36% LP/P variants in pediatric DCM and the spectrum of genes involved are 
thus in line with international literature, but also leave room for further increase in yield, 
e.g. by systematically offering ES with analysis of an expanded gene panel or of all disease-
associated genes. This is especially important for children <1 year of age at diagnosis, 
where the diagnostic yield of ES goes up to 55% (5/9) and three of five (60%) genes with 
pathogenic variants were not part of (adult-onset) cardiomyopathy panels because they 
are involved in metabolic and syndromic diagnoses (31).
The predictive value of the variants detected
In adults with non-ischemic DCM, there is increasing insight into the association between 
certain pathogenic variants and outcome. In a large meta-analysis, the highest HTx rate 
was found in LMNA mutation carriers (27%), while RBM20 mutation carriers underwent 
HTx at a younger age (mean 28.5 years) than carriers of pathogenic variants in other 
genes (mean 41 to 43 years) (36). Another study in 5,267 individuals, ranging from healthy 
volunteers to end-stage DCM patients, showed that TTN-truncating variant-positive 
DCM patients reached the SE of death, HTx or ventricular assist device at earlier ages 
and sooner after enrolment than TTN-truncating variant-negative DCM patients (37). 
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Janswijer et al. found that truncating TTN mutations were associated with a milder form 
of DCM compared to that seen in patients with LMNA variants or idiopathic DCM (38). 
These findings were (partly) explained by differences in disease severity and the number 
of adverse events between the cohorts. In a study on the prognosis of 52 adults with 
DCM carrying rare variants in sarcomeric genes (MYH6, MYH7, MYBPC3, TNNT2 and TTN), 
it was shown that death/HTx‐free survival dramatically decreased after 50 years of age in 
variant-positive patients compared to variant-negative patients (39).
When predicting outcome in children with DCM, the genetic contribution is less clear. 
Specific variants (e.g. in LMNA or SCN5A) have been linked to sudden cardiac death, as this 
is related to malignant ventricular arrhythmias (8, 40). However, as sudden cardiac death is 
rare in children with DCM (5-year incidence of 3%), this is a less prevalent clinical issue than 
death due to heart failure or the need for HTx (41). To the best of our knowledge, only one 
study has systematically evaluated children with non-HCM cardiomyopathy (with 56 of 70 
patients diagnosed with DCM) for genetic disease and association with outcome: Ellepola et 
al. showed that HTx were more often performed in variant-positive children than in variant-
negative subgroups (48% vs. 34%), and the variant-positive children had higher mortality 
(17% vs. 2%). Of note, outcome was not specified for the 56 DCM patients (42).
In our study, which reports on the largest cohort of genetically tested children with DCM 
to date, we also observed decreased survival in children with a LP/P genetic variant. Our 
study is thus an important contribution to the mounting evidence that carrying a LP/P 
variant puts children at an increased risk of death or HTx. We also found that MYH7 variant 
carriers were less likely to die or undergo HTx compared to patients with LP/P variants 
in other genes, although our numbers were small. Whether this truly implies that MYH7 
variants are relatively benign remains unknown. In adult DCM studies such a favorable 
genotype–phenotype relation could not be demonstrated for MYH7 compared to LMNA, 
PLN, RBM20, MYBPC3, TNNT2 and TNNI3 (29).
Clinical implications of our study
The results of our study justify incorporating genetic testing early on in the diagnostic 
work-up of all children with DCM (7). Since determining disease etiology is essential for 
prognosis and counseling, genetic testing should be offered as soon as possible after 
diagnosis. In both adults and children, there is also increasing evidence the presence of 
external causal factors (e.g. chemotherapy or myocarditis) does not preclude there being 
a genetic cause for the DCM (43-45). In our study we identified a pathogenic LMNA variant 
in a child diagnosed with myocarditis, which is a good example of how previously silent 
genetic defects might predispose to heart failure early in life when viral myocarditis acts 
as a second hit (46). These findings urge us to genetically evaluate all children diagnosed 
with DCM, regardless of presumed disease etiology. They also call for genetic re-evaluation 
of all children with DCM who have been tested previously, but to whom ES has not been 
offered. In our cohort, 74% percent of children were genetically evaluated, which clearly 
leaves room for improvement. Optimizing collaboration between pediatric cardiologists 
and clinical geneticists and genetic counseling of parents might increase the uptake of 
genetic testing.
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At present, the direct translation of a genetic variant into individual clinical risk prediction 
is challenging. DCM in children is characterized by genetic heterogeneity, a situation 
contrary to that for HCM, where a relatively limited number of genes seem to be involved, 
predominantly those related to the sarcomere (47). Penetrance and age of presentation 
also vary in DCM (48-50). Based on our findings, children who carry a LP/P variant should 
be considered at an increased risk for adverse outcomes. The use of genetic information 
for better management and risk prediction will require close collaboration between 
research centers and analysis of pooled data. In this respect, the results of the ‘PCM Genes 
study’ of the PCMR, which aims to offer ES to 600 children with DCM, will provide more 
insight into genetic testing and associations with outcome (21). As long as it is not clear 
how to differentiate between recovery and remission, children who are variant-positive 
but recover should continue to receive follow-up care (51).
Limitations
Our study has limitations. Initially, diagnostic categories were assigned following the 
etiologic categories of the PCMR (11). However, these data pre-dated many clinically 
available genetic tests and, along with other epidemiologic studies, highlight the 
uncertain etiological basis of cardiomyopathy given that the majority of DCM patients 
were identified as idiopathic. Future directions of the registry include the use of ES to 
improve diagnostic strategies, which may lead to different etiologic classification (21). In 
our study, several idiopathic cases turned out to be familial/genetic. Furthermore, IEM 
and NMD are considered distinct categories even though a genetic diagnosis typically 
underlies these diseases as well. For that reason, we have included IEM and NMD as LP/P 
variant-positive in our analyses. It might have been more transparent if we had assigned 
one genetic diagnostic category that included subcategories of IEM and NMD in addition 
to those with a LP/P variant in an explanatory gene and those with two or more affected 
first degree family members. Secondly, some of our data were retrospective, and missing 
data might be an issue here despite the efforts we made to obtain all available data. Thirdly, 
genetic testing panels changed during the study period, which influences genetic yield. 
Furthermore, we could only be certain that a variant was de novo in cases with genetic 
evaluation of both parents, so the true number of de novo cases and possible relation 
to worse outcome remains unknown. Finally, our sample size was too small to test the 
associations between individual variants/genes and phenotype.
Conclusion
Genetic testing is a valuable tool to predict outcome in children with DCM, and patients 
with a LP/P variant have an overall worse prognosis. Genetic testing should therefore be 
incorporated in clinical care of all children with DCM, regardless of presumed disease etiology.
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Supplementary Table 1. Genetic findings in children with DCM. Number of likely pathogenic (LP) 
or pathogenic (P) variants, and variants of unknown significance (VUS).
Genes LP/P variant VUS
ABCC9 - -
ACADVL 1 -
ACTC - -
ACTN2 - -
ALDH3A2 - 2
ALMS 1 2 -
ALPK3 - 1 (compound heterozygous)
ANKRD - 3
ANO5 (TMEM16E) - -
ASNA1 1 (compound heterozygous) -
BAG3 - -
CALR3 - -
CAV3 - 1
CRYAB - -
CSRP3 - -
DES 1 -
DMD 6 -
DSC2 - 1
DSG2 - -
DSP 1 1
DTNA - 3
EMD - -
FKTN - -
FLNC - 1
GLA - -
HCN4 - -
JPH2 - -
JUP - 2
KCNQ1 1
LAMA4 - 1
LAMP2 - -
LDB3 - 2
LDB3 - 1
LMNA 1 -
MIB1 - -
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MYBPC3 1 2
MYH6 - 2
MYH7 9 5
MYL2 1 -
MYL3 - -
MYLK2 - -
MYOZ1 - -
MYOZ2 - 1
MYPN - 2
NEXN - 1
NKX2.5 1 -
NOTCH1 - -
PCCA 1 -
PKP2 3 (1 compound heterozygous)
PLN 1 -
PRDM16 - 1
PRKAG2 - -
RBM20 - 3
RYR2 1 (compound heterozygous) 1
SCN5A 2 -
SGCD - -
SPEG 1 (compound heterozygous) -
TAZ (G4.5) - 2
TBX20 1 -
TCAP - -
TLL1 1 -
TMEM43 - -
TNNC1 - 4
TNNI3 - 1
TNNT2 2 -
TPM1 3 -
TTN 3 17
TTR - -
TXNRD2 - -
VCL - 1
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ABSTRACT
Dilated cardiomyopathy amongst children (pediatric cardiomyopathy, pedicatric CM) is 
associated with a high morbidity and mortality. Moreover, treatment based on adult heart 
failure therapy is often ineffective. However, the reason for high morbidity and mortality 
is largely unknown as data on cellular pathomechanisms are limited. Here, we assessed 
cardiomyocyte contractility and protein expression to define cellular pathomechanisms in 
pediatric CM. For this study explanted heart tissue of 11 pediatric CM and 18 controls was 
studied. Contractility was measured in single membrane-permeabilized cardiomyocytes 
and protein expression was assessed with gel electrophoresis and western blot 
analysis. We observed increased Ca2+-sensitivity of myofilaments which was due to 
hypohosphorylation of cardiac troponin I, a feature commonly observed in adult DCM. 
Unlike adult DCM we did not find an increase in compliant titin expression. We also found 
a significantly reduced maximal force generating capacity of cardiomyocytes, caused by 
reduced myofibril density. The limited ability of pediatric CM patients to induce cardiac 
remodeling might have contributed to their early disease onset and severity. 
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INTRODUCTION
Dilated cardiomyopathy (DCM) is a cardiac disease characterized by the dilatation of 
the (left) ventricle and systolic dysfunction. A genetic cause is found in 20-50% of DCM 
cases (1-3). The disease often develops in adulthood and disease progression can be 
slow if treatment is optimized though recovery remains unlikely (4). In children, DCM 
is a rare disease with an annual incidence estimated around 0.6/100 000 (5) and it may 
be associated with an aggressive disease progression. In two large studies the 1- and 
5-year transplantation-free survival rates have been reported only 69-74 % and 54-65 
% respectively (5, 6). More than 5 years after presentation the rate of events is low (6). 
Most children die or get transplanted because of pump failure, the rate of sudden cardiac 
death is relatively low at 2.4% at 5 years (7). Poor prognosis in pediatric DCM patients 
was associated with thin left ventricular (LV) wall (LV posterior wall thickness z-score 
<-1.7) and age <13.1 years at time of diagnosis (5-7). In contrast, after 2 years a 22% full 
recovery has also been reported (8) which implies pediatric cardiomyopathy can also be 
reversible. The aggressive nature of DCM and the contradictory relative high recovery rate 
was also reported in a recent Dutch study with a 1- and 5-year survival rate of 85% and 
84%, respectively, implying that most patients died within the first year after diagnosis 
(9). In this study a low transplantation rate in the 1st year after presentation and a 38% 
recovery rate, of which 50% within 1 year, was reported (9). Determinants underlying the 
highly diverse response to therapy, recovery rates and mortality are largely unknown. 
While several pathomechanisms have been elucidated in adult DCM, knowledge on 
pathogenesis underlying the aggressive progression of DCM at young age is scarce. A 
recent study showed that pediatric DCM patients harbor a different gene expression 
profile compared to adult onset DCM (10). pediatric CM samples were characterized by 
an expression profile that reflected a more undifferentiated cellular state, and reduced 
hypertrophy response compared to adult DCM (10).
Here we defined the cellular phenotype in a unique collection of pediatric CM samples 
by combining functional measurements in single isolated cardiomyocytes, protein 
analyses and electron microscopy. Our studies revealed highly reduced force generating 
capacity of single cardiomyocytes caused by significant reductions in myofibril density. 
We observed troponin I hypophopshorylation and an associated increased myofilament 
Ca2+-sensitivity and impaired myofilament length-dependent activation. We did not find 
an increase in compliant titin in the pediatric samples, which is a common form of disease 
remodeling in various forms of adult heart failure (11-13). However, we did find a large 
spread in titin isoform composition in the pediatric CM group. Overall, our data indicate 
that the pediatric CM heart that progresses to end-stage failure has limited capacity to 
adequately respond to increased wall stress.
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METHODS
Clinical characteristics
Echocardiographic examinations were performed in a uniform way. All children were at rest 
and in sinus rhythm during examination an a complete 2-dimensional echocardiographic 
study was performed. M-mode of the parasternal long-axis was used to measure 
LVPWs, LVPWd, LVEDD and LVESD and were expressed as Z score for body surface area. 
Subsequently, FS was calculated using the formula ((LVEDD-LVESD) / LVEDD) *100%.
Cardiomyocyte force measurements
Single cardiomyocytes were mechanically isolated from cardiac tissue and membrane-
permeabilized as previously described(29). Maximal force (Fmax) and passive force (Fpass) of 
sarcomeres were measured at high [Ca2+] and low [Ca2+] (pCa 4.5 and pCa 9.0 respectively). 
Force-[Ca2+] curves were constructed at various submaximal [Ca2+] and are shown as 
relative forces to Fmax. Myofilament Ca
2+-sensitivity was measured as the [Ca2+] needed to 
achieve 50% of Fmax (EC50). length-dependent activation was measured as the shift in EC50 
(ΔEC50) at a sarcomere length of 1.8 μm and 2.2 μm. 
Titin expression and cTnI phosphorylation
Titin isoforms were separated on a 1% w/v agarose gel and stained with SYPRO Ruby 
protein gel stain (Invitrogen) as previously described (30). All samples were measured in 
triplicate and average of triplicate measurement per sample is shown. Phosphorylation of 
cTnI was assessed as previously described (31, 32). 
HSP27, HSP70, LC3B-I/II and p62 expression
For HSP70 and HSP27 analysis proteins were separated on pre-cast 10% criterion gels 
(BioRad) and membranes were incubated with HSP70 antibody (Enzo) or HSP27 antibody 
(Cell Signaling), and GAPDH antibody (Cell signaling) to correct for loading differences. 
For LC3B-I and LC3B-II analysis proteins were separated on pre-cast 8-16% gradient TGX 
gels (BioRad) and membranes were incubated with LC3B-I/II antibody. Analysis of p62 
expression was performed by separating proteins on a 12% acrylamide gel and membrane 
was cut in two pieces. The upper piece was incubated with p62 antibody (Cell signaling) 
and the lower piece with GAPDH antibody.
Electron microscopy
Cardiac tissue of pediatric CM and control samples were studied with transmission electron 
microscopy. Myocardium was fixed in 2% paraformaldehyde + 2,5% glutaraldehyde in 
0,1M phosphate buffer (pH 7.4), embedded in Epon and cut in 70 nm sections. The sections 
were mounted onto formvar-coated copper grids and stained with a 5% solution of uranyl 
acetate, followed by Reynold’s lead citrate. Sections were viewed with Philips CM100 
Transmission Electron Microscope. The myofibril density was determined with ImageJ 
software and expressed as percentage of myofibrils of whole cell area in that picture of 
which the nucleus was excluded. For each sample 2-7 different images were analysed in 
order to determine average myofibril density. Maximal, and passive forces were corrected 
for average myofibril density of the corresponding sample. 
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Statistics
Graphpad Prism v7 software was used for statistical analysis. Means were compared 
between groups with T-test if data was confirmed to be normally distributed. Maximal 
force data was not normally distributed and therefore means were compared with a 
Mann-Whitney test. A p-value<0.05 was considered to represent a statistically significantly 
difference between groups. N= number of samples, n= number of cardiomyocytes 
measured. 
Ethical approval
This study was approved by the local ethics board of the Erasmus Medical Center (protocol 
number MEC-2015-233) and written consent of patients and/or parents was obtained. 
Samples were obtained during cardiac transplantation. As we do not have access to 
control cardiac tissue from age-matched individuals, 18 control samples were used from 
explanted Left ventricular (LV) heart tissue of healthy donors (age range 21 to 65 years 
old); people died from a non-cardiac cause, typically motor vehicle accidents and were 
acquired from the University of Sydney, Australia, with the ethical approval of the Human 
Research Ethics Committee #2012/2814. The codes of used samples are: 6.034, 8.004, 
5.086, 3.141, 3.164, 4.049, 4.104, 7.040, 6.020, 5.128, 3.160, 6.008, 7.054, 7.044, 6.056, 3.112 
6.042 and 3.162. All samples were stored in liquid nitrogen or at -80ᵒC until use. 
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RESULTS
Patient characteristics
Heart tissue was obtained from 9 pediatric patients diagnosed with DCM and 2 pediatric 
patients diagnosed with non-compaction cardiomyopathy during cardiac transplantation. 
Z-scores are commonly used to define growth of the heart during development and are 
used to distinguish between physiological and pathological changes in pediatric patients 
(14). Patient characteristics are shown in Table 1. LV end systolic diameter (LVESD) and LV 
end diastolic diameter (LVEDD) were increased and LV posterior wall systole (LVPWs) and 
LV posterior wall diastole (LVPWd) were decreased, all in line with the dilated phenotype 
and diagnosis of DCM. 
Table 1. Patient characteristics
  Controls (N=18) Pediatric CM (N=11)
Age 44,1 ± 3,1 years (N=18) 10,5 ± 1,3 years (N=11)
Sex (% male) 55,6% (N=18) 45,5% (N=11)
Time between echo and HTX   15 days (11-64)
LVEDD Z-score   7,9 ± 1.0 (N=11)
LVESD Z-score   11,7 ± 1,0 (N=11)
LVPWd Z-score   -0,8 ± 0,5 (N-11)
LVPWs Z-score   -3,4 ± 0,5 (N=8)
FS % at presentation 8 (7-10)
FS % at HTx 15 (8-19)
NT-pro-BNP at HTx 483 (206-1034)
Age, LVEDD, LVESD, LVPWd, LVPWs are shown as mean ±SEM.
Time between echo and HTX, FS% and NT-pro-BNP (pmol/L) are shown as median (interquartile range).
HTX: Cardiac transplantation.
Hypocontractility and increased myofilament Ca2+-sensitivity in pediatric CM 
compared to controls
Measurements in single cardiomyocytes revealed significantly lower Fmax (Figure 1A) and 
Fpass (Figure 1B) in pediatric CM compared to controls. A leftward shift of the force-[Ca
2+] 
curve indicated an increased myofilament Ca2+-sensitivity in pediatric CM compared 
to controls (Figure 1C). The combination of reduced Fmax, reduced Fpass and increased 
Ca2+-sensitivity of myofilaments results in lower force development at high (saturating) 
[Ca2+], lower force at very low [Ca2+] and higher force development at intermediate [Ca2+] 
respectively (Figure 1D). The increase in myofilament Ca2+-sensitivity was evident at both 
sarcomere lengths (1.8 μm and 2.2 μm; Figure 1E) and associated with impaired length-
dependent activation depicted  as ΔEC50 (Figure 1F). 
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Figure 1. Baseline characteristics 
A: Maximal force was significantly lower in pediatric CM (23.8±1.1, N=11, n=78) compared to 
controls (37.4±2.6, N=6, n=27, p<0.0001). B: Fpass was significantly lower in pediatric CM (N=11, n=40) 
compared to controls (N=10, n=29, p<0.0001) over a range of sarcomere lengths. C: A leftward shift 
of the relative force vs [Ca2+] indicates higher myofilament Ca2+ -sensitivity in pediatric CM (N=11, 
n=38) compared to controls (N=5, n=12, p<0.0001). D: The absolute force development over a 
range of [Ca2+] showed pediatric CM have impaired maximal force development at saturating [Ca2+], 
increased force development at lower [Ca2+] and a decreased Fpass. E: Ca
2+-sensitivity was significantly 
higher at sarcomere length 1.8 and 2.2 in pediatric CM (N=11, n=38) compared to controls (N=5, 
n=12, p<0.0001). F: LDA, measured as ΔEC50 was significantly lower in pediatric CM (0.60±0.05, 
N=11, n=38) compared to controls (0.86±0.09, N=5, n=12, p=0.007). N= number of samples, n= 
number of cardiomyocytes measured. 
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Figure 2. Titin isoform composition has limited effect on contractility in pediatric CM
A: Separation of titin N2BA and N2B with gel electrophoresis. B: N2BA/N2B ratio was not significantly 
different between pediatric CM (0.62±0.12, N=11) and controls (0.53±0.03, N=15). C: LDA was mostly 
impaired in pediatric CM patients who had higher N2BA/N2B ratio (N2BA/N2B >0.65, N=5, n=19) 
compared to pediatric CM patients who had lower N2BA/N2B ratio (N2BA/N2B <0.4, N=6, n=19). 
Dotted line indicates control values. D: Mean ΔEC50 per sample plotted against the N2BA/N2B ratio 
did not show a significant correlation between ΔEC50 and N2BA/N2B. E: There was no difference 
in Fpass between pediatric CM patients who had higher N2BA/N2B ratio (N2BA/N2B >0.65, N=5, 
n=18) compared to pediatric CM patients who had lowerN2BA/N2B ratio (N2BA/N2B <0.4, N=6, 
n=22). F: N2BA/N2B ratio was not significantly related to age. G: A higher N2BA/N2B ratio was non-
significantly associated with a smaller LVEDD z-score. H: A small non-significant trend was observed 
in which a higher N2BA/N2B ratio was associated with a smaller LVESD z-score. I: No correlation was 
observed between N2BA/N2B and LVPWd z-score. J: A significant correlation was found in which a 
higher N2BA/N2B ratio was associated with a less reduced LVPWs z-score (p<0.05). N= number of 
samples, n= number of cardiomyocytes measured.
Titin isoform composition variation in pediatric CM has limited effect on 
contractility
A shift towards more N2BA titin has been shown to lower Fpass (11, 12, 15) and reduce 
length-dependent activation (16). Analysis of titin isoform composition did not reveal 
a difference  in the N2BA/N2B ratio between pediatric CM and controls (Figure 2A,B). 
However, a wide variation in titin isoform composition was observed in the pediatric 
CM group (Figure 2B). Since titin isoform composition has been shown to affect length-
dependent activation we divided samples into a group that had a high N2BA/N2B ratio 
(N2BA/N2B>0.65) and a low N2BA/N2B ratio (N2BA/N2B<0.4). The group of samples with 
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a high N2BA/N2B ratio showed a greater reduction in ΔEC50 than the group of samples 
with a low N2BA/N2B ratio (Figure 2C). However, ΔEC50 was not significantly different 
between the two groups. In addition, ΔEC50 did not significantly correlate with the N2BA/
N2B ratio (Figure 2D). Accordingly, Fpass was reduced to the same extent in the groups of 
pediatric CM samples with a relatively high N2BA/N2B ratio (N2BA/N2B>0.65) and a low 
N2BA/N2B ratio (N2BA/N2B<0.4) (Figure 2E). This indicated that other factors underlie the 
reduction of Fpass. The wide spread in age of our patient population was not responsible 
for the spread of titin isoform composition since no correlation was found between age 
and N2BA/N2B ratio (Figure 2F). We observed a significant correlation between N2BA/N2B 
and LVPWs (Figure 2J) in which a high N2BA/N2B ratio was associated with a less negative 
LVPWs z-score. This implies that patients with an increase in compliant titin had a smaller 
reduction in systolic LV wall thickness. 
Figure 3. Hypophosphoryalation in pediatric CM compared to controls
A: ProQ staining identifying phosphorylated proteins of pediatric CM and control samples. B: 
Corresponding SYPRO staining identifying proteins of pediatric CM and control samples. C: cTnI 
phosphorylation is significantly decreased in pediatric CM (N=13) compared to controls (N=13, 
p<0.0001). D: Phostag showed separation of non-, mono- and bisphosphorylated cTnI. E: While 
controls (N=11) showed predominatly mono- and bisphosphorylated cTnI, pediatric CM samples 
(N=11) showed mostly non-phosphorylated cTnI. 
Chapter 3
56
Reduced phosphorylation of cTnI in pediatric CM compared to controls
Phosphorylation of cTnI is reduced in various forms of adult heart failure and causes 
increased myofilament Ca2+-sensitivity (13, 17-19). In line with published data in adult 
DCM (13, 18, 20), phosphorylation of cTnI was significantly lower in pediatric CM 
compared to controls (Figure 3A,B,C). PhosTag analysis showed separation of non-, 
mono- and bisphosphorylated cTnI (Figure 3D). While controls showed predominantly 
bisphosphorylated cTnI, in pediatric CM patients the non-phosphorylated cTnI was more 
prevalent (Figure 3E). In order to confirm that cTnI hypophosphorylation causes the high 
myofilament Ca2+-sensitivity in pediatric CM samples, force measurements were repeated 
after incubation with exogenous protein kinase A which phosphorylates cTnI. Both 
myofilament Ca2+-sensitivity and LDA normalized to control values upon incubation with 
exogenous PKA (Figure 4A,B). With normalized phosphorylation status of cTnI, there was 
no difference in ΔEC50 between the group of pediatric CM samples with a low N2BA/N2B 
ratio and a high N2BA/N2B ratio (Figure 4C). Fpass also remained low after incubation with 
exogenous PKA (Figure 4D). In addition, no difference in Fpass was observed between PKA-
treated groups of pediatric CM samples with different N2BA/N2B ratios (Figure 4E). 
Figure 4. Restoration of sarcomere function after incubation with exogenous PKA
A: Exogenous PKA restored myofilament Ca2+-sensitivity in pediatric CM (N=11, n=30) to control 
(n=5, n=12) values. B: Exogenous PKA eliminated the difference in length-dependent activation 
(ΔEC50) between pediatric CM patients with higher N2BA/N2B ratio (N2BA/N2B >0.65, N=5, n=14) 
than pediatric CM patients who had lower N2BA/N2B ratio (N2BA/N2B <0.4, N=6, n=16) ; relative 
to  control value. Dotted line indicates control values. C: There was no difference between patients 
with high or low N2BA/N2B ratio with respect to ΔEC50 after incubation with exogenous PKA. D: 
Exogenous PKA did not affect Fpass
 in controls or pediatric CM and remained significantly lower in 
pediatric CM compared to controls. N= number of samples, n= number of cardiomyocytes measured.
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Figure 6. Protein quality control system in pediatric CM
A: Representative blot images for HSP27 expression. B: Representative blot images for HSP70 
expression. C: Expression of HSP27 was not altered in pediatric CM (N=11) compared to controls 
(N=11). D: Expression of HSP70 was not altered in pediatric CM (N=11) compared to controls (N= 
11). E: Representative blot images for LC3BI and LC3B-II expression. G: Expression of LC3B-I/LC3-
BII was significantly (p<0.05) reduced in pediatric CM (N=11) compared to controls (N=11). F: 
Representative blot images for p62 expression. H: Expression of p62 was not altered in pediatric CM 
(N=11) compared to controls (N=7). 
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Decreased myofibril density underlies the hypocontractility in pediatric CM 
As titin isoform composition was ruled out as causes of the observed decrease in Fpass and 
Fmax, we determined myofibril density with transmission electron microscopy. We observed 
a significant decrease in myofibril density in pediatric CM compared to controls (Figure 
5A,B). Correction of Fmax for myofibril density eliminated the difference between pediatric 
CM and controls indicating the hypocontractility was due to myolysis or the inability 
to create sufficient myofibrils (Figure 5C). Also Fpass of pediatric CM cardiomyocytes was 
restored to control values after correction for myofibril density (Figure 5D). 
Protein quality control system is unaltered in pediatric CM 
We then studied whether changes in the protein quality control system occurred, which 
may underlie reduced myofibril density. Heat shock proteins (HSPs) are upregulated 
in stressful situations in order to prevent protein denaturation and aid in refolding of 
misfolded proteins. We did not find an induction of HSP70 (Figure 6A,C) or the cytoskeletal 
HSP27 (Figure 6B,D) in our pediatric CM group compared to controls. We did find a 
significantly decreased LC3B1/LC3B-II ratio (Figure 6E,G), which implies an induction of 
autophagy. However, p62, another autophagy marker was not upregulated in pediatric 
CM compared to controls (Figure 6F,H). 
DISCUSSION
Characterization of pediatric CM myocardium revealed reduced active and passive 
cardiomyocyte force development, high myofilament Ca2+-sensitivity and a blunted 
length-dependent activation compared to controls. High myofilament Ca2+-sensitivity 
and blunted length-dependent activation were explained by low PKA-mediated 
phosphorylation of cTnI, which is a general feature observed in cardiac disease. We 
showed that the decrease in Fmax and Fpass is due to decreased myofibril density.
No indications for alterations in protein quality control system in pediatric CM
We observed a decrease in myofibril density which was causal to the hypocontractile 
cellular phenotype in pediatric CM. Reduced HSP expression has been shown to increase 
cardiac damage after brief ischemia, and pretreatment with heat to induce HSPs reduced 
cardiac damage after infarction. However, in conditions of continuous stress as is the case 
in DCM, the HSP responses are less clear. HSP27 has been shown to be upregulated in 
adult DCM and not in ischemic heart disease (21). There are conflicting reports about 
HSP70 in adult DCM ranging from no change (21), to an increased expression (22). HSPs 
may lose their responsiveness in conditions of continuous cardiac stress. We did not find 
an induction of heat shock response, and we also did not find more autophagosomes 
in pediatric CM compared to controls. Future studies are warranted to reveal if reduced 
myofibril density in pediatric CM is due to an inability of cardioymocytes to increase 
myofibril synthesis and/or is caused by increased myofibril degradation.
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Low PKA-mediated phosphorylation, high myofilament Ca2+-sensitivity and 
blunted length-dependent activation
In line with what has been found in adult DCM patients (13, 17), we observed decreased 
PKA-mediated phosphorylation and coincident increased Ca2+-sensitivity due to low 
cTnI phosphorylation in pediatric CM patients. Hypophosphorylation of cTnI has been 
shown to occur in various forms of heart failure. It is likely due to desensitization of the 
β-adrenergic receptor signaling pathway and subsequent decrease in PKA-mediated 
phosphorylation (23). Hypophosphorylation of cTnI has been shown to underlie a blunted 
length-dependent activation (20, 24, 25). Treatment of cardiomyocytes with exogenous 
PKA corrected both Ca2+-sensitivity  of myofilaments and length-dependent activation, 
independent of the titin isoform composition present in the heart. 
Titin isoform composition is highly diverse in pediatric CM
Titin is composed of two isoforms, a compliant N2BA and a stiff N2B isoform. On average 
we observed no significant change in titin isoform composition in pediatric CM compared 
to controls. An increase in N2BA/N2B ratio has been reported in various forms of heart 
failure including adult DCM (11-13) and is considered a general hallmark of DCM. 
However, in our pediatric CM study population we observed a wide variation of N2BA/
N2B ratios: 5 patients showed a higher N2BA/N2B ratio, while  6 patients showed a normal 
or even lower N2BA/N2B ratio compared to controls. An increase in N2BA titin has been 
shown to cause a blunted length-dependent activation in animal models, (16, 24, 26, 
27) while we only observed a modest effect of N2BA on length-dependent activation 
of myofilaments in human pediatric CM samples. The length-dependent increase in 
myofilament Ca2+-sensitivity was slightly, though not significantly lower in pediatric CM 
samples with a high N2BA/N2B compared to samples with  a low N2BA/N2B ratio. Length-
dependent activation of myofilaments was normalized in all pediatric CM samples to 
control values after incubation with PKA which indicates that the increase in compliant 
titin only affects length-dependent activation when cTnI is hypophosphorylated. This is in 
line with what has been reported in adult DCM (13, 18). While increased N2BA/N2B ratio 
has been associated with impaired systolic function, a low N2BA/N2B ratio is associated 
with improved diastolic function and a positive correlation between N2BA/N2B and peak 
oxygen consumption, a measure for exercise tolerance, in DCM patients has been found 
(11). We observed that a high N2BA/N2B ratio coincided with a smaller reduction in LV 
wall thickness during systole (LVPWs). An increase in N2BA/N2B ratio may represent a 
compensatory mechanism in order to cope with altered cardiac stress. Overall, the increase 
in N2BA/N2B did not have a large impact on sarcomere function. However, it should be 
stated that all studied heart tissue was derived from end-stage pediatric CM patients and 
therefore might suffer from severe cardiac remodeling. It might be possible that N2BA/
N2B aids in this remodeling in a positive way by creating more flexibility in the sarcomeric 
structure to function under overstretched conditions at the initial disease stage. 
Cardiac remodeling: friend or foe?
The increase in compliant titin might not have a direct causal role in disease pathogenesis, 
but may rather represent an adaptive response in order to cope with altered cardiac 
demand. The inability of pediatric CM patients to upregulate N2BA expression might be a 
reflection of their limited capability to adapt to altered cardiac demands. This is in line with 
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Patel et al. who recently published limited adverse remodeling in pediatric CM patients 
compared to adult onset DCM (28). They showed that hypertrophy and perivascular and 
interstitial fibrosis increased in adult DCM but not in pediatric CM patients compared 
age-matched controls. In addition, they showed sarcomere thickness is increased in 
adult DCM, but not in pediatric CM (28). Together with our results this implies that limited 
cardiac remodeling in pediatric CM patients might hamper the hearts to cope with altered 
cardiac demands and might have contributed to their early disease onset and severity. 
However, whether the limited adaptive capabilities of the heart are indeed causal to the 
early and progressive disease onset warrants further research. 
Limitations
We have compared pediatric DCM patients with healthy adult controls since acquisition 
of healthy control tissue of children is near impossible. However, we did not find any 
correlations between age and protein expression or sarcomere function. Therefore we 
believe the observed effects are not related to difference in age alone. 
Three patients were supported with a ventricular assist device (VAD) prior to 
transplantation. The duration of VAD support was short, 1-2 months. We did not see a 
difference in any parameter between patients that were supported with a VAD or not 
prior to transplantation. However, we can not exclude that despite the short VAD support 
duration, VAD induced cardiac remodeling. 
Conclusion
In summary, we show that pediatric CM patients harbor similar changes in protein 
modifications and sarcomeric function compared to adult DCM. Hypophoshorylation 
of cTnI, most likely due to secondary disease remodeling and desensitized β-adrenergic 
receptor signaling, led to increased Ca2+-sensitivity and blunted length-dependent 
activation of myofilaments. However, we did not find a consistent upregulation of 
compliant N2BA titin as has been observed in adult DCM. Increased N2BA/N2B ratio was 
significantly related to a lower LVPWs z-score. The limited cardiac remodeling in pediatric 
CM patients, illustrated in this study by the limited shift in titin isoform composition, 
might have hampered the ability to cope with altered cardiac demands and might have 
contributed to their early disease onset and progression. Cardiomyocyte hypocontractility 
was observed which was due to a decrease in myofibril density. The severe reduction in 
force generating capacity of cardiomyocytes may underlie the fast progression of cardiac 
disease in pediatric patients. 
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ABSTRACT 
BACKGROUND A single six-minute walk test (6MWT) can be used to identify children 
with dilated cardiomyopathy (DCM) with a high risk of death or heart transplantation.
OBJECTIVES To determine if repeated 6MWT has added value in addition to a single 
6MWT in predicting death or heart transplantation in children with DCM.
METHODS Prospective multi-center cohort study including ambulatory DCM patients ≥ 6 
years. A 6MWT was performed 1 to 4 times per year. The distance walked was expressed as 
percentage of predicted (6MWD%) . We compared the temporal evolution of 6MWD% in 
patients with and without the study endpoint (SE: all-cause death or heart transplantation), 
using a linear mixed effects model.
RESULTS In 57 patients, we obtained a median of 4 (IQR 2-6) 6MWTs per patient during a 
median of 3.0 years of observation (IQR 1.5-5.1). Fourteen patients reached a SE (3 deaths, 
11 heart transplantations). At any time during follow-up, the average estimate of 6MWD% 
was significantly lower in patients with a SE compared to patients without a SE. In both 
patients groups, 6MWD% remained constant over time. An absolute 1% lower 6MWD% 
was associated with an 11% higher risk (hazard) of the SE (HR 0.90, 95% CI 0.86-0.95 
p<0.001). 
CONCLUSION Children with DCM who died or underwent heart transplantation, had 
systematically reduced 6MWD%. The performance of all patients was stable over time, 
so repeated measurement of 6MWT within this time frame had little added value over a 
single test. 
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INTRODUCTION
The 6-minute walk test (6MWT) is a safe, simple and well-accepted prognostic tool in 
adults with heart failure (1). The test is used as an outcome measure in clinical trials, and 
short-term change in 6MWT is considered an indicator of prognosis as well (2-4).
In children, the 6MWT is also feasible and has been shown to be reproducible (5). The 
distance walked in a 6MWT can be expressed as a percentage of predicted, taken into 
account height, gender and age (6MWD%) (6). The 6MWT has been successfully used to 
predict outcome in pediatric patients with pulmonary hypertension (7) and to evaluate 
therapy effects in patients with Duchenne muscular dystrophy (8) and pulmonary 
hypertension (9). Previously, we showed that in children with dilated cardiomyopathy 
(DCM), a single 6MWD% below 63% identified patients with the highest risk of dying or 
heart transplantation (HTx)(10).
In this study we report the results of repeated 6MWT in children with DCM. We studied the 
evolution of 6MWD% over time in relation to death or HTx. We aim to determine whether 
6MWD% changes over time, and if so, if this change is associated with the risk of dying or 
HTx. We hypothesize that repeated measurement of 6MWT has added value over a single 
measurement in predicting these clinical outcomes.
METHODS
Data were collected in a multi-center, prospective study design.  In total, patients from eight 
tertiary cardiac centers were included, covering potentially the whole Dutch population 
of children with DCM. Our research program started in October 2010 and ended July 2017. 
In this period, we enrolled children with a previous diagnosis of DCM until 2010, relatively 
late after diagnosis, or with a new diagnosis from 2010 and onward, early after diagnosis. 
DCM was defined as the presence of impaired systolic function (fractional shortening (FS) 
≤25%) and left ventricular (LV) dilation (LV end-diastolic dimension (LVEDD)> +2 Z-score 
for body surface area). Patients with neuromuscular disease, cognitive impairment or 
structural heart disease were excluded. The research program was organized in such a 
way that study visits coincided with routine outpatient clinic visits. In the first year after 
diagnosis 6MWTs were obtained 1 to 4 times per year, and 1 to 2 times per year thereafter, 
dependent on the frequency of visits. This study was approved by the medical ethical 
committee of the Erasmus MC (MEC 2014-062) and performed in accordance with the 
declaration of Helsinki. All parents and children ≥12 years gave their written informed 
consent.
All included patients were asked to perform 6MWTs as part of our follow-up study 
program, at the outpatient clinic in the participating centers. The 6MWT was conducted 
according to the guidelines of the American Thoracic Society (11). The local conditions at 
the outpatient clinics required adaptation of the walking track, as described previously 
(10). In summary, patients were instructed to walk as far as possible on an 8-meter track 
within a 6-minute time frame.  Patients were instructed and encouraged in a standardized 
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manner. Running was not allowed, if necessary, patients could slow down or stop walking. 
After 6 minutes, the total amount of 16 meter ‘laps’ was counted and the distance walked 
in a partially finished lap was added, which resulted in a total walking distance (6 MWD). If 
the patient stopped walking before the end of 6 minutes, e.g. due to fatigue, we accepted 
the walked distance as 6MWD. All 6MWT study data were collected by study personnel and 
stored in the study database, the treating cardiologists were blinded to the study results. 
The distance covered was expressed as percentage of predicted (6MWD%) according to 
Geiger et al, accounting for height, gender and age (6). Calculation of 6MWD% was done 
after closure of the database and used for study purposes only.
As part of the follow up study, in addition to the 6MWT, multiple data were recorded 
on the same patient visit: weight and height, current heart failure medication and 
dosage, New York Pediatric Heart Failure Index (NYPHFI), NT pro-BNP and a standardized 
echocardiogram including left ventricular end-diastolic dimension (LVEDD) and fractional 
shortening (FS).
The study endpoint was death or heart transplantation (HTx). The decision to list a patient 
for HTx was made by a team of treating physicians based on commonly accepted criteria 
(12). The team was blinded to the results of the 6MWT. In addition, we recorded the 
status of the patients at the end of the study, after their last study visit: ongoing disease 
or recovered. Recovery was defined as 2 consecutive echocardiograms with normalized 
LVEDD and FS, the date of the first normalized echocardiogram was considered as date 
of recovery. Echocardiograms were analyzed and reviewed by study personnel who were 
blinded to the patient’s name, previous echocardiograms, and other study results.
Continuous variables with normal distribution are described as mean (standard deviation, 
sd), or as median (interquartile range, IQR) otherwise. Categorical variables are described 
as numbers and percentages. Differences in 6MWT characteristics between patients with 
and without the study endpoint were compared by Student’s t-tests (normal distribution) 
or Mann-Whitney tests. 
We applied a linear mixed effects model (LMEM) for longitudinal data to study the temporal 
evolution of 6MWD%, while accounting for the correlation between measurements in 
the individual patient. Subsequently, the LMEM was combined with a Cox proportional 
hazard regression model in a so-called joint model (JM) to explore the association 
between 6MWD% (repeatedly measured) and the study endpoint. We included time since 
diagnosis as covariate in the JM.
We studied cumulative event-free survival of the study endpoint by the method of 
Kaplan-Meier. In a previous study we showed that pediatric DCM patients with baseline 
6MWD% <63% have high risk of death or heart transplant during prolonged follow-up 
(10). Against this background, we separated our study cohort according to this threshold, 
and compared cumulative event-free survival by a log-rank test.
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The level of statistical significance for all analyses was set at p=0.05. Analyses were 
performed using IBM SPSS statistics 24 (IBM, New York, USA) and R statistical software 
version 3.5.1 (package JMbayes).
RESULTS
Eighty-five patients met the inclusion criteria, of which 57 performed at least one 6MWT. 
Twenty-eight patients did not perform a 6MWT: 14 patients were too ill (eg admitted at the 
PICU) and reached an endpoint before a 6MWT could be obtained. Another 14 patients 
did not perform a 6MWT due to logistical reasons (Figure 1.). Nineteen of the 57 patients 
were included early after diagnosis, whereas 38 patients had been diagnosed before 2010 
and were included relatively late after diagnosis. Patient characteristics are described in 
Table 1. At the first 6MWT, the median age was 11.1 years (IQR 7.3-14.5), median time 
since diagnosis was 3.6 years (IQR 0.5-7.1) and median time since study inclusion was 0.1 
years (IQR 0.0-0.9). Idiopathic DCM was diagnosed in 47%, and the majority of patients 
was treated with ACE- inhibitors (90%) and β-blockers (78%). The median NYPHFI at the 
baseline 6MWT was 8 (IQR 4-11;Table 1). For 49 patients we previously reported the results 
of a single 6MWT and outcome(10).
Figure 1. Flow diagram of eligible patients and included patients.
6MWT 6-minute walk test, PICU pediatric intensive care unit 
N= 85 eligible patients
N=57 one ore more 
6MWT
N=14 too ill to 
perform 6MWT, eg 
admitted on PICU
N=14 no 6MWT due 
to logistical reasons
Median observation time per patient was 3.0 years, (IQR 1.5-5.1), in patients with the study 
endpoint median observation was 1.3 years (IQR 0.2-2.1) and in patients without the study 
endpoint median observation was 3.8 years (IQR 2.1-5.3; p= 0.001). In this time frame, 277 
6MWTs were performed, and 47 of the 57 patients performed more than one 6MWT. The 
median number of 6MWTs per patient was 4 (IQR 2-6). The median number of 6MWTs 
per year follow up was 2.7 (IQR 1.0-2.9). The mean distance walked, including all available 
tests, was 462 meters (±122), the mean 6MWD% was 69% (±17) (Table 1.). 
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Table 1. Characteristics of the study cohort (n=57) at the moment of baseline 6-minute walk test
Time since diagnosis, years, median (IQR) 3.5 (0.5-7.1)
Time since study inclusion, years, median (IQR) 0.1 (0.1-0.9)
Gender, female , n(%) 68 (47%)
Age, years, median IQR 11.1 (IQR 7.3-14.5)
Cause of DCM (n,%)
Idiopathic 26 (47)
Genetic or familial 8 (14)
Other 23 (40)
Heart failure score, NYPHFI median (IQR) 8 (4-11)
Medication, n(%)
β-blockers 45 (78%)
Ace inhibitors 51 (90%)
Anti-coagulants 29 (51%)
Diuretics 32 (56%)
Echocardiografic parameters, mean(sd) 
LVEDD z score 4.7 (2.9)
SF 18.3 (6.7)
NT-pro BNP,  pg/ml, median (IQR) 1873 (390-5021)
Endpoint
Death/transplantation 14
Ongoing disease 39
Recovered 4
Number of 6MWT per patient, median (IQR) 4 (2-6)
6MWT, meters, mean (sd) 462 (122)
6MWD% of predicted,  %, mean (sd) 69 (17)
Total follow up time per patient, years, median (IQR) 3.0 (1.5-5.1)
DCM dilated cardiomyopathy, 6MWT six-minute walk test, NYPHF New York University Pediatric 
Heart Failure Index, range 0-30, LVEDD  Left Ventricular End Diastolic Dimension, SF Shortening 
Fraction 
In the course of the study, 14 of the 57 patients in whom a 6MWT was available, reached 
a study endpoint: 11 patients were transplanted at a median of 5.7 years after diagnosis 
(IQR 2.5-11.0) and 3 patients died, 1.3 and 2.3 and 8.3 years after diagnosis. Death was 
caused by DCM related ventricular arrhythmia in one patient, end-stage heart failure in 
a setting of a contra-indication for HTx in a second patient, and multi-organ failure in a 
patient with an additional glycogen storage disease.
In patients who reached a study endpoint, median time from the last 6MWT to the study 
endpoint was 0.25 years (IQR 0.16-0.77). Median time since diagnosis to the first 6MWT 
was 3.2 years (IQR 0.4-6.8), which was the same as in patients who did not reach a study 
endpoint. The median number of 6MWTs was the same in patients with and without a 
study endpoint (Table 2). At the last follow up visit, 4 of the remaining 43 patients had 
recovered, whereas 39 patients had ongoing disease. Three recovered children showed 
an increase in 6MWD%, the fourth performed only one test. The low number of recovered 
patients did not allow for statistical analysis. 
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Figure 2. Transplant-free survival curves of DCM patients with 6MWD ≤ 63% of predicted compared 
to patients with 6MWD > 63% of predicted.
At the first 6MWT, median 6MWD% was 68% (IQR 53-82%). In patients with a study 
endpoint, 6MWD% was 53% (IQR 33-61), compared to 74% (IQR 60-84) in patients without 
a study endpoint (p=0.003) (Table 2.). Transplant free survival was significantly higher 
in patients with a first 6MWD% ≥ 63%. In children with a first 6MWD% ≥ 63%, one-year 
transplant-free survival was 96% (95% CI 89 to 100), two-year transplant-free survival 
was 92% (95% CI 81 to 100) in contrast to children with a first 6MWD% < 63% in whom 
one-year transplant-free survival was 74% (95% CI 56 to 92) and two-year transplant-free 
survival was 64% (95% CI 44 to 84) (log rank test p=0.002; Figure 2). Thus, a 6MWD% lower 
than 63% was associated with an increased risk of heart transplantation or death (hazard 
ratio 10.8; 95% CI 2.4 to 49).
Table 2. Repeated measurement of 6MWT, comparing patients with a study endpoint to patients 
without a study endpoint
All patients (n=57) SE (n=14) no SE (n=43) p-value
Time Dx-fist 6MWTb 3.6 (0.5-7.1) 3.2 (0.4-6.8) 3.6 (0.5-7.4) 0.81
Time last 6MWD% to 
PEP or end of studyb
0.08 (0.0-0.46) 0.25(0.16-0.77) 0.00(0.00-0.38) 0.004
Total FU timeb 3.0 (1.3-5.1) 1.3 (0.2-2.1) 3.8 (2.1-5.3) 0.007
Number of 6MWT per 
patient
4 (2-6) 3 (1-6) 4 (2-7) 0.70
Number of 6MWT per 
year follow-up
2.7 (1.0-2.9) 3.7 (2.4-6.6) 1.6 (0.9-2.5) 0.004
SE Study Endpoint, Dx diagnosis
All numbers are median and Inter Quartile Range (IQR) 
a  percentage of predicted,  calculated according to Geiger(6)
b years
Comparison of patients with SE vs patients without SE using Mann-Whitney test
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At any time during follow-up, the average estimate of 6MWD% was significantly lower 
in patients with a study endpoint compared to patients without a study endpoint 
(Figure 3.). Furthermore, we found no meaningful change in 6MWD% over time both in 
patients with and without a study endpoint (Figure 3.). Notably, in patients who reached 
an endpoint, 6MWD% did not change over time and did not suddenly decrease prior to 
the endpoint. When we plotted the results of the 6MWD% against years since diagnosis, 
we also found that they were constant over time (Figure 4.), indicating that there was no 
systematic difference in the results obtained early and later after diagnosis. The variability 
of the 6MWD% within the individual patient was considerable (Fig 5.), suggesting that 
obtaining more than one 6MWT would be useful to obtain a reliable mean estimate of the 
patient. An absolute 1% lower 6MWD% was associated with a 11% higher risk (hazard) of 
the study endpoint (HR 0.90, 95% CI 0.86-0.95 p<0.001). In clinical practice this means that 
when comparing 2 patients at any given moment after diagnosis, the one with a 1% lower 
6MDW% has an 11% increased risk of death or HTx.
Figure 3. Serial measurement of 6MWD expressed as percentage of predicted, time before study 
endpoint. 
The average estimates of the longitudinal trajectory of 6MWD%: the black line indicates the patients 
without a study endpoint, the red line the patients with a study endpoint. The dashed lines depict 
the 95% confidence interval.
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Figure 4. Serial measurement of 6MWD expressed as percentage of predicted, time since diagnosis
The average estimates of the longitudinal trajectory of 6MWD%: the black line indicates the patients 
without a study endpoint, the red line the patients with a study endpoint. The dashed lines depict 
the 95% confidence interval.  
Figure 5 Serial measurement of 6MWD expressed as percentage of predicted, time before study 
endpoint.
 
The average estimates of the longitudinal trajectory of 6MWD%: the black line indicates the patients 
without a study endpoint, the red line the patients with a study endpoint. The dashed lines depict 
the 95% confidence interval. The individual patients are plotted, the colored lines indicate the 
patients with the study endpoint. 
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DISCUSSION
In this study we confirm the usefulness of the 6MWT as a tool to identify children with DCM 
at a high risk of adverse outcome. In the studied timeframe, 6MWD% was significantly 
lower in patients who reached the study endpoint of death or HTx, compared to those 
who did not. The 6MWD% remained constant throughout three years of observation, 
both in patients who reached the study endpoint, and in those who did not. As 6MWD% 
tends to vary within the individual patient, at least two 6MWTs seem to be needed to 
obtain a reliable adequate indication of 6MWD%. Thereafter, repeating the 6MWT seems 
to have little added value.
In adult heart failure literature, data on the use of serial 6MWT is scarce, but a number of 
studies have shown that repeating 6MWT is useful to evaluate effectiveness of therapeutic 
interventions. A short term improvement in 6 MWD after a drug intervention in hospitalized 
patients with chronic heart failure, was a significant independent predictor of survival 
(2). Likewise, in patients with moderate to severe heart failure, cardiac resynchronization 
therapy results in significant improvement in 6MWD and in survival (3). In contrast, in the 
majority of trials that were reviewed, the 6MWD did not increase after a pharmacological 
intervention in patients with chronic stable heart failure (13). Combining both findings 
would indicate that repeating the 6MWT is helpful to evaluate the effect of a therapeutic 
intervention on survival in patients with moderate to severe heart failure. 
Upfront, we expected that 6MWD% would decrease in the patients who reached an 
endpoint. Also, we hypothesized that 6MWD% might increase in the combined group of 
patients who recover or have ongoing disease.  However, our results did not confirm these 
expectations as 6MWD% was stable from early after diagnosis onward, both in children who 
reached an endpoint and those who did not. Moreover, it was significantly lower in those 
reaching an endpoint throughout the time of observation (Fig. 3). Notably, 6MWTs were 
only obtained in patients who were relatively stable. In two potentially unstable phases of 
the disease, directly after diagnosis and shortly before death or HTx, a substantial number 
of patients did not perform a 6MWT. Sixteen percent of potentially eligible patients never 
performed a 6MWT, because they were too ill and reached an endpoint before a 6MWT 
could be done. In that respect, not being able to perform a 6MWT can be considered an 
ominous sign. On the other end of the spectrum, most patients who did perform one or 
more 6MWT and reached an endpoint within the study period, did not perform a 6 MWT 
in the last phase of the disease: 8 of the 14 children with a study endpoint were listed for 
HTx after the last available 6MWT, and were hospitalized awaiting transplantation.
There are several limitations to this study. Firstly, we could not obtain a 6MWT in a number 
of patients due to logistical difficulties that come with a multicenter study. However, the 
14 patients we missed were not significantly different from the study cohort in terms 
of age, gender, cause of DCM, NYPHFI and percentage of study endpoints (results not 
shown). We believe therefore that the study cohort was an unbiased selection and that 
missing 6MWTs have not led to an important change in the results and conclusions of our 
study. Secondly, the studied cohort is relatively small, though compared to other pediatric 
studies using 6MWT to predict outcome comparable or larger in the number of children 
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that we studied and the number of 6MWTs that were obtained. REFS Moreover, it is the first 
study on serial measurements of 6MWD% in children with DCM.  Nevertheless, one could 
hypothesize that in a study with a larger cohort of children with DCM patients, we would 
have been able to demonstrate that 6MWD% significantly changes over time and that this 
change would identify patients with a higher risk of reaching an endpoint.  The graph in 
Figure 3, however does not provide much support for that idea as it depicts that there is 
no change at all over time in 6MWD%, in both groups. We pose that expanding the study 
cohort would not lead to a fundamental change in the results we found. Thirdly, the great 
majority of study endpoints reached in this study was HTx, the number of deaths was low. 
This is in line with other studies reporting on outcomes in children with DCM, showing 
that in general, deaths occur relatively early after diagnosis and that HTx takes place later 
after diagnosis (14-16). In this respect it is fair to state that 6MWTs identify the patients at a 
high risk for HTx rather than the patients at a high risk to die. Fourthly, a similar amount of 
6MWTs were performed in children who did and did not reach a study endpoint, but the 
6MWT were performed in a shorter time frame. This reflects the clinical practice in which 
the most seriously affected children are seen more often at the outpatient clinic. Lastly, 
the patient cohort we studied contains a low number of children that recover compared 
to our previous reports and large cohorts of children with DCM. The fact that children 
under 6 years were not included in this study is probably an important explanation as 
recovery in this age group is relatively common (14-17). 
We conclude, that based on the current study, 6MWT is a useful tool to identify children 
with DCM at a high risk of death or heart transplantation. In children who are able to 
perform a 6MWT, 6MWD% remains constant over time, early after diagnosis and in the 
years thereafter. In those reaching an endpoint, 6MWD% is significantly lower throughout 
time, than in those not reaching an endpoint. Initially, at least 2 6MWT are needed to 
reliably estimate 6MWD%, thereafter repeating 6 MWT has little added value.
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ABSTRACT
AIMS We aimed to determine whether in children with dilated cardiomyopathy (DCM) 
repeated measurement of known risk factors for death or heart transplantation (HTx) can 
identify children at the highest risk for adverse outcome.
METHODS AND RESULTS Of 137 children we included in a prospective cohort, 36 (26%) 
reached the study endpoint (SE: all-cause death or HTx), 15 (11%) died and 21 (15%) 
underwent HTx. Median follow-up was 2.1 years [IQR 0.8-4.3]. Children who reached the 
SE can be distinguished from those who do not, based on the temporal evolution of 4 
risk factors: stunting of length growth (-0.29 vs -0.04 length Z-score/year), less decrease 
in N-terminal pro-B-type natriuretic peptide (NT-proBNP) (-0.19 vs -0.41 2log pg/mL/year), 
no decrease in Left Ventricular Internal Diastolic Dimension (0.14 vs -0.23 Boston Z-score/
year) and increase in New York University Pediatric Heart Failure Index (0.36 vs -0.49/year). 
When we compared children who reached the SE to those with ongoing disease (leaving 
out the children who recovered) we found similar results, though the effect was smaller. 
In multivariate models, NT-proBNP appeared the only independent predictor for adverse 
outcome, a twofold higher NT-proBNP was associated with an 2.8 times higher risk of the 
SE (HR 2.78, 95% CI 1.81 to 3.94, p<0.001).
CONCLUSION The evolution over time of NT-proBNP, LVIDd, length growth and NYU 
PHFI identified a subgroup of children with DCM at high risk for adverse outcome. In this 
sample, with a limited number of endpoints, NT-proBNP was the strongest independent 
predictor for adverse outcome.
5Repeated measurements of known risk factors 
81
INTRODUCTION
In children with dilated cardiomyopathy (DCM), up to 50% of children die or undergo 
heart transplantation (HTx) within 5 years after diagnosis (1-3).
To recognize the children at the highest risk for adverse outcome is essential as these 
are the patients who should be monitored closely and, importantly, be listed for heart 
transplantation at a timely stage.
Worldwide, several large pediatric DCM cohorts have reported risk factors for adverse 
outcome and identified older age (>6 year), worse left ventricular fractional shortening, 
congestive heart failure at presentation, idiopathic DCM and higher N-terminal pro-B-
type natriuretic peptide (NT-proBNP) as risk factors for death or transplantation (1-4). 
Previously, we reported on similar risk factors in our national cohort of children with DCM 
(5-8), which we determined at the time of inclusion. However, changes in these risk factors 
during the course of the disease, such as the level of NT-proBNP or echo-derived fractional 
shortening, might be predictive of adverse outcomes as well (2, 6, 9).
In this present study we prospectively and repeatedly collected established clinical 
and echocardiographic risk factors for death and transplantation in a national cohort 
of children with DCM. We explored the temporal evolution of these factors, as these 
potentially hold relevant information for clinical decision making.
METHODS
Patients
Data were collected in a multi-center, prospective study design. Patients from eight 
tertiary cardiac centers were included from October 2010 to July 2017. We enrolled 
children with prior (until 2010) or new diagnosis (from 2010 onward). DCM was defined 
as the presence of impaired systolic function based on echocardiography: a fractional 
shortening (FS) ≤25% in combination with a left ventricular (LV) end-diastolic dimension 
(LVEDD)> +2 Z-score for body surface area. Patients with structural heart disease or 
neuromuscular disease were excluded. Data were collected during routine outpatient 
clinic visits or coincided with hospital admissions. In the first year after diagnosis patients 
were evaluated 1 to 4 times per year, and 1 to 2 times per year thereafter, depending on 
the frequency of outpatient visits. Subjects were followed until death or HTx, until the 
age of 18 years, or until the last outpatient visit within the study window. This study was 
approved by the Medical Ethical Committee of the Erasmus MC (MEC 2014-062) and was 
performed in accordance with the declaration of Helsinki. All parents as well as children 
≥12 years gave written informed consent.
Study variables
In this study we focused on 6 known risk factors for adverse outcome.
NT-proBNP: NT-proBNP values were measured using the Roche® assay in all participating 
centers.
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New York University Pediatric Heart Failure Index (NYU PHFI): pediatric heart failure score 
that quantifies the degree of heart failure in terms of symptoms and medication use and 
ranges from 0-30 points (10). The treating pediatric cardiologist completed the NYU PHFI.
Length Z-score: length was normalized to Z- scores using growth analyser©, which is based 
on reference values for Dutch children(11).
Left Ventricular Internal Diastolic diameter (LVIDd): a standardized echocardiogram was 
performed and data was analyzed using the mean value of three consecutive cardiac 
cycles. Echocardiograms were analyzed by study personnel who were blinded to the 
patient’s name, previous echocardiograms, and other study results. The LVIDd was 
normalized to a Boston Z-score for BSA, age and gender (12).
Global longitudinal Strain (GLS): GLS was calculated as the mean of the peak strain of all 
left ventricular segments in a longitudinal 6-segment model as previously described (8).
6-minute walking distance (6MWD%): The distance walked within 6 minutes on a 8-meter 
track was recorded and expressed as percentage of predicted (6MWD%) according to 
Geiger et al, accounting for height, gender and age (7, 13).
The clinical team was blinded to the results of the 6MWD% and GLS, the other study 
variables were readily available. In addition to the above mentioned study variables, 
DCM etiology, age at diagnosis, weight (normalized to Z-score), and current heart failure 
medication was collected as well. Genetic etiology was defined as the presence of a 
mutation in a known pathogenic DCM gene. Myocarditis was accepted as etiology if 
diagnosis was definite or probable (14). 
Study endpoint
The study endpoint (SE) was all cause death or HTx. We also recorded the status of the 
surviving patients at the end of the study period: ongoing disease or recovered. Recovery 
was defined as 2 consecutive echocardiograms with normalized LVIDd and FS, the date of 
the first normalized echocardiogram was considered as date of recovery.
Statistical analysis 
Continuous variables with normal distribution are described as mean (standard deviation, 
SD), or as median (interquartile range, IQR) otherwise. Categorical variables are described 
as numbers and percentages. Differences in characteristics between patients with and 
without the study endpoint were compared by Student’s t-tests (normal distribution) 
or Mann-Whitney tests. We applied the method of Kaplan-Meier to study survival and 
transplant-free survival.
To explore the temporal evolution of the study variables, while accounting for the 
correlation between measurements in the individual patient, we applied a linear mixed 
effects model (LMEM) for longitudinal data. To study the association between study 
variables (repeatedly measured) and the study endpoint, we subsequently combined the 
LMEM with a Cox proportional hazard regression model in a so-called joint model (JM). 
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In the multivariable joint model, we included stepwise the studied risk factors starting 
with NT-proBNP based on the fact that NT-proBNP has shown to be a robust marker 
for outcome. To further characterize the children who reached the study endpoint, we 
compared them with the patients who remained endpoint free, but still had ongoing 
disease at the end of the follow-up period, thus leaving out the children who recovered. 
Temporal evolution of the study variables was studied, in the same way as described 
above. The level of statistical significance for all analyses was set at p=0.05. Analyses were 
performed using IBM SPSS statistics 24 (IBM, New York, USA) and R statistical software 
version 3.5.1 (package JMbayes).
RESULTS
Patients and clinical outcome
A total of 137 children with DCM were included, 3 patients were lost to follow up. Of these 
137 children, 96 were included directly after diagnosis, whereas 41 children had a prior 
diagnosis. Thirty-six children (26%) reached the study endpoint (SE), 15 children (11%) died 
and 21 children (15%) underwent transplantation. Seventeen children reached a study 
endpoint within 1 year after diagnosis (12 died and 5 underwent transplantation), and 9 
of those 17 early endpoints were reached within 1 month after diagnosis (7 children died 
and 2 were transplanted). The majority of deaths occurred within 1 year after diagnosis, 
12 out of 15 (80%). Median time from diagnosis to death was one month (0.09 years [IQR 
0.03-0.7]), median time to HTx was 2.9 years [IQR 0.8 to 6.1]. At some stage, during the 
first year after inclusion, the majority of children was on heart failure medication: 84% 
of children was on an ACE-inhibitor, and 65% was on a β-blocker and 87% was on one of 
both. Sixteen of seventeen children who were not on heart failure medication reached a 
SE before medication could be started. All medication was up-titrated to the maximum 
tolerated dose at the discretion of the treating physician.
At the end of the study, after a median follow-up of 3.0 years [IQR 1.5-4.7], 23 children 
(24% of newly diagnosed patients) had recovered and 78 children (57%) had ongoing 
disease. Time from diagnosis to recovery was 0.6 years [IQR 0.5 to 1.4]. When comparing 
children who reached a SE and those who did not, we found no important differences in 
patient - and clinical characteristics, see Table 1.
One-year survival after first diagnosis was 88% (95% CI 83 to 95%) and 5-year survival of 
82% (95% CI 74 to 90%). The transplant-free survival was 82% (95% CI 74 to 89%) after 1 
year and 72% (95% CI 62 to 82%) after 5 years (Supplementary Figure 1).
In the children with a previous diagnosis (n=41), 13 patients (32%) reached a study 
endpoint, 2 children died and 11 patients underwent transplantation. Median time from 
diagnosis to inclusion was 3.8 years [IQR 2.5 to 8.7] years, median time from diagnosis 
to SE was 6.0 years [IQR 3.1to 9.7] year. At the end of the study, 28 patients had ongoing 
disease and no patient had recovered.
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Table 1. Patient - and clinical characteristics at the time of diagnosis, comparing children who died 
or underwent transplantation with children who survived without transplantation 
Study Endpoint
N=36
No Study Endpoint
N=101
Age, years, IQR)* 5.3 [0.2-11.3] 0.9 [0.1-4.8]
< 1 year, n (%) 14 (39) 50 (49)
1 to < 6 years, n (%) 5 (14) 28 (28)
 6 to < 18 years, n (%) 17 (47) 23 (23)
Female** 23 (64) 45 (45)
Time Dx to study inclusion, years, [IQR]* 0.01[0.0-2.5] 0.05 [0.0-2.3]
Time inclusion to last FU, years [IQR]* 0.15 [0-1.7]† 3.0 [1.5-4.7]
Time diagnosis to last FU 1.3 [0.1-4.3] † 3.5 [2.0-6.1]
Primary diagnosis, n (%)
Idiopathic 15 (42) 47 (47)
Myocarditis 2 (6) 18 (17)
Other 19 (53 36 (36)
Weight for age, Z-score, mean (SD)*** -0.6 (1.7) -0.8 (1.3)
Weight for height, Z-score, mean (SD) -0.4 (1.5) -0.4 (1.8)
Height for age, Z-score, mean (SD) -0.4 (1.4) -0.5 (1.5)
Shortening fraction (%) 13 (9-16) 16 (12-20)
IQR Inter Quartile Range, Dx diagnosis, FU Follow Up
* Mann-Whitney U test ** Chi square test
*** Weight for age only in children under 15 months (n=43)
† p < 0.05 
Differences in risk factors, SE vs no SE
At the moment of first diagnosis, children who ultimately reached the SE had an 
unfavorable clinical profile compared to those who remained event-free. In particular 
(mean) NT-proBNP levels and NYU PHFI scores were higher, whereas global longitudinal 
strain and 6MWD% were lower (Table 2).
The temporal evolution of 4 risk factors was clearly different between children with and 
without the SE (Table 2; Figure 1). NT-proBNP levels, LVIDd and NYU PHFI score remained 
high in those who reached the SE, while event-free children showed (steadily) decreasing 
values. Furthermore, length growth was severely stunted in children with the SE, while a 
normal length growth was maintained over time in their event-free counterparts.
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Figure 1. Serial measurement of risk factors: NT-proBNP (2log pg/mL), Length Z-score, LVIDd Boston 
Z-score, Global longitudinal strain (%), 6MWD% (%) and NYU PHFI
The average estimates of the longitudinal trajectory risk factors: the black line indicates the patients 
without a study endpoint, the red line the patients with a study endpoint. The dashed lines depict 
the 95% confidence interval. The colored lines show the individual patients with a study endpoint.
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Figure 2.Serial measurement of risk factors: NT-proBNP (2log pg/mL), Length Z-score, LVIDd Boston 
Z-score, Global longitudinal strain (%), 6MWD% (%) and NYU PHFI
The average estimates of the longitudinal trajectory risk factors: the black line indicates the patients 
with ongoing disease, the red line the patients with a study endpoint. The dashed lines depict the 
95% confidence interval. The colored lines show the individual patients with a study endpoint.
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Differences in risk factors, SE vs ongoing disease
Comparable differences between patients with and without SE were observed in a 
sensitivity analysis that excluded the patients who clinically recovered, although effect 
sizes were smaller (Table 3; Figure 2). Thus, in children with the SE the mean value at the 
time of diagnosis of NT-proBNP and NYU PHFI were significantly higher, and GLS and 
6MWD% were significantly lower. Furthermore, in children with the SE, NT-proBNP, LVIDd 
and NYU PHFI all remained high, while in the children without the SE all decreased over 
time. Length Z-core indicated that in children who reached an endpoint length growth 
was severely stunted, while in those with ongoing disease growth was less severely 
impaired.
Risk factors for death or heart transplantation (Table 4)
Factors that were associated with an increased risk of death or heart transplantation 
included age older than 6 years at diagnosis and at any time during follow up: NT-proBNP, 
length Z-score, LVIDd Z-score, global longitudinal strain, 6MWD% and NYU PHFI. In 
multivariable analyses, 6MWD% appeared the only risk factor that was independent of 
NT-proBNP.
Table 4. Risk factors for the composite study endpoint of death or heart transplantation
No. patients No. repeated 
observations
No. 
endpoints
HR 95%CI P-value
Age over 6 years 137 -- 36 3.97 (1.94, 8.15) <0.001
Idiopathic DCM 137 -- 36 0.79 (0.41, 1.55) 0.502
NT-proBNP (2log pg/mL) 113 605 32 2.78 (1.81, 3.94) <0.001
Length Z-score 133 880 36 0.77 (0.56, 1.06) <0.001
LVIDd Boston Z-score 126 540 33 1.29 (1.12, 1.52) <0.001
Global longitudinal strain (%) 110 384 22 0.45 (0.34, 0.77) <0.001
6MWD% (%) 55 249 14 0.91 (0.86, 0.95) <0.001
NYU PHFI * 129 755 33 3.16 (2.25, 4.52) <0.001
Age over 6 years
113 605 32
2.96 (0.65, 12.5) 0.113
NT-proBNP (2log pg/mL) 2.86 (2.01, 3.71) <0.001
Idiopathic DCM
113 605 32
1.78 (0.36, 11.9) 0.391
NT-proBNP (2log pg/mL) 2.89 (1.76, 3.99) <0.001
Length Z-score
112 605 32
1.09 (0.65, 1.81) 0.712
NT-proBNP (2log pg/mL) 6.96 (3.74, 1.30) <0.001
LVIDd Boston Z-score
109 602 30
0.92 (0.74, 1.10) 0.376
NT-proBNP (2log pg/mL) 7.74 (4.03, 16.5) <0.001
Global longitudinal strain (%)
95 549 19
0.89 (0.74, 1.06) 0.234
NT-proBNP (2log pg/mL) 8.33 (3.76, 20.5) <0.001
6MWD% (%)
44 286 13
0.95 (0.89, 1.00) 0.046
NT-proBNP (2log pg/mL) 8.34 (3.76, 20.5) <0.001
NYU PHFI *
106 508 29
0.78 (0.29, 2.63) 0.618
NT-proBNP (2log pg/mL) 10.9 (3.65, 35.6) <0.001
DCM: dilated cardiomyopathy; CI: confidence interval; HR: hazard ratio
* After Box-Cox transformation
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DISCUSSION
In this study we found that the temporal evolution of 4 risk factors distinguished the 
children who died or underwent transplantation from those who have ongoing disease 
or recover: no decrease in NT-proBNP or LVIDd, a severe decrease in length Z-score, and 
an increase in NYU PHFI. Similarly, when comparing children who reached an endpoint 
with children with ongoing disease solely, excluding those who recovered, we found 
comparable differences in the evolution of risk factors, although the effect size was 
smaller. In the multivariate analysis, NT-proBNP remained the only independent risk factor 
for adverse outcome.
We performed 2 analyses and excluded the children who recover in the secondary analysis 
because, in general, children who recover tend do clinically well at a relatively early stage 
after diagnosis. The clinical challenge is to identify within the group of children those who 
do not recover, who are at the highest risk for adverse outcome and should be considered 
for HTx. In this study, 23% of the children, who newly presented, recovered and median 
time from diagnosis to recovery was 0.6 years and confirmed that recovery tends to be 
an early event (1, 3). This the first study to our knowledge to analyze this subgroup of 
children who remain ill but do not reach the SE. The finding that the abovementioned 
risk factors also discern these children from those who reached a SE supports outpatient 
management and the decision to suspend listing for HTx.
In the adult counterpart of pediatric dilated cardiomyopathy, non-ischemic 
cardiomyopathy, studies of risk factors for outcome have focused on the prevention of 
sudden cardiac death (15). However, in children with dilated cardiomyopathy the risk 
of sudden cardiac death is considerably lower than in adults, and most children die or 
undergo HTx because of pump failure (16). Studies on risk factors for adverse outcome 
in adult non-ischemic heart failure secondary to pump failure are, therefore, potentially 
better comparable to the results of the pediatric studies. In parallel with the risk factors 
we noted in pediatric DCM, natriuretic peptides, including NT-proBNP, have been shown 
robust prognostic markers for outcome in adult heart failure, including also in the non-
ischemic subgroup (17-19). Longitudinal strain on CMR imaging has documented 
incremental predictive value for adverse events in addition to LGE and indexed LV end-
diastolic volume (20). In contrast, LV dimension has not been identified as a solid marker 
for adverse events (21). However, in patients demonstrating reverse remodeling, LV 
dimensions at presentation were lower and significantly decreased over time (22). The six-
minute walking test at presentation and the change during follow-up has been associated 
with heart failure outcome (23). However, the application of the test in adults has been 
limited, but may be useful in those with severe heart failure (24).
When comparing the results of the above-mentioned adult reports to the results of our 
study, NT-proBNP also remains a strong predictor of outcome in pediatric DCM. Even 
after exclusion of the children who recovered, the differences in temporal evolution of 
NT-proBNP remained significant in the univariate model. In this study we reported a 
difference in NT-proBNP at diagnosis between children who reached the SE versus those 
who did not. This seems to contradict our previous publication in which we reported no 
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difference in NT-proBNP at diagnosis (6). A likely explanation is the steep decline of NT-
proBNP in children without the SE in the first 30 days after diagnosis, as shown by den 
Boer et al (6). In this study we analyzed the data in one timeframe, and the linear model 
underestimated NT-proBNP at diagnosis. We could confirm this as median NT-proBNP at 
diagnosis were not different in standard statistical tests (results not shown). Our results 
further corroborate the association of NT-proBNP and outcome in children and adults 
with heart (6, 17, 25-27). Whether the evolution of NT-proBNP truly is the only predictor of 
outcome or whether the other risk factors also hold independent predictive information 
remains to be studied in a larger cohort or with longer follow-up. Moreover, our findings 
apply to the mid-term outcome with a median time after diagnosis to last follow up of 
3.5 years. In addition, we found that the 6MWD% was independently associated with 
outcome, but this should be interpreted with some constraint as the number of children 
(> 6 years of age) who performed a 6MWD test was limited.
Although in the multivariate analysis all risk factors but NT-pro BNP lost their association 
with the SE, the temporal evolution of the other 3 risk factors still holds important 
information. First, LVIDd in children who reached an endpoint did not change over time in 
contrast to children not reaching an endpoint where LVIDd decreased, even after exclusion 
of children who recovered (Table 2 and 3). Temporal evolution of global longitudinal strain 
cannot be used to predict outcome because the slopes are not different in the two analyses. 
However, GLS at the time of diagnosis still might be useful. In the model in the intercepts 
of global longitudinal strain were significantly different between the two groups (Table 2 
and 3), suggesting that early after presentation it may be an indicator for outcome. That 
observation is compatible with our previous report that lower global longitudinal strain 
was associated with an increased risk of death or heart transplantation in a cross-sectional 
sample and similar to observations in adults with chronic heart failure (8, 28). The second 
and the third risk factor specifically pertain to the pediatric population: length Z-score 
and a pediatric heart failure score (NYU PHFI). Length growth is considered a solid proxy 
for overall health in children and provides a long-term reflection of disease severity. The 
development of length Z-score distinguished children who reached an endpoint from 
those with ongoing disease (Table 3). In clinical practice, length growth virtually ceased 
in children reaching an endpoint. Similarly, Alvarez et al reported that small height-for-
age was associated with a risk of death, but not for being listed for transplantation, also 
suggesting that length growth may be a useful indicator for disease severity in these 
children (3). Previously we reported that NYU PHFI independently predicts death and HTx 
in children with DCM in a cross-sectional sample (29). Now we have demonstrated that 
children who reach the SE were characterized by an increase in NYU PHFI opposed to 
those with ongoing disease.
In the light of the interpretation and generalization of our findings it is important that 
after the first year after diagnosis the (transplant free) survival curves of the PCMR and the 
NACCS are similar to ours (1, 2). We have previously reported a low HTx rate in children 
with DCM in the first year after diagnosis, without an increase in mortality (5). The data 
presented in this study confirm that finding and support the idea that a low early HTx 
rate does not lead to an increase in mortality or Htx rate in the years following diagnosis 
as a result of postponing HTx. This implies that the children with DCM in both cohorts are 
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comparable in disease severity. The results we found would therefore be applicable in 
other populations of children with DCM, after the first year after diagnosis.
Study limitations
This study has limitations. First, our study cohort is a combination of 2 cohorts and consists 
of children with a prior diagnosis before inclusion in this study, as well as children who are 
included directly after diagnosis. This may have induced a selection bias. However, the 
outcome of the cohort of newly diagnosed children that we included (Suppl. Figure 1) 
is the same as the outcome of the children that we previously reported that presented 
between 2005-2010 indicating that the large majority of children that we included with 
a prior diagnosis were obtained from a cohort with the same characteristics (5). Second, 
missing data was an issue. In particular, 6MWD% could only be obtained in outpatient 
children older than 6 years. Thirdly, the number of endpoints was limited which hampered 
multivariate analysis. Lastly, the decision to list a patient for HTx is based on multiple 
clinical factors. It could be that the reported risk factors predict decision-making by 
clinicians rather than outcome. However, the children that underwent HTx were in such a 
condition that they most likely would have died otherwise (30).
Conclusion 
In summary, we conclude that in children with DCM, change over time in known risk factors 
for death or HTx is predictive for outcome. In children who do not recover, persistent high 
levels of NT-proBNP, no decrease in LVIDd, severe stunting of growth and an increase in 
the heart failure score identifies those at the highest risk for death or HTx. In this study, 
with limited study endpoints, we identified NT-proBNP as the strongest independent 
predictor for adverse outcome.
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Supplementary figure 1. Kaplan-Meier plot showing survival and transplant-free survival since 
diagnosis of 96 newly diagnosed children with DCM
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SCENARIO
A 1-year-old boy, recently diagnosed with dilated cardiomyopathy, has to be treated 
with Enalapril according to the heart failure protocol. The physician wants to know which 
adverse events she can expect. 
Structured Clinical Question
What are the potential adverse events related to administration of an ACE-inhibitor to 
children with heart failure, what is the prevalence and what are the possible risk factors.
Search
Secondary sources – nil
Electronic databases (Pubmed/Medline and Embase) and reference lists of relevant 
articles were searched with the following strategy: ’angiotensin-converting enzyme 
inhibitors’ and ‘heart failure’ and ‘children’. The search yielded 415 individual articles, of 
which 14 were identified as relevant.
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SUMMARY 
Table 1. Summary of study results
Citation Study group Study type Outcome Key Result Comments
Scammell et al
Int J Cardiol
1987;16(3):
295-301(1)
18 infants, 4 - 41 
weeks, CHD and 
HF
Retrospective 
Cohort (4)
Hypotension ‘Mild’ in 
11% (Mild 
defined as ‘no 
resuscitation 
needed”) A*
Captopril 
considered safe.
Neutropenia nil
Skin rash nil
proteinuria nil
Loyd et al
The Journal of 
Pediatrics
1989 114 (4):650-
654 (2)
10 infants, 
6 weeks - 8 
months, CHD 
with HF, effect of 
different doses 
on enalprilat 
concentrations 
and AEs, on 
enalapril
Clinical Trial
(3b)
Incidence of 
hypotension
nil Enalapril in 3 
relatively low 
doses: 0.02 ; 0.04 
and 0.08 mg/kg.
Rise in Serum 
creatinin
nil
Incidence of 
proteinuria
nil
Decrease in 
urine volume
nil
Dutertre et al
Br J Clin Pharmacol
1993; 35(5): 528-
30 (3)
18 infants, 
3 weeks - 6 
months, 
CHD with HF, 
comparing 
baseline ACE 
activity in 8 
children on 
enalapril and 10 
controls,
Clinical Trial 
(3b)
Incidence of 
hypotension
nil AEs including 
renal 
dysfunction or 
hyperkalemia 
were not 
evaluated.Incidence of 
vomiting
6%, E*
Leversha et al
Arch Dis Child 
1994 70(1):35-39 
(4)
63 children, 1 
week -17 years, 
CHD with HF, on 
enalapril
Clinical Trial 
(3b)
Incidence of 
renal failure
8 of 63 (13%) 
6 rise in creat 
and 2 oliguria, 
all D*
Renal failure in 
eight patients
was related to 
young age, low 
weight, and
left-to-right 
shunt group. 
Three patients
died in 
congestive 
heart failure 
with renal
failure.
Incidence of 
hypotension
9 of 63 (14%), 8 
(89%) in C* and 
1 (11%) in D*
Other SAE’s 1 cough and 1 
neutropenia
Both A*
Gantenbein et al
J Perinat Med 
2008; 36 (5): 448-
52 (5)
43 infants of 1-44 
weeks, CHD with 
HF, on captopril
Retrospective 
cohort (4)
Incidence of 
renal failure
6 of 43 
(14%) renal 
impairment or 
failure, 4 (67%) 
in C* or D*
Renal side 
effects occurred 
more often in 
smaller infants.
Incidence of 
hypotension
8 of 43 (19%)1 
(13%) in C* 
or D*
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Hsu et al 
Circulation
2010; 122(4):333-
340 (6)
185 infants, 
1-6 weeks with 
single ventricle 
physiology, on 
enalapril
Randomized 
controlled trial 
(3b)
Incidence of 
renal failure
1 of 185 (0.5%) 
E*
No difference in 
the number of 
adverse events
between the 
treatment 
groups (423 in 
the enalapril 
group and
389 in the 
placebo group; 
P=0.23).
Orchard et al
Arch Dis Child 
2010; 95(7):566-
7 (7)
66 infants, 6 
weeks-8 months, 
heart failure 
(cause unknown), 
on enalapril
Clinical trial 
(3b)
Incidence of 
renal failure
nil Hypotension 
was
well tolerated 
and only 
two patients 
discontinued
captopril.
Incidence of 
hyperkalemia
nil
Incidence of 
hypotension
10 of 66 (15%) 
showed a > 
25% drop in 
blood pressure, 
2 of which 
(20%) in D*
Lindle et al
Pediatr Cardiol 
2013; (8)
206 children, 
16–18 days (20% 
preterm), 95 % 
CHD with HF, 
on enalapril or 
captopril
Retrospective 
cohort (2b)
Incidence of 
renal failure
29% failure 
according 
to ipRIFLE 
definition, E*
Premature 
neonates were 
more likely to
experience ACE-
i-related renal 
failure (55%) 
than
their term 
counterparts 
(23%; 
p < 0.001).
Incidence of 
hyperkalemia
rise of K from 
4.2 to 5.7 
mEq/L), no 
hyperkalemia, 
E*
Terano et al
Eur J Pediatr 2016; 
175(5):631-7 (9)
312 children, 
2 months - 13 
years, 86% CHD 
with HF and 8% 
myoarditis with 
HF, on enalapril, 
captopril or 
lisinopril
Retrospective 
cohort (2b)
Incidence of 
AKI
45 of 312 (14%) 
AKI 2-3, E*
Younger age, 
myocardial 
disease, 
cyanotic 
congenital 
heart disease, 
concomitant 
use of 
spironolactone, 
and cardiac 
surgery were 
risk factors for 
AKI.
Incidence of 
hyperkalemia
14/312 (5%), K≥ 
5.5 mmol/L, E*
Roche et al
J Am Heart Assoc. 
2016;5:e003230 
(10)
46 infants, 2.3 
± 4.7 years, 
(82% HF, 13% 
pulmonary 
overflow) 
comparing a 
rapid (RU) versus 
prolonged 
uptitration (PU) 
protocol of ACE-i
Clinical trial 
(3b)
Symptomati-
chypotension
RU: 28%, E*
PU: 10%, E*
No significant 
difference 
between 
incidence of 
adverse events 
between the RU 
and PU group.
Serum creat 
increase  > 2x 
baseline
RU: 0%, E*
PU:5%, E*
Serum 
potassium > 5 
mmol/L
RU:8%, E*
PU:5%, E*
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Ku et al
Pediatr Cardiolo
2017; 38:155–161 
(11)
662 neonates,
< 120 days 
postnatal 
age, exposed 
to enalapril, 
indications 
unknown, CHD 
excluded
Retrospective 
Cohort
(2b)
Incidence of 
adverse events
142 (21%), E* Significant 
risk factors for 
adverse events 
were postnatal
age < 30 days 
at first exposure 
and longer 
exposure
duration.
Incidence of 
hyperkalemia
Serum 
potassium > 
6 mmol/L in 
13%, E*
Incidence of 
renal failure
Serum creat  > 
1.3 mg/dL in 
2%, E*
Incidence of 
hypotension 
requiring 
inotropes
4%, E*
Incidence of 
death
0.5%, E*
In bold, the studies with adverse effects as primary outcome
CHD: congenital heart disease; HF: heart failure; AKI: acute kidney injury
* In key results, categories of measures taken following AEs: A. no dose change, B. dose interruption, 
C. lowering of dose, D. discontinuation of ACE-i, E. unknown or not applicable
Commentary
Heart failure is an important cause of morbidity and mortality in children (12).
It is commonly treated with ACE-inhibitors (ACE-i) despite the lack of evidence on 
its efficacy (13). This treatment is based on the assumption that blocking of the renin-
angiotensin-aldosterone system has a positive effect on morbidity and mortality, as it 
does in adults with heart failure (14-17). In adults, the most prevalent adverse events (AEs) 
related to the use of ACER-i are renal failure (18, 19), hypotension (20, 21), hyperkalemia 
(20, 22), cough (23) and angioedema (24). It is assumed that the safety profile of ACE-i 
differs for children and differs from that for adults, but also for children of different ages, 
as growth and development contribute to variation in the disposition and effect of most 
drugs administered to children (25).
Our search yielded seven studies (1, 5, 7-11) in which the primary outcome was AEs of 
ACE-i. The other seven studies included, either described the actual AEs, or did not report 
whether they specifically looked into the AEs. One of the studies was a randomized 
placebo-controlled trial, one a randomized clinical trial, 4 were clinical trials, and 5 were 
retrospective cohort studies (Table 1). The total number of patients in these studies 
was 1629, in the age range from 1 week to 17 years. The prescribed ACE-inhibitors were 
enalapril (n=1050 patients), captopril (n=409), lisinopril (n=4), and 34 patients switched 
from captopril to enalapril. The dose of enalapril ranged from 0.02 mg/kg/day to 1.8 mg/
kg/day; that of captopril from 0.07 to 2.5 mg/kg/day. The treatment duration ranged from 
1 day to 3 years.
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ACE-i related adverse events
Two studies reported death as an AE possibly related to ACE-i use: Three in the study 
of Leversha et al (4) and three in the study of Ku et al (11) Leversha et al do not draw a 
conclusion on the relationship between ACE-I use and death, however, Ku et al state that 
it is unlikely that these three deaths can be attributed to the use of ACE-i.
Renal impairment is a descriptive term, and was defined differently in the presented 
studies: anuria, oliguria with creatinine rise, creatinine rise only, creatinine clearance, 
stage 2-3 acute kidney injury (AKI) based on the KDIGO guidelines (26) and renal risk, 
renal injury or renal failure by modified pRIFLE criteria (27). From 0 to 29% of all patients 
suffered from a form of renal impairment during exposure to ACE-i. In most cases, normal 
renal function was regained after interruption of ACE-i and/or lowering of the ACE-i dose. 
None of the studies made mention of kidney replacing therapy. Terano et al described 
seven cases of stage 2 chronic kidney disease (9). In the remaining studies, long-term renal 
sequelae were either not reported or not observed.
Hypotensive episodes during ACE-i use were described in eight studies. Only Ku et 
al reported severe hypotension that required inotropes administration. Whether 
hypotension in milder cases led to ACE-i dose adjustments is not clear. Hypotension was 
reported in a range of 0 to 19% of patients on ACE-i.
Hyperkalemia was described in 3 studies. We found no reports of hyperkalemia resulting 
in cardiac arrhythmias or requirement of dialysis. Hyperkalemia was reported in a range of 
0-13% of patients on ACE-i.
Several other adverse effects were reported, including vomiting once in one child (3), 
cough in one and neutropenia in one (4). The cough and neutropenia resolved after 
reduction or stop of enalapril. No cases of angioedema were reported.
Risk factors for ACE-i related AE
Children are possibly at an increased risk for ACE-i related adverse events compared to 
adults (28). Pathophysiologically this could be explained by several mechanisms: reduced 
GFR at young age (29), impaired autoregulation of renal blood flow in newborns (30), and 
increased ACE-i levels due to immature renal clearance.
In general, we found no clear relationship between dose level and risk of AEs. Regarding 
renal failure, multiple studies suggest that young age and low weight predispose to renal 
failure. In the study of Leversha et al, young age (< 4 months) and low weight were risk 
factors for renal failure (4). Lindle et al reported that nearly one third of the term neonates 
and more than half of the preterm neonates were in the pRIFLE kidney failure category 
(8). Furthermore, Gantenbein et al noted that the six children who developed renal 
impairment or failure weighed on average 500 g less than the other children (5) Terano et 
al denoted younger age as an independent risk factor for AKI (9). Ku et al also identified a 
postnatal age of less than 30 days as a risk factor for AEs.
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Concomitant medication should also be considered a risk factor for AEs. Diuretic-mediated 
lowering of renal perfusion may increase the risk of ACE-i-mediated nephrotoxicity (10). 
Terano et al identified the use of spironolactone as an independent risk factor for AKI (9). 
Lindle et al noted trends towards significant decrease in creatinine clearance in patients 
on chlorothiazide or spironolactone (8).
Lastly, conditions which may lead to hypovolemia, (e.g. acute gastroenteritis or inadequate 
food/water intake), are risk factors for AEs. Terano et al reported that 37% of all AKI cases 
occurred under such circumstances (9).
A major limitation of this review is the heterogeneity among the included studies in terms 
of patient characteristics and outcome parameters. Most importantly, patients differed in 
disease severity or severity of heart failure was unknown; dosages of ACE-i differed, and 
clear and consistent definitions of adverse events were lacking.
Clinical bottom lines
1. ACE-i are considered relatively safe for children with heart failure, but renal impairment, 
hypotension and hyperkalemia are common adverse reactions (grade of recommendation: B)
2. Low weight, young age, and being prone to dehydration, (e.g. an account of 
gastroenteritis or high doses of diuretics) are factors carrying an increased risk for adverse 
reactions related to ACE-1 consumption (grade of recommendation: B)
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ABSTRACT
BACKGROUND Dilated cardiomyopathy (DCM) in children is an important cause of 
severe heart failure and carries a poor prognosis. Adults with heart failure are at increased 
risk of anxiety and depression and such symptoms predict adverse clinical outcomes such 
as mortality. In children with DCM, studies examining these associations are scarce.
AIMS We studied whether in children with DCM: (1) the level of emotional and behavioral 
problems was increased as compared to normative data, and (2) depressive and anxiety 
problems were associated with the combined risk of death or cardiac transplantation.
METHODS To assess emotional and behavioral problems in children with DCM, parents 
of 68 children, aged 1.5-18 years (6.9±5.7 years) completed the Child Behavior Checklist.
RESULTS Compared to normative data, more young children (1.5-5 years) with DCM had 
somatic complaints (24.3% vs. 8.0%; p < .001), but fewer had externalizing problems (5.4% 
vs. 17.0%; p = .049). Overall internalizing problems did not reach significance. Compared 
to normative data, more older children (6-18 years) showed internalizing problems (38.7% 
vs. 17.0%; p = .001), including depressive (29.0% vs. 8.0%; p < .001) and anxiety problems 
(19.4% vs. 8.0%; p = .023), and somatic complaints (29.0% vs. 8.0%; p < .001). Anxiety and 
depressive problems, corrected for heart failure severity, did not predict the risk of death 
or cardiac transplantation.
CONCLUSION Children of 6 years and older showed more depressive and anxiety 
problems than the normative population. Moreover, in both age groups, somatic problems 
were common. No association with outcome could be demonstrated.
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INTRODUCTION
Cardiomyopathies are disorders characterized by structural and functional abnormalities 
of the heart. The most common subtype in children is dilated cardiomyopathy (DCM), 
accounting for approximately 60% of pediatric cardiomyopathies (1, 2). DCM, which 
is characterized by impaired systolic function and dilation of the left ventricle (3), is 
estimated to affect 0.57 per 100,000 children annually (4). Though disease presentation 
can vary greatly, 80% of patients show symptoms related to heart failure, such as fatigue, 
orthopnea, edema, and excessive sweating. Symptoms can also include circulatory 
collapse, arrhythmias, thromboembolic events, and sudden death (5). Although some 
children recover (6), the prognosis of DCM generally is poor: within 2 years after diagnosis, 
approximately 40% of children die or undergo cardiac transplantation (4, 6-8), making 
DCM the leading indication for cardiac transplantation worldwide (9-11). Considering the 
symptoms and prognosis of DCM, substantial effects on psychosocial wellbeing can be 
expected (12).
Compelling evidence from two meta-analyses shows that adults with heart failure are 
at increased risk of anxiety and depression (13, 14). Few studies have examined the 
psychosocial wellbeing of children with DCM, but, indeed, it has been found that children 
with DCM have a lower health-related quality of life (HRQoL) than healthy children (12, 
15-18). However, studies examining emotional and behavioral problems in children with 
DCM are scarce. Moreover, the currently available studies have small sample sizes (n ≤ 15) 
and show contradictory results. In a cross-sectional study, half (n = 6 out of 12) of children 
with cardiomyopathy listed for cardiac transplantation showed clinically significant 
overall emotional and behavioral problems (19). In contrast, a study examining depressive 
symptoms in children with DCM (n = 15) did not find higher rates of symptoms compared 
with healthy children (20). However, it should be noted that these studies used different 
questionnaires.
Regarding the impact of impaired HRQoL on cardiac outcomes, two studies have shown 
that children’s physical HRQoL (reported by parents) predicts mortality and cardiac 
transplantation, independent from heart failure severity (15, 17). Also, a meta-analysis 
(13) and reviews (21, 22) have consistently found that depressive and anxiety symptoms 
in adults with heart failure predict mortality and other adverse clinical outcomes, such as 
hospitalization and arrhythmias. However, to the best of our knowledge, the predictive 
value of depressive and anxiety symptoms in children with DCM has not been previously 
studied. Information on the predictive value of depressive and anxiety symptoms may be 
valuable for clinical management strategies. Depressive and anxiety problems may lead 
to poorer self-care and, in turn, to disease progression (22).
The aim of the present study was twofold: firstly, we evaluated the level of parent-reported 
emotional and behavioral problems in children with DCM compared with the general 
population. Secondly, we exploratively examined whether the level of parent-reported 
anxiety and depressive problems predicted the combined risk of death and cardiac 
transplantation whilst controlling for heart failure severity. Based on the aforementioned 
adult studies, we hypothesized that children with DCM would show more anxiety and 
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depressive problems than children in the general population. Moreover, we hypothesized 
that anxiety and depressive problems would predict mortality in children with DCM 
independent from heart failure severity.
METHODS
All data used in this observational, cross-sectional study were derived from a larger 
multicenter longitudinal study in children with heart failure secondary to cardiomyopathy 
(15). The study protocol was approved by the Medical Ethics Committee of the Erasmus 
Medical Center (protocol number NL45663.078) and by the institutional review boards 
of all participating centers. The study performed conformed to the ethical guidelines of 
the Declaration of Helsinki (23) and reported following the STROBE statement. Before 
participation, written informed consent was obtained from all patients’ parents or legal 
guardians and from all patients aged 12 years or above.
Participants
Participants were recruited from 1 October 2010 to 1 November 2015 through seven 
tertiary centers for pediatric cardiology in the Netherlands. The database was closed on 
1 July 2017. Children were eligible to participate if they had heart failure secondary to 
DCM. DCM was defined as fractional shortening ≤25% and left ventricular end-diastolic 
dimension z-score >2 for body surface area. DCM could be idiopathic or secondary to 
other causes. Exclusion criteria were known mental retardation, congenital heart disease, 
neuromuscular disease, and insufficient mastery of the Dutch language by parents. In the 
current study, we only included 1.5-18-year-old children due to age restrictions of the 
used questionnaire. Since age and gender-matched normative data on emotional and 
behavioral problems is available, we did not recruit a healthy control group (24).
Procedure
Children were either included at DCM diagnosis or were included at an outpatient 
appointment for a previously diagnosed DCM in one of the participating tertiary pediatric 
cardiology centers. Demographic variables were obtained at inclusion. Socioeconomic 
status was based on the highest of both parents’ occupations and categorized into low, low 
to middle, middle, or high according to the international classification system (25). Parents 
were asked to complete a questionnaire assessing their child’s emotional and behavioral 
problems during an outpatient clinic visit. During the same visit, a pediatric cardiologist 
completed the New York University Pediatric Heart Failure Index (NYU PHFI) (26). This 
validated index assesses heart failure severity based on symptoms and medication use. 
Scores range from 0 to 30. A higher score indicates more severe heart failure.
Emotional and behavioral problems
One of each participant’s parents completed the problem section of the Child Behavior 
Checklist (CBCL) (27). Depending on the child’s age, the CBCL 1½-5 (100 items; children 
aged 1.5-5 years) or the CBCL/6-18 (120 items; children aged 6-18 years) was completed. 
For both versions, response categories range from 0 (not true) to 2 (very true or often 
true). The CBCL assesses overall emotional and behavioral problems and specific aspects 
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of mental health and problem behavior. In addition to an overall total problem score, 
broadband scale scores can be calculated for Externalizing Problems (i.e., externally 
directed problems affecting the environment, such as aggression and delinquency) and 
Internalizing Problems (i.e., internally directed problems such as depression, anxiety, 
and somatic complaints). Furthermore, the CBCL 1½-5 consists of five scales based on 
the fifth edition of the Diagnostic and Statistical Manual Of Mental Disorders (DSM-5; 
i.e., Depressive Problems, Anxiety Problems, Attention Deficit/Hyperactivity Problems, 
Oppositional Defiant Problems, and Autism Spectrum Problems). In addition, seven 
empirical scales can be calculated (i.e., Anxious/Depressed, Somatic Complaints, Attention 
Problems, Aggressive Behavior, Emotionally Reactive, Withdrawn, and Sleep Problems). 
The CBCL/6-18 consists of six DSM-5 based scales (i.e., Depressive Symptoms, Anxiety 
Problems, Somatic Problems, Attention Deficit/Hyperactivity Problems, Oppositional 
Defiant Problems, and Conduct Problems) and 8 empirical scales (i.e., Anxious/Depressed, 
Withdrawn/Depressed, Somatic Complaints, Social Problems, Thought Problems, 
Attention Problems, Rule-Breaking Behavior, and Aggressive Behavior). On all scales, 
higher scores indicate more problems. For each scale, scores can be interpreted as falling 
in the normal, borderline, or clinical range by comparing scale scores with norm data. 
Scores in the borderline or clinical range indicate psychopathological problems with a 
need for clinical follow-up and/or intervention. The CBCL has adequate psychometric 
properties and normative data from the Dutch general population are available (24).
Endpoint
We used a combined endpoint of death and cardiac transplantation. Information on 
mortality and cardiac transplantation was retrieved from patient records. Follow-up was 
censored at July 1, 2017.
Statistical analyses
Firstly, we examined whether the proportion of children scoring in the borderline or clinical 
range of emotional and behavioral problems was larger in our DCM study population than 
in the general population. All raw scale scores were converted to percentiles using the 
Achenbach System of Empirically Based Assessment Standard norm data, which is based 
on data of Dutch children from the general population and accounts for age and gender 
(27). Conforming with the CBCL manual (27), for the Total Problems scale, Internalizing 
Problems scale, and Externalizing Problems scale, percentile scores of 83 or lower were 
defined as non-clinical and percentile scores of 84 or higher were defined as borderline/
clinical. For the DSM scales and empirical scales, percentile scores of 92 or lower were 
defined as non-clinical and percentile scores of 93 or higher were defined as borderline/
clinical. One sample binomial tests were conducted for each scale of the CBCL 1½-5 
and the CBCL/6-18 to test whether the proportion of children with DCM scoring in the 
borderline/clinical range was higher than the proportion in the norm group.
Secondly, we conducted a Cox regression analysis to examine whether anxiety 
and depressive problems predicted the combined endpoint of death and cardiac 
transplantation whilst controlling for heart failure severity. The covariates entered into the 
model were the CBCL scale scores for Anxiety Problems and Depressive Problems and the 
NYU PHFI. We used t-scores to account for differences between the two versions of the 
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CBCL (i.e., CBCL/1½-5 and CBCL/6-18) Anxiety Problems and Depressive Problems scale 
scores. The NYU PHFI was added to the model because heart failure severity is a known 
predictor of mortality (15). All analyses were performed using SPSS Statistics version 24.0 
(28).
RESULTS
In total, 144 children with DCM participated in the larger multicenter longitudinal study 
in children with heart failure secondary to cardiomyopathy from which data for the 
current study was derived. Of this group, 52 children were excluded from participation 
in the current study (N = 26 had a too short follow-up period to fill out the CBCL, N = 14 
were younger than 1.5 years, N = 7 had a neuromuscular disease, N = 5 did not master 
the Dutch language sufficiently). Therefore, 92 children met the eligibility criteria for the 
current study, 68 of whom consented to participate in the current study (see Figure 1). 
Participant characteristics are presented in Table 1.
Emotional and behavioral problems compared with the general population
1.5- to 5-year-old children (CBCL 1½-5)
The proportion of parent-reported emotional and behavioral problems in 1.5- to 5-year-
old children with DCM and children in the norm group is shown in Table 2. The CBCL 
1½-5 was completed for 37 participants (by N = 9 fathers, N = 25 mothers, N = 3 parents 
together) at a median time of 19.0 months after DCM diagnosis (range 10.0-65.0 months; 
see Table 1). Compared with the normative data of same-aged children (8.0% borderline 
or clinical score), a significantly larger proportion of children with DCM (24.0% borderline 
or clinical score) showed somatic complaints in the borderline or clinical range, p < .001. In 
contrast, the proportion of children showing a borderline or clinical level of externalizing 
problems was significantly smaller in the DCM study group (5.4% clinical or borderline 
score) than in the general population (17.0% borderline or clinical score), p = .049.
For the other scales, the proportions of borderline and clinical problems in children with 
DCM and children from the general population did not significantly differ. However, trends 
towards significance were found for more emotionally reactive (p = .062) and depressive 
problems (p = .062), and less attention deficit/hyperactivity problems (p = .068).
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Figure 1 Participation fl owchart.Figure 1 Participation flowchart.
Participated in larger study
N = 144
Excluded N = 52
• Too short follow-up, i.e. < 9 months (N = 26)
• Younger than 1.5 years (N = 14)
• Neuromuscular disease (N = 7)
• Insufficient mastery of Dutch (N = 5)
Eligible for participation in current study
N = 92
    Consented to participate N = 68 
• Completed CBCL 1½-5 (N = 37) 
• Completed CBCL/6-18 (N = 31)
Reached endpoint
N = 11
Did not reach endpoint
N = 57
Table 1 Participant characteristics.
Overall group (N=68) Did not reach endpoint 
(N=57)
Reached endpoint 
(N=11)
Characteristic
1.5-5 
years 
(N=37)
6-18 
years 
(N=31)
1.5-5 
years 
(N=31)
6-18 years 
(N=26)
1.5-5 
years 
(N=6)
6-18 years
(N=5)
Male gender, N (%) 20 (54.1%) 17 (54.8%) 18 (58.1%) 16 (61.5%) 2 (33.3%) 1 (20.0%)
Age in years, M (SD) 2.2 (1.3) 12.4 (3.5) 2.0 (0.5) 12.5 (3.6) 3.3 (1.2) 11.8 (3.4)
Time since DCM diagnosis in 
months, median (IQR*)
19.0 (12.0-
36.0)
57.0 (24.0-
107.0)
18.0 (12.0-
24.0)
58.5 (27.0-
110.0)
40.5 (24.5-
59.0)
24.0 (17.0-
73.5)
NYU PHFI†, M (SD) 6.3 (4.8) 7.2 (3.8) 4.8 (3.2) 5.5 (3.1) 14.2 (3.9) 12.6 (2.1)
Socioeconomic status‡, N (%)
Low 1 (2.7%) 2 (6.5%) 1 (3.2%) 2 (7.7%) 0 (0.0%) 0 (0.0%)
Low to middle 10 (27.0%) 10 (32.3%) 8 (25.8%) 10 (38.5%) 2 (33.3%) 0 (0.0%)
Middle 3 (8.1%) 6 (19.4%) 3 (9.7%) 6 (23.1%) 0 (0.0%) 0 (0.0%)
High 16 (43.2%) 10 (32.3%) 13 (41.9%) 5 (19.2%) 3 (50.0%) 5 (100.0%)
Missing 7 (18.9%) 3 (9.7%) 6 (19.4%) 3 (11.5%) 1 (16.7%) 0 (0.0%)
* IQR = Interquartile range.
† NYU PHFI = New York University Pediatric Heart Failure Index.
‡ SES was determined by parents’ occupation level(25).
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Six- to 18-year-old children (CBCL/6-18)
The distribution of parent-reported emotional and behavioral problems in 6- to 18-year-
old children with DCM and children from the general population is shown in Table 3. 
The CBCL/6-18 was completed for 31 children (by N = 5 fathers, N = 23 mothers, N = 3 
parents together) at a median time of 39.0 months after DCM diagnosis (range 12.0-177.0 
months; see Table 1). Compared with normative data of same-aged peers, significantly 
larger proportions of children with DCM showed problems in the borderline or clinical 
range on the following scales: Internalizing Problems (p = .001; 17.0% vs. 38.7%), anxious/
depressed problems (p = .023; 8.0% vs. 19.4%), somatic complaints (p < .001; 8.0% vs. 
29.0%), depressive problems (p < .001; 8.0% vs. 29.0%), anxiety problems (p = .023; 
8.0% vs. 19.4%), and somatic problems (p < .001; 8.0% vs. 25.8%). For the other scales, 
the proportion of borderline and clinical problems did not significantly differ between 
children with DCM and children from the general population.
Table 2 Distribution of non-clinical versus borderline/clinical emotional and behavioral problems 
reported by parents of 1.5- to 5-year-old children (CBCL 1½-5).
CBCL 1½-5 scale
DCM patients (N = 37) * General population
Non-clinical, 
N (%)
Borderline/
clinical, N (%) Non-clinical %
Borderline/
clinical % p-value
Broadband scales
Internalizing Problems 29 (78.4%) 8 (21.6%) 83% 17% .298
Externalizing Problems 35 (94.6%) 2 (5.4%) 83% 17% .049
Total Problems 31 (83.8%) 6 (16.2%) 83% 17% .500
Syndrome scales
Anxious/Depressed 36 (97.3%) 1 (2.7%) 92% 8% .188
Somatic Complaints 28 (75.7%) 9 (24.3%) 92% 8% < .001
Attention Problems 36 (97.3%) 1 (2.7%) 92% 8% .188
Aggressive Behavior 35 (94.6%) 2 (5.4%) 92% 8% .390
Emotionally Reactive 31 (83.8%) 6 (16.2%) 92% 8% .062
Withdrawn 33 (89.2%) 4 (10.8%) 92% 8% .372
Sleep Problems 34 (91.9%) 3 (8.1%) 92% 8% .500
DSM-oriented scales
Depressive Problems 31 (83.8%) 6 (16.2%) 92% 8% .062
Anxiety Problems 32 (86.5%) 5 (13.5%) 92% 8% .175
Attention Deficit/
Hyperactivity Problems 37 (100%) 0 (0%) 92% 8% .068
Oppositional Defiant 
Problems 36 (97.3%) 1 (2.7%) 92% 8% .188
Autism Spectrum Problems 34 (91.9%) 3 (8.1%) 92% 8% .500
* Reported by fathers (N=9), mothers (N=25), or both parents together (N=3).
Predictive value of anxiety and depressive problems on endpoint
We examined whether anxiety and depressive symptoms predicted the combined risk of 
death or cardiac transplantation whilst controlling for NYU PHFI. The proportional hazard 
assumptions were not violated. Before July 1, 2017, 11 participants (16.2%) had reached 
an endpoint. One had died and 10 had undergone cardiac transplantation. The results of 
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the Cox regression analysis are presented in Table 4. Anxiety problems and depressive 
problems did not significantly predict death or cardiac transplantation. However, the 
NYU PHFI did significantly predict the risk of death or cardiac transplantation, p < .001. 
A one unit increase in the NYU PHFI resulted in a 42% higher risk of death or cardiac 
transplantation (hazard ratio 1.42, 95% confidence interval 1.19-1.69).
Table 3 Distribution of non-clinical versus borderline/clinical emotional and behavioral problems 
reported by parents of 6- to 18-year-old children (CBCL/6-18).
CBCL/6-18 scale
DCM patients (N = 31)a General population
Non-
clinical, 
N (%)
Borderline/
clinical, N (%)
Non-clinical 
%
Borderline/
clinical % p-value
Broadband scales
Internalizing Problems 19 (61.3%) 12 (38.7%) 83% 17% .001
Externalizing Problems 28 (90.3%) 3 (9.7%) 83% 17% .199
Total Problems 26 (83.8%) 5 (16.1%) 83% 17% .500
Syndrome scales
Anxious/Depressed 25 (80.6%) 6 (19.4%) 92% 8% .023
Withdrawn/Depressed 28 (90.3%) 3 (9.7%) 92% 8% .495
Somatic Complaints 22 (71.0%) 9 (29.0%) 92% 8% < .001
Social Problems 28 (90.3%) 3 (9.7%) 92% 8% .495
Thought Problems 26 (83.9%) 5 (16.1%) 92% 8% .091
Attention Problems 27 (87.1%) 4 (12.9%) 92% 8% .250
Rule Breaking Behavior 31 (100%) 0 (0%) 92% 8% .095
Aggressive Behavior 29 (93.5%) 2 (6.5%) 92% 8% .500
DSM-oriented scales
Depressive Problems 22 (71.0%) 9 (29.0%) 92% 8% < .001
Anxiety Problems 25 (80.6%) 6 (19.4%) 92% 8% .023
Somatic Problems 23 (74.2%) 8 (25.8%) 92% 8% < .001
Attention Deficit/
Hyperactivity Problems 28 (90.3%) 3 (9.7%) 92% 8% .495
Oppositional defiant 
problems 28 (90.3%) 3 (9.7%) 92% 8% .495
Conduct problems 29 (93.5%) 2 (6.5%) 92% 8% .500
a Reported by fathers (N=5), mothers (N=23), or both parents together (N=3).
Table 4 Results of Cox regression analysis.
95% CI*
Variable HR† Lower Upper p-value
Anxiety Problems (t-score) 0.98 0.89 1.09 .72
Depressive Problems (t-score) 0.98 0.88 1.08 .64
NYU PHFI‡ (per unit) 1.42 1.19 1.69 < .001
*CI = confidence interval
† HR = hazard ratio
‡ NYU PHFI =  New York University Pediatric Heart Failure Index
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DISCUSSION
The current study is the first to investigate emotional and behavioral problems in a substantial 
cohort of children with DCM. Some results are in line with our expectations. Importantly, 
we found that, compared with normative data of same-aged peers, larger percentages of 
older children (6-18 years old) with DCM showed overall internalizing problems, anxiety 
problems, and depressive problems. Also, we found trends towards significance suggesting 
that, compared with normative data of same-aged peers, larger percentages of younger 
children (1.5-5 years old) with DCM showed emotionally reactive problems and depressive 
problems. These results are in line with meta-analyses in adult heart failure populations, 
which demonstrate an increased risk of anxiety and depression (13, 14). 
Until now, only two studies have examined emotional and behavioral problems in children 
with DCM. The first study was conducted by Wray and Radley-Smith(19) who found that 
50% of the children with cardiomyopathy in their study (N=19, age 3½-17 years) showed 
a clinical level of overall emotional and behavioral problems on the CBCL questionnaire. In 
our study, this percentage was markedly lower (i.e., 10.8% in younger children and 16.1% in 
older children). This difference may be due to the fact that all children with cardiomyopathy 
in Wray and Radley-Smith’s study were listed for cardiac transplantation, whereas in our 
study this was not the case.
In the second study, Menteer and colleagues (20) compared the level of depressive 
symptoms in children (aged 7-21 years) with DCM (N = 15), children who had successfully 
undergone cardiac transplantation for heart failure (N = 23), and healthy children (N = 24). In 
contrast to our results, they found similar levels of depressive symptoms in all groups. That is, 
the level of depressive symptoms in children with DCM did not significantly differ from the 
level of depressive symptoms in healthy children and children who had undergone cardiac 
transplantation. However, it should be noted that Menteer and colleagues used small sample 
sizes, which limits the statistical power to detect differences between groups. Moreover, this 
discordance in results may be explained by the fact that we assessed depressive problems 
through the CBCL questionnaire whereas Menteer and colleagues used the Children’s 
Depression Inventory (CDI) (29). Although both instruments assess depressive symptoms, 
previously, moderate correlations between CDI total scores and CBCL depressive problems 
scores have been found(30).
Depressive and anxiety problems in children with DCM may be caused by factors directly 
or indirectly related to the illness. For example, in other chronic illnesses, it has been shown 
that the symptoms of the illness itself (31, 32) and side effects of medical treatments (33) 
can provoke anxiety and depressive symptoms. More indirectly, illness uncertainty (i.e., 
uncertainty regarding prognosis, disease course, and treatment) can increase symptoms 
of depression and anxiety (31, 34). This can be explained by the cognitive coping theory 
(35), which states that children interpret situations based on previous knowledge and 
experiences. When such information is lacking, a situation may be interpreted as a threat, 
which consequently increases symptoms of depression and anxiety (31, 36-39). Similarly, 
medical treatments such as injections may be experienced as distressing and threatening, 
thereby increasing children’s anxiety levels (31). Furthermore, it is known that parental 
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overprotectiveness can promote anxiety and depressive symptoms in children with a 
chronic illness (31, 34, 40). Depressive and anxiety problems may also have a biological 
cause. In adult (41, 42) and pediatric (43) heart failure populations, reduced brain tissue 
volumes have been found in brain areas which regulate mood. Future research is needed to 
draw definite conclusions as to biological causes of mood problems in DCM.
Besides increased anxiety and depressive problems, we demonstrated that, compared 
with normative data, a larger percentage of young and older children with DCM showed a 
borderline or clinical level of somatic problems. This is not surprising considering all children 
had heart failure problems secondary to DCM. Furthermore, previous studies have reported 
reduced levels of physical health related quality of life in this population (15).
Other results of the current study were unexpected or contrary to our hypotheses. Firstly, 
we found that, compared with normative data, a smaller percentage of young children with 
DCM showed a borderline or clinical level of externalizing problems. In line with this result, 
we found a trend towards significance suggesting that, compared with normative data, a 
smaller percentage of young children with DCM showed attention deficit/hyperactivity 
problems. This might be explained by increased levels of fatigue reported in DCM (5), which 
may contribute to children showing less hyperactive behavior. 
Secondly, contrary to our hypothesis, we found that anxiety and depressive problems in 
children with DCM did not predict the risk of death and cardiac transplantation whilst 
controlling for heart failure severity. However, in line with the results of a previous DCM study, 
heart failure severity (NYU PHFI) did predict the risk of death and cardiac transplantation (15). 
In contrast with our findings, in adult heart failure populations, a multitude of studies have 
shown that depressive problems predict mortality and other adverse clinical outcomes (e.g., 
13, 21, 44, 45-48). Furthermore, increasing evidence shows that anxiety problems predict 
mortality in adult heart failure (22). An explanation for our different findings is that, in adults, 
depressive and anxiety problems can lead to poorer self-care (49). In children, however, 
parents may compensate for children’s poorer self-care behaviors which subsequently 
diminishes the impact of depressive and anxiety problems on their physical health. Also, it 
should be noted that statistical power to detect associations was limited.
This study has several strengths. Studies exclusively examining pediatric cardiomyopathy 
patients are scarce (12). As stated, the current study is the first to examine emotional and 
behavioral problems in a relatively large cohort of children with DCM. We recruited children 
with DCM through seven tertiary centers for pediatric cardiology. Also, we investigated 
problems in a broad age range (1.5 to 18 years), using an internationally well-validated 
questionnaire (CBCL) to assess a wide range of emotional and behavioral problems. The 
multicenter recruitment and the inclusion of a broad age range improve the generalizability 
of our results in the pediatric DCM population.  Moreover, we examined the predictive 
value of depressive and anxiety problems on mortality and cardiac transplantation whilst 
controlling for heart failure severity, which is a known predictor of adverse outcomes. 
Furthermore, results from our study population were compared to representative normative 
data matched on age and gender.
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The results of this study must also be interpreted in light of a few limitations. Firstly, although 
the study sample is relatively large considering the prevalence of DCM, the number of events 
in the study was 11, which limits the statistical power of the prediction analyses. Secondly, 
we only used proxy-reports completed by parents because most participating children were 
too young to complete the self-report version of the CBCL (50). Of the children who were old 
enough to complete the self-report version of the CBCL an insufficient number to analyze 
completed the questionnaire. The use of proxy-reports has been frequently debated. Studies 
have found that parent proxy-reports of quality of life in pediatric cardiac populations may 
differ from child self-reports (51, 52). In another pediatric cardiac population, Patel and 
colleagues (53) found that parent-child agreement was stronger for more readily observable 
variables such as physical functioning and externalizing behavior and lower for variables 
which tend to be less visible, such as anxiety, emotional functioning, and internalizing 
behavior. In contrast, in a pediatric cardiac population, Marino and colleagues (54) found 
that parent-proxy reports and child self-reports on quality of life did not differ. Moreover, 
Wilmot and colleagues (16) reported moderate parent-child agreement on quality of life 
of children with cardiomyopathy. Considering the scarcity of research into emotional and 
behavioral problems in children with DCM, further research is needed using well-attuned 
self-reports as well. Thirdly, we combined both father and mother reports in our analyses. 
Although this may induce bias (55), it should be noted that the majority of questionnaires 
were completed by mothers and previous research has found moderately high inter-parent 
agreement on the CBCL (56). Fourthly, considering the relatively long period of time between 
DCM diagnosis and participation in the current study (see Table 1), it should be noted that 
the current cohort represents children with chronic heart failure. Children who reached an 
endpoint or recovered shortly after diagnosis are likely underrepresented. 
In conclusion, this first study specifically examining emotional and behavioral problems of 
children with DCM showed, compared with normative data, significantly more borderline or 
clinical levels of anxiety, depressive problems, and somatic problems in 6-18-year-olds and 
significantly more borderline or clinical somatic problems and less externalizing problems in 
1.5-5-year-olds. These findings demonstrate the importance of including routine screening 
for internalizing problems to the clinical management of children with DCM (10) and of 
providing psychosocial support attuned to the needs of these children. Considering the 
previously mentioned influence of parental behavior on anxiety and depressive symptoms 
in pediatric chronic illness, such psychosocial support should not only focus on the children 
themselves but also include their parents. Future research should focus on evidence-
based psychosocial programs to treat and prevent internalizing problems in pediatric 
cardiomyopathy. As the available literature on emotional and behavioral wellbeing in 
pediatric cardiomyopathy is limited, many aspects remain to  be studied. Considering 
previous adult studies and our findings, future research should focus on anxiety and 
depression in pediatric DCM. Moreover, as the results of our study show that emotional and 
behavioral problems in DCM seem to differ per age group, it would be useful to examine 
this in more age groups. Furthermore, a previous study (15), found that HRQoL in children 
with DCM was more impaired at diagnosis than more than 1 year after diagnosis. Whether 
this is also the case for emotional and behavioral problems remains to be studied. Also, since 
little is known about the psychosocial wellbeing of children with cardiomyopathy, future 
qualitative studies would be valuable.
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ABSTRACT
OBJECTIVE Mechanical circulatory support (MCS) with a Ventricular Assist Device (VAD) 
as a bridge to heart transplantation (HTx) or recovery may improve outcome in children 
with terminal heart failure. We report our experience with mechanical circulatory support 
in children eligible for HTx and its effect on waiting list mortality. 
METHODS Retrospective single center cohort study, national pediatric HTx program 
including all children eligible for HTx, from introduction of MCS-VAD in 2006.
RESULTS A total of 43 patients were eligible for HTx, median age 11.7 years, (IQR 3.0-14.7). 
In 18 patients (42 %) a VAD was implanted, 11 (61%) survived to HTx (n=9) or recovery 
(n=2). Techniques and devices used were LVAD (n=16, 89%), in 4 cases preceded by ECMO, 
and BiVAD (n=2, 11%), both preceded by ECMO. In the VAD group median time to death 
(n= 7) was 18 days (IQR 7-75), median time to HTx (n=9) 66 days (IQR 33-223), and 2 patients 
recovered after 30 and 308 days. The main cause of death on MCS was neurological injury 
in 4 patients (22%) and systemic thrombo-embolic events in 2 (11%). The most common 
Serious Adverse Events included confirmed thrombus requiring pump replacement (in 
11 patients, 61%) and pericardial effusion leading to rethoracotomy (in 5 patients, 28%). 
Compared to the era before MCS (1998-2006), waiting list mortality decreased from 44% 
to 21% and was now mainly related to complications of VAD support. 
CONCLUSIONS Since the introduction of MCS-VAD waiting list mortality halved and more 
children with end-stage heart failure survived to heart transplantation, thus improving 
outcome. Although there is substantial mortality and morbidity, overall mortality 
decreases, making MCS-VAD an essential therapeutic tool. The need for donor organs 
remains critically urgent.
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INTRODUCTION
Heart failure is an important cause of morbidity and mortality in children. The majority 
of children are diagnosed with (idiopathic) dilating cardiomyopathy (iDCM) or 
congenital heart disease (1). At presentation, 87% of children suffer from severe cardiac 
decompensation (2). Estimates are that 50% of children with DCM die or undergo heart 
transplantation within 5 years after diagnosis (3, 4). For children with medically incurable 
end-stage heart failure, heart transplantation is the only long term therapeutic option. 
As donor availability is limited, children face a prolonged time on the waiting list. 
North American studies report a waiting list mortality of 25%, which is the highest in 
transplantation medicine (5, 6).
In order to improve survival in patients with terminal heart failure who fail medical 
therapy, much effort has been put into the development of mechanical support of the 
circulation. Extra Corporeal Membrane Oxygenation (ECMO) has successfully been used 
to sustain the circulation for several days to weeks, but has serious limitations in providing 
long term support (7).
Ventricular Assist Devices (VADs) are nowadays a well-accepted, long-term therapeutic 
option in adult end stage heart failure (8). Implementation of VADs in the pediatric 
population has been troublesome due to technical problems and difficulties in medical 
management. However, in recent years, several centers have presented their experience 
with Berlin Heart Excor VAD as long-term support. They have shown that Berlin Heart Excor 
VAD is a reliable and relatively safe device in bridging children to heart transplantation or 
recovery (9-13).
Since 1998 our institute serves as a referral hospital in the Netherlands for end-stage heart 
failure and heart transplantation in children. Since 2006 the Berlin Heart Excor Pediatric 
Ventricular Assist Device has become available in our hospital. The primary aim of this 
study is to describe the outcome of children supported with a VAD. Secondly, we aim to 
determine the effect of the introduction of the VAD on waiting list mortality.
METHODS
Patients
This study was approved by the local medical ethical committee (MEC 2014 – 525). All 
children listed for heart transplantation, as well as those who were eligible for heart 
transplantation at the time of VAD implantation at our centre, from September 1, 2006 to 
July 31, 2014 were included in the study. Medical records were retrospectively reviewed. In 
addition, medical records of patients listed for heart transplantation from 1998 to September 
1st 2006 were reviewed to serve as historical control group of the era before introduction 
of VADs. Primary end points for analysis were all cause mortality, heart transplantation 
and weaning from VAD. Serious Adverse Events (SAE) were assessed in the VAD group only 
and consisted of: major bleeding, pericardial effusion requiring rethoracotomy, infection-
sepsis, neurological dysfunction thrombo-embolic and hemorrhagic), renal dysfunction, 
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right heart failure, hepatic dysfunction , arterial non-CNS thrombo-embolism, device 
malfunction, including confirmed pump thrombus requiring pump replacement and others 
(definitions adapted from INTERMACS) (14). Demographic data were defined at listing for 
heart transplantation. In the VAD group additional demographics, including INTERMACS 
profile, were determined at the time of VAD implantation. Glomerular Filtration Rate was 
estimated using the Schwartz formula (15).
VADs and Surgical procedure
The Berlin Heart Excor Pediatric Ventricular Assist Device (Berlin Heart AG, Berlin, Germany) 
is a paracorporal, pneumatically driven, polyurethane bloodpump (stroke volumes of 
10-25-30-50-60 ml) and can be implanted as left ventricular assist device (LVAD), right 
ventricular assist device (RVAD) or biventricular assist device (BiVAD).
All operations were performed through a standard median sternotomy using 
normothermic extra-corporeal circulation. The heart was kept beating throughout 
the procedure. For LVAD the inflow cannula was inserted at the left ventricular apex, 
the outflow cannula in the ascending aorta. Additional right atrial to main pulmonary 
artery cannulation was used in case BiVAD was required. In our hospital it was standard 
to first connect the Berlin Heart Excor cannulae to a Centrimag Levitronix centrifugal 
pump (Levitronix GmbH, Zurich, Switzerland). In the initial phase of our pediatric VAD 
program this approach was primarily based on logistic reasons. The Levitronix pump can 
be connected to all sizes of Berlin Heart Excor cannulae, thus only the different cannulea 
sizes had to be in stock. Furthermore, this policy allows for a less strict anti-coagulatory 
regimen in case of actual or expected bleeding complications (16). In the course of days, 
when patients were clinically stable and hemostasis was achieved, the Levitronix pump 
was changed for a matching Berlin Heart Excor ventricle.
Criteria for VAD implantation
In general, patients had to be eligible for heart transplantation (17). Furthermore the 
following criteria were applied: a) deterioration of the circulation with increasing dosages 
of inotropes and/or development of metabolic acidosis, b) development of end-organ 
failure including inability to wean from respiratory support on the ventilator, signs of 
renal or hepatic damage and altered neurological state e.g. confusion. An individualized 
decision was made by the clinical team, based on these criteria and the rate of clinical 
deterioration.
Anticoagulation during VAD support
All children on VAD were treated with a standardized anticoagulation and antiplatelet 
regimen known as the Edmonton protocol (12, 18). This protocol is developed by 
pediatric specialists in hematology, mechanical support, heart failure, and surgery, and 
encompasses 15 years of experience with the Berlin Heart Excor worldwide. In general, 
children were treated with unfractionated heparin, low-molecular-weight heparin, or 
warfarin, in combination with anti-platelet agents (dipyridamole and/or acetylsalicylic 
acid).
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Weaning criteria
Children with ongoing improvement of myocardial function, laboratory parameters 
(declining N-terminal Pro-BNP levels), echocardiographic signs of reverse remodeling 
and echocardiographic findings matching improvement of systolic function (opening of 
aortic valve, increasing shortening fraction), were considered for weaning. The pump flow 
was decreased by decreasing pump rate as described by Stiller et al. (19). Pump stops 
were evaluated by assessment of clinical hemodynamic parameters (e.g. blood pressure, 
peripheral perfusion), and the above mentioned echocardiographic parameters, followed 
by surgical explantation when weaning was tolerated well.
Statistical analysis
Statistical analysis was conducted with IBM SPSS statistics 21 (IBM, NY, US). Continuous 
variables were expressed as medians (Inter Quartile Range) or numbers (percentage). The 
Independent median test was used to compare continues variables, categorical analysis 
was conducted by chi-square and Fisher’s exact test. Mortality was compared between 
groups by Cox regression analysis. The level of significance was 0.05.
RESULTS
Patients
Data of 15 patients were collected over a study period from 1998 to 2006, the pre-VAD 
era (cohort I), and data of 43 patients were collected from September 2006 to July 2014 
(cohort II). In cohort II, 18 patients underwent implantation of a VAD (VAD group). Baseline 
clinical characteristics are described in Table 1. There was no difference in age or weight 
between patients on VAD and non-VAD patients. VAD patients were more often diagnosed 
with iDCM. A GFR < 30% of predicted was found in 2 patients (11%), 1 patient died while 
on VAD and the in the other renal function fully recovered after 7 days on VAD. A bilirubin 
above the upper level of normal was found in 65% of VAD patients. In the VAD group, 94% 
of patients were on inotropic support at the time of VAD implantation and 89% had an 
INTERMACS profile of I or II.
VAD
Of the 18 implanted VADs, there were 16 LVADs and 2 BiVADs. In 6 cases implantation of 
a VAD was preceded by ECMO followed by LVAD in 4 patients and BiVAD in 2 patients. 
Duration of ECMO in these 6 cases was 2.5 days median (IQR 1.0-10.3 days). In 3 cases 
the rapidly deteriorating clinical condition precluded a suitable timeframe for direct 
implantation of a VAD, in 2 cases patients were supported by ECMO in a ‘crash’ condition, 
and 1 patient was referred to our hospital while already on ECMO. Median duration of 
treatment on Levitronix pump prior to placement of a Berlin Heart Ventricle was 6 days 
(IQR 1.0-9.3 days). Three children were treated with a Levitronix system only. The first child 
died after 6 days in ongoing multi-organ failure . The other two were older children in 
whom we expected a short waiting time as they were waiting for larger donors. These two 
patients underwent successful transplantation after 10 and 13 days on MCS, respectively. 
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Primary end points
In cohort I, the pre-VAD era, 7/15 patients died (47%) and 8/15 patients were transplanted 
(53%), see Figure 1. In cohort II, after the introduction of VADs, 9/43 patients died (21%) and 
31/43 patients were transplanted (72%). Cox regression analysis showed a trend towards 
a significant reduction in waiting list mortality after the introduction of VAD (p = 0.08). 
In the VAD-group of cohort II, 9/18 patients were transplanted (50%), 7/18 patients died 
(38%; 2/2 BiVAD and 5/16 LVAD) and 2/18 patients were successfully weaned from VAD, 
one diagnosed with myocarditis and one with iDCM, after 30 and 308 days respectively. 
Median time to death (n=7) was 18 days (IQR 7-75), median time to HTx (n=9) was 66 days 
(IQR 33-223). Of the 9 VAD patients undergoing heart transplantation, 1 died 3 years after 
transplantation, due to non-compliancy to medical treatment. The most important causes 
of death for children who died on VAD were thrombo-embolic stroke (43%) and systemic 
thrombo-embolic events (29%), see Table 2. One patient in the VAD group died while he 
was still on a Levitronix system.
Table 1. Characteristics of patients listed for heart transplantation.
Demographic total (n=43) VAD (n=18) non VAD (n=25) p value
Age, median (IQR), y* 12 (3-15) 11 (2-13) 12 (4-12) 0.30¹
Weight, median (IQR), kg* 33 (12-45) 20 (9-44) 36 (13-51) 0.32¹
Female sex, n (%) 23 (54) 10 (56) 13 (52) 0.81²
Diagnosis n (%) 0.006³
(i)DCM 23 (54) 13 (72) 9 (36)
myocarditis 1 (2) 1 (6) 0 
other** 19 (44) 4 (22) 16 (64)
At VAD implantation:
INTERMACS status
I/II n (% of 18) 16 (89%)
I/IV n (% of 18) 2 (11%)
Serum creatinine µmol/L, median (IQR) 58 (36-91)
GFR categories (age adjusted), n (% of 18)
< 30% predicted 2 (11%)
30-99% predicted 10 (56%)
> 99% predicted 6 (33%)
Total Bilirubin µmol/L, median, (IQR), n (% of 17) 16 (8-34%)
≤ 16 µmol/L 6 (35%)
> 16 µmol/L 11 (65%)
Preoperative inotropic support no. (%) 17/18 (94%)
* At listing for HTx
** Others consist of congenital heart diseases (n=3) restrictive cmp (n=6), hypertrofic cmp (n=2) 
anthracycline induced cmp (n=4), Beckers muscular dystropy (n=1) and rythm disturbances induced 
cmp (n=3)
p value: differences between VAD and non-VAD patients
¹Non parametric test, independent samples
²Chi square test
³Fisher’s exact
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Table 2. Cause of death for children who died on a VAD.
Factor n (% of 7)
Neurological 4 57%
Thromboembolic stroke 3 43%
Intracranial bleeding 1 14%
Systemic 3 43%
Thromboembolic 2 29%
Bleeding 1 14%
Total 7
In the non-VAD group of cohort II, 22/25 patients were transplanted (88%), 2/25 patients 
died (8%) and 1 patient is still listed, no patients were delisted, see Figure 1. Median time 
to transplantation was 137 days (IQR 18-417). Regarding the 2 deaths in the non-VAD 
group: the parents of one patient refused implantation of a VAD, the parents of the other 
patient postponed their consent for VAD implantation until continued cardiopulmonary 
resuscitation was needed and implantation of a VAD was not achievable anymore. 
Comparing the VAD-group with the non-VAD patients, we found no difference in median 
time to death or transplantation.
Figure 1. Flow diagram of Dutch National Pediatric Heart transplantation Program before and after 
availability of VAD.
Figure 1. Flow diagram of Dutch National Pediatric Heart transplantation Program before 
and after availability of VAD. 
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Figure 2. Competing outcomes (HTx, deceased, explanted)  for children on waiting list supported 
with VAD
  
The primary endpoints are shown as competing events (Figure 2), depicting that the 
majority of end points were reached in the first 100 days after VAD implantation. In Figure 
3 patient survival on VAD is shown.
Figure 3. Survival of VAD patients
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Serious Adverse Events
The most common SAEs that occurred in the VAD patients are described in Table 3. In 16/18 
(89%) of patients, at least one SAE occurred. The most prevalent SAEs were confirmed 
thrombus requiring pump replacement in 11 patients (61%), neurological dysfunction in 7 
patients (39%) and pericardial effusion requiring rethoracotomy in 5 patients (28%). Pump 
replacements occurred in 4/5 (80%) of children who died of a thromboembolic event. The 
median number of pump replacements was 1 per patient, in 4 patients the pump was 
replaced 3 times or more. In those 4 patients median time on VAD was 306 days, they all 
survived. The range of Berlin Heart Excor ventricle sizes was 10 to 60 ml: 1 ventricle of 10 
ml, 6 ventricles of 25 ml, 1 ventricle of 30 ml, 5 ventricles of 50 ml, 2 ventricles of 60 ml and 
3 children were assisted with a Levitronix system only. Considering children below 15 kg 
as “small patients”, our series included  5 small patients ( 4 with 25 ml ventricle, 1 with a 10 
ml ventricle) of which 3 patients developed a thrombo-embolic stroke.
Of the 7 patients with thrombo-embolic stroke or intracranial bleeding, 4 patients 
died and 3 patients suffered from neurologic disability. In the latter 3, the degree of 
neurological damage did not preclude heart transplantation. Follow up data of 8, 3 and 
2,5 years respectively after VAD implantation were available. One patient had a right sided 
hemiplegia, disabling dystonia of the right arm and mild problems with the study of 
(foreign) language and calculus. A second patient suffered from a left sided hemiplegia, but 
fully recovered. The third patient has recovered completely from a right sided hemiplegia. 
Table 3. Serious Adverse Events during VAD support, summary.*
Serious Adverse Event events patients with event n (% of 18)
Any SAE 40 16 (89%)
Major Bleeding 2 2 (11%)
Pericardial effusion requiring rethoracotomy 5 5 (28%)
Infection-Sepsis 1 1 (6%)
Neurological Dysfunction 7 7 (39%)
Thromboembolic 6 6 (33%)
Hemorrhagic 1 1 (6%)
Renal Dysfunction 2 2(11%)
Right Heart Failure 2 2 (11%)
Hepatic Dysfunction 1 1 (6%)
Arterial Non-CNS Thromboembolism 1 1 (6%)
Device Malfunction 
Confirmed thrombus requiring pump 
replacement
16 11 (61%)
Major Device Malfunction 1 1 (6%)
Other** 2 2 (11%)
*SAE’s are defined according to the INTERMACS criteria
** including possible airembolism and Posterior Reversible Encephalopathy Syndrome  
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DISCUSSION
In this study we found that since 2006, 18 patients were supported on VAD and 61% of 
these children survived to heart transplantation or recovery. The majority of children 
who died on VAD were struck by thrombo-embolic events. Similarly, lasting neurological 
damage was caused by thrombo-embolic events as well.  Furthermore we found that, 
compared to the era before VADs, waiting list mortality decreased from 44% to 21% and 
mortality was largely related to complications of VAD support. Our study points out that 
the overall survival of children with end stage heart failure increases with the availability 
of VADs, but this comes at a high prize. A significant number of children die on a VAD or 
have lasting neurological disability. This urges to critically consider the results and to aim 
for an improvement of outcome in these patients.
In this regard a reflection on the mortality in our VAD patients is relevant. Data from 
prior studies demonstrated a wide range of mortality in pediatric patients on a VAD, 
varying from 38% to 6% (9-13, 20-22), placing our outcome on the unfavourable end of 
the spectrum. Several factors might contribute to mortality in our patient population, of 
which patient selection may play an important role. The studies with the lowest mortality 
are those with the most strict inclusion criteria for implantation of a VAD. For example, 
in the North American IDE-trial, children with significant end-organ dysfunction were 
excluded. In this study they found a low mortality rate (10). Clinical centers who used 
VADs on a ‘compassionate use’ basis presented mortality data of 37%, which is more 
comparable to our findings. They found that the degree of end-organ dysfunction, in 
particular the severity of renal failure, had an important effect on outcome (12). Patient 
profiles of the ‘compassionate use’ group were much like our patient group in terms of 
INTERMACS profile and percentage of significant end-organ failure. Other single center 
studies reporting on pediatric VAD outcome, either showed quite similar mortality (21), 
were difficult to compare with regard to patient characteristics at implantation of VAD 
(22), or showed an encouraging learning curve in demonstrating that mortality decreased 
to 18% in the last 4 years of their experience (23). The relatively low mortality found in the 
IDE-trial suggests that favorable patient selection leads to improvement of outcome. Our 
mortality data may reflect our somewhat prudent policy in implanting VADs in children, 
resulting in a severely ill patient group with (beginning) end-organ failure. However, we 
also found that mortality in the non-VAD patients was very low (2/25, 8%) and in the 2 
children who died, parents did not consent to VAD implantation. This suggests that 
although we implant VADs relatively late in the disease process, we do not lose patients as 
a result of this conservative policy.
With regard to SAE, we found a significant number of these events during VAD treatment. 
The most common SAE was formation of thrombus in the system leading to VAD 
replacement, occurring in 61% of patients. Brancaccio et al report pump replacement in 
52% of patients (23), similar to Malaisrie et al who found 50% (21). The comprehensive 
study performed by Almond et al and the single center study by Rockett et al are not clear 
on this matter (12, 22). 
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In the days following VAD implantation 5 patients (28%) developed pericardial effusion 
necessitating rethoracotomy.  This figure is comparable to the rethoracotomy percentages 
in other studies (22).
The most alarming Serious Adverse Events are the thrombo-embolic events, which are 
even more disconcerting in the face of our relative high number of pump replacements. 
The limited number of observations did not allow a formal analysis with regard to a 
possible association between Berlin Heart Excor ventricle size and thrombo-embolic 
events. Considering children below 15 kg as “small patients”, our series included 5 small 
patients (4 with a ventricle of 25 ml, 1 with a ventricle of 10 ml), 3 patients developed 
a thrombo-embolic event. In the whole VAD group we found 7/18 (38%) patients with 
a thrombo-embolic event, 4/13(31%) in the patients over 15 kg versus 3/5 (60%) in the 
small patients. This suggests that in smaller children more (lethal) thrombo-embolisms 
may occur. In the present study we found thrombo-embolic stroke in 33% of children 
and thrombo-embolic stroke accounted for 43% of all deaths on VAD. The number of 
thrombo-embolic strokes in our study is similar to other single centre outcomes (21, 22), 
but higher than the earlier mentioned compassionate use cohort (12). This might suggest 
that the high stroke rate cannot be fully explained by patient selection only. Preventing 
thrombo-embolic events is quite challenging. In our hospital we follow the well accepted 
Edmonton protocol (16,17). Closer monitoring of coagulation and possibly exploration of 
other anti-coagulatory strategies (18) might lead to reduction of thrombo-embolic events.
In spite of a considerable mortality and morbidity in VAD patients, we still believe 
that a VAD is an acceptable therapeutic tool. Taken into account that survival of heart 
transplantation patients is unaffected by previous VAD implantation (24), we are inclined 
to believe that the positive effect of VAD support on survival in end-stage pediatric heart 
failure outweighs the disconcerting mortality and morbidity rate. We conclude that 
optimal timing in placement of a VAD is to be determined for every individual patient and 
antithrombotic monitoring deserves highest priority. It is clear that we need to continue 
to closely monitor our results and aim for improvement of outcome.
This study has several limitations. First of all, the study is prone to selection bias as a result 
of its retrospective design. We expect however that selection bias was minimal as we 
serve as referral hospital, and were to our knowledge, able to evaluate all Dutch pediatric 
VAD patients. Secondly, the number of patients is small preventing robust statistical 
analysis. Nevertheless, the trends that we observed in our study are comparable to other 
reports on the use of VADs in the pediatric age group. Thirdly, we present the cumulative 
experience over the course of 8 years, reflecting a learning curve of selecting patients 
as well as surgical and medical management of patients on VAD. Lastly, we reported 
the outcome of patients from 2 consecutive eras, inherently resulting in a historical 
comparison. Indeed, our data reflect a growing heart transplantation program and over 
the course of years the number of patients referred to our hospital and listed for heart 
transplantation increased accordingly. Nevertheless patient profiles in the 2 cohorts were 
quite similar. In cohort 1 all patients were on the waiting list. In this era, we did not use any 
form of mechanical support (including ECMO) as a bridge to transplantation. In cohort 2, 
all patients were on the waiting list or were eligible for heart transplantation at the time of 
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admission for mechanical support. Patients with expected short time mechanical support, 
for example patients with myocarditis, were excluded as they were not considered eligible 
for heart transplantation. Except for one patient with a protracted disease course (> 6 
weeks). Therefore, we believe that the data presented in this study reliably describe all 
patients who were referred to our hospital and who were considered eligible for heart 
transplantation. This implies that cohort 1 and 2 are a fair representation of children 
requiring transplantation in the respective eras, and patient profiles were sufficiently 
similar to meaningfully compare the two cohorts.
Conclusion
We found that in our hands 61% of children with end-stage heart failure, supported on 
VAD, survive to heart transplantation or recovery. This modest survival rate most likely 
reflects a selection of a severely ill patient population. Although thrombo-embolic events 
on VAD lead to considerable mortality and morbidity, overall mortality in the children on 
the waiting list halved since introduction of VADs. This supports the growing evidence that 
VADs are an acceptable therapeutic tool to bridge children with end-stage heart failure 
to transplantation or recovery. Improvement of outcome in these children is to be sought 
in optimal timing of VAD implantation for every individual patient, and in improvement 
of anti-coagulatory strategies. We expect that in future years, an increasing number of 
children with end-stage heart failure will survive and will be possible candidates for heart 
transplantation, leaving the need for donor organs critically urgent.
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ABSTRACT
BACKGROUND Previously, we reported a low heart transplantation (HTx) rate (3%) in 
children with dilated cardiomyopathy in the first year after diagnosis as compared to 
other registries (18%), without increased mortality. This low early transplantation rate 
might reflect our reluctance to list children early after diagnosis which might have led to 
a selection of children with an unfavorable risk profile. Therefore, we evaluated outcomes 
on the waiting list and after HTx.
METHODS A retrospective, descriptive study of all Dutch children listed for HTx between 
1998 and 2017.
RESULTS 69 children were listed for HTx, at median age of 10.3 years [IQR 2.5 to 13.1]. 
Median time from diagnosis to HTx listing was 1.3 years [IQR 0.3 to 3.9]. The majority of 
children was diagnosed with DCM (n=51, 74%). Sixteen children (23%) died on the waiting 
list, 8 of whom on mechanical circulatory support.
Forty-seven (68%) children underwent successful transplantation at the age of 11.7 years, 
[IQR 6.3 to 13.9]. Five-years’ survival after HTx was 95% (95% CI 88 to 100). Three patients 
died, 2 at adolescent age after severe rejections related to non-compliance. The functional 
outcome after HTx was favorable: the majority of patients were able to carry on normal 
activity. The most important transplantation-related complications were post-transplant 
lymphoproliferative disease (n=6, 13%) and cardiac allograft vasculopathy (n=3, 6%).
CONCLUSION Our low early transplantation rate does not seem to have a negative 
impact on waiting list and post HTx outcomes, which are favorable and comparable to 
published international experience.
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INTRODUCTION
Heart transplantation (HTx) is a widely accepted treatment for both adults and children 
with end-stage heart failure without alternative therapeutic options (1, 2).
In the Netherlands, the paediatric heart failure- and heart transplantation program is 
centralized in one center and covers a population of 3.8 million children.
In our center, patient volume is small- to medium-sized and our patient population 
predominantly consists of children with dilated cardiomyopathy and only a small minority 
of children have a congenital heart disease (CHD). Our program can thus be characterized 
as a typical European HTx program based on the yearly ISHLT reports (2).
Previously, we reported a low transplantation rate in children with dilated cardiomyopathy 
in the first year after diagnosis (3%), as compared to the large PCMR registry which reported 
a 18% transplantation rate in the 1st year after diagnosis. Similar data were shown by 
the Australian NACCS (3,4). Also, median time to listing was considerably longer in our 
cohort, 18 months versus 1.4 months. We did not find differences in clinical characteristics 
of our cohort as compared to other (large) registries and importantly, we did not find 
an increased mortality (5). Our low early transplantation rate might reflect a policy that 
defers listing patients for HTx as long as possible, and that pursues stabilizing patients on 
oral heart failure therapy before listing. This listing strategy may, however, select children 
with more severe heart failure at listing, having an unfavorable risk profile that could 
affect outcome on the waiting list, and after HTx.
It is against this background of a small- to medium- sized program mainly consisting of 
children with DCM, and a low early transplantation rate that we evaluate the outcome 
of 18 years of paediatric HTx in the Netherlands. We report waiting list - and heart 
transplantation outcome, and compare our results to published international experience. 
PATIENTS AND METHODS
Patients
We included all patients < 18 years old listed for HTx from 1998 to April 2017. Two 
independent researchers (MM, SR) reviewed the medical records. Patients were listed for 
HTx in accordance with the ISHLT guidelines (1). Use and duration of mechanical circulatory 
support (MCS) was recorded. We used either ventricular assist device (VAD, Berlin Heart 
EXCOR) or extra corporal membrane oxygenation (ECMO) which were available as of 2007 
in our center. The primary endpoint of the study was waiting list outcome (HTx or death) 
and survival after HTx. Secondary endpoints were transplantation-related complications, 
categorized as (acute) rejection, cardiac allograft vasculopathy (CAV), post-transplant 
lymphoproliferative disorders (PTLD), renal failure (estimated glomerular filtration 
rate (eGFR), using the Schwartz formula (6), psychological and psychiatric disorders, 
and infections. PTLD was considered a continuum of: early lesions (i.e. infectious 
mononucleosis-like PTLD), polymorphic - and monomorphic PTLD(7). EBV infection 
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was defined as a viral load >1000 copies/ml with or without clinical symptoms, leading 
to an adjustment of medication. Functional assessment included 2D echocardiography 
(shortening fraction (SF)) and cardiopulmonary exercise testing (CPET) (8). Functional 
status of the patient was determined by the 100-point Karnofsky and Lansky scale (9). 
Growth data were collected at HTx, 1 year after HTx and at the last follow-up visit and 
expressed as SD scores using Growth Analyser©. The study was approved by the local 
medical ethical committee (MEC 2018-1348). 
Donors
Donor characteristics were collected and included donor age, body weight, country of 
origin, blood type and total ischemia time.
HTx and post-HTx regimen
HTx procedure
All transplants were ABO- compatible. The standard surgical procedure was a biatrial 
anastomose, in 1 patient with congenital heart disease (CHD) a bicaval anastomosis 
technique was used.
Immunosuppression
The immunosuppression consisted of induction therapy with anti-thymocyte globulin, 
followed by triple therapy: before 2000 patients were treated with 1. steroids and 
successive tapering, 2. cyclosporin and 3. Azathioprine. After 2000, tacrolimus replaced 
cyclosporin and mycophenolate mofetil (MMF) replaced azathioprine. Rejection therapy 
consisted of pulse dose of methylprednisolone (10-15 mg/kg), incidentally followed by 
ATG.
Graft surveillance 
Routine surveillance endomyocardial biopsies were taken at: week 1-2, 3-4, 6 and 12, 
month 4-5, 6, 9 and 12 and also when rejection was suspected on clinical grounds. 
Rejection was graded according to ISHLT classification, grade 2R and higher were 
recorded. Classifications before 2005 were revised according to ISHLT guidelines (10). CAV 
was graded according to the ISHLT guidelines and evaluated 1 and 2 years post-HTx with 
coronary angiography and subsequently every 2 years by CT angiography or by coronary 
angiography (11).
Statistical analysis
Categorical variables were reported as numbers and percentages. Continuous variables 
were reported as means with standard deviation (SD) when normally distributed, and 
medians with interquartile range (IQR) when distribution was not normal. Differences 
in characteristics between patient groups were compared by Student’s T-tests (normal 
distribution) or Mann-Whitney U tests. Categorical analysis was conducted by χ2 and 
Fisher’s exact test. Differences in length SD score at HTx and at the last follow-up after 
HTx were compared using Wilcoxon signed rank test. Survival after HTx was estimated 
using Kaplan-Meier curves and the log-rank test was used to compare survival curves. 
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All analyses were performed using IBM SPSS Statistics for Windows, version 24 (IMB Corp, 
Armonk, NY).
RESULTS
Patients
Sixty-nine children were listed for HTx at a median age of 10.3 years [IQR 2.5 to 13.1], 51 
children (74%) were diagnosed with DCM. Median time from diagnosis to HTx listing was 
1.3 years [IQR 0.3 to 3.9]. Median time on the waiting list was 53 days [IQR 21 to 188], Table 1. 
Table 1. Characteristics of patients listed for HTx (n=69)
Diagnosis, n (%)
Cardiomyopathy
  Dilated 51 (74)
  Hypertrophic 3 (4)
  Restrictive 8 (12)
Congenital heart disease 3 (4)
Other* 4 (6)
Female, n (%) 39 (56)
Time from diagnosis to HTx listing years,
median [IQR]
1.3 [0.3 to 3.9]
Age at HTx listing, years, median [IQR] 10.3 [2.5 to 13.1]
Age at HTx, years, median [IQR] 10.4 [6.3 to 13.9]
 < 1 year, n (%) 1 (1)
 1-10 years, n (%) 17 (25)
 11-18 years, n (%) 29 (42)
Length SDS at HTx, median [IQR] -1.2 [-2.5 to 0.6]
ET classification at HTx listing, n (%)
 Hospitalized 52 (75)
 At home 17 (25)
Days at WL of HTx patients, median [IQR] 53 [21 to 188]
Pre HTx MCS, n 22 (21 VAD, 1 ECMO) 
Post HTx follow-up, months, median [IQR] 63 [35 to 106]
* Other consists of chemo induced cardiomyopathy (n=3) and low cardiac output syndrome after 
VSD surgery (n=1)
ECMO, Extra Corporal Membrane Oxygenation; HTx heart transplantation; IQR, Inter Quartile Range; 
MCS, Mechanical Support of the Circulation; SDS standard deviation score; VAD, Ventricular Assist 
Device
Waiting list outcome
The level of support and mortality on the waiting list was considerably higher in children 
who died or underwent transplantation within 1 year of diagnosis as compared to those 
who died or underwent HTx more than 1 year after diagnosis. In children with DCM, 59% 
was on MCS versus 23% (p=0.02), and waiting list mortality was 47% versus 7% (p=0.002), 
Fig 1a and 1b.
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Figure 1a. Patients with HTx or death within 1 year after diagnosis, percentage of n=23
DCM Dilated Cardiomyopathy, HTx heart transplantation, WL waiting list
Figure 1b. Patients with HTx or death more than 1 year after diagnosis, percentage of n=40
DCM Dilated Cardiomyopathy, HTx heart transplantation, WL waiting list
Forty-seven (68%) children were successfully transplanted at median age of 11.7 years, 
[IQR 6.3 to 13.9]. Median time from listing to Htx was 0.14 years [IQR 0.1 to 0.5] and 41 
children (59%) underwent HTx within one year after listing.
Since the introduction of VADs in our program, 22 children (41%) were on MCS (21 patients 
on VAD, 1 patient on ECMO), and 12 of them (54%) underwent successful transplantation. 
Survival was significantly higher in patients without MCS. (Log rank test p=0.001, Figure 2). 
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Figure 2. Kaplan-Meier survival curve of children on the waiting list, children on MCS compared to 
children without MCS 
MCS Mechanical support of the circulation
Twenty-two children (32%) on the waiting list did not undergo transplantation. Sixteen 
children (23%) died, median time on the waiting list until death was 65 days [IQR 21 to 
161]. Six of 16 children died on inotropic support as a result of intractable heart failure in 
the era before VAD-support was available. One patient developed irreversible pulmonary 
hypertension and was delisted, and subsequently died. Seven patients died of VAD-
related complications, and 2 died as parents withheld their consent for VAD placement. 
Of the remaining 6 children, 1 patient was delisted with improved cardiac function after 
9 months on VAD, 1 patient was delisted on parents request and is still alive after 8 years, 
and 4 patients were still listed at the end of the study.
Survival after HTx
All transplantations, except one, were performed in children 1 to 18 years. Median follow-
up was 5.3 years IQR [2.9 to 8.9], nine patients had a follow-up longer than 10 years. Five-
year survival was 95% (95% CI 88 to 100) and 10 -year survival was 88% (95% CI 76 to 
100), Figure 3. One patient required MCS directly after HTx due to primary graft failure, 
within 2 weeks cardiac function recovered completely. Three patients died at 0.8, 3.5 
and 7.6 years after HTx. The first died of infectious complications after intensification of 
immunosuppression for uncontrollable cellular rejection. Two adolescents died after graft 
failure secondary to severe (grade 3R) rejection related to non-compliance.
Donor characteristics
Donors were allocated through Euro transplant. The majority (78%) of the donors 
originated from outside the Netherlands, the median age was 15 years [IQR 8 to 25]. 
Median donor/recipient weight ratio was 1.6 [IQR 1.4 to 1.8], ranging from 1.0 to 2.5. Mean 
Chapter 9
146
total ischemia time was 218 minutes (± 51). Fourteen grafts (30%) had a total ischemia 
time longer than 4 hours.
Figure 3. Kaplan-Meier survival curve of all HTx patients (n=47)
HTx, heart transplantation
Immunosuppressive regimens and graft rejection
Induction therapy with ATG and corticosteroids was started in all patients. One year after 
HTx, 49% of the patients were still treated with steroids. Maintenance therapy consisted 
of cyclosporin, after 2000 replaced by tacrolimus in all patients. At discharge, 94% of 
patients were treated with MMF. Everolimus was used in 3 patients (6%), and sirolimus in 
2 patients (4%). Biopsy proven graft rejection was present in 21 patients (45%), in 20 of 
them rejection occurred in the first year after HTx. Median time from HTx to first rejection 
was 1.8 months [IQR 0.6 to 6.3]. The majority of patients with rejection encountered only 1 
episode (62%) and in 88% of cases rejection was graded as 2R. Figure 4a and 4b.
Cardiac Allograft Vasculopathy
CAV was diagnosed in 3 patients (6%), all in patients > 18 years, grade 3 in two patients 
and grade 2 in one. Time from HTx to CAV was 3.4, 9.1 and 12.8 years.
Malignancy
Six (13%) patients were diagnosed with PTLD and one patient with a melanoma. 
The PTLD cases all occurred within 1 year after HTx, and all cases were EBV-related. 
Treatment consisted of Rituximab in 4 patients, lowering of immunosuppression in 1 and 
chemotherapy in 1 patient who was diagnosed with monomorphic PTLD and central 
nervous system involvement. None of the patients died as a result of malignancy.
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Figure 4a. Frequency of rejection episodes per patient 
Figure 4b. Grades of rejection, as percentages of total amount of treated rejections
2R and 3R grading based on the ISHLT classification, NBP: non-biopsy proven graft rejection
Infectious complications
Fifteen (32%) patients had an EBV infection, 11 patients (23%) a CMV infection, and 7 
patients (15%) a varicella zoster infection. Four bacterial infections were found. Other 
infections consisted of Candida Albicans infections (1 spondylodiscitis, 1 sepsis), 1 
pulmonary Aspergillus infection, 1 Cryptosporidium diarrhea, 1 Pneumocystis Jerovici 
Pneumonia infection, 1 clostridium difficile colitis and 1 paronychium with lymphangitis.
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Psychiatric disorders
Nineteen (40%) patients were newly diagnosed with some sort of psychiatric disorder. 
The most common disorders were an anxiety disorder (n=7, 14%), depression (n=4, 9%), 
sleeping disorder (n=2, 4%) and eating disorder (n=2, 4%).
Other complications
Neurological complications were found in 7 patients (15%) and consisted of Posterior 
Reversible Encephalopathy Syndrome (n=3), epileptic insult (n=2), peripheral neuropathy 
(n=1) and a transient ischemic attack (n=1), all without long-term sequelae. Temporary 
insulin dependent diabetes was diagnosed in 5 patients (10%). Kidney function was 
reduced in 21 patients (45%), GFR was 30-90 ml/min/1.73 m2, none required dialysis or 
kidney transplantation.
Long-term outcome
On the Karnovsky Lansky scale, at the last follow to up visit, patients scored median 100 
points, [IQR 80 to 100], indicating that the majority of patients was able to carry on normal 
activity. Mean shortening fraction on echocardiography was 39% (SD: 6). Twenty patients 
performed a CPET on the last follow -up visit, median peak VO2 was 29 ml/kg/min [IQR 
23 to 37], 78% [IQR 63 to 89] of predicted. At last follow -up visit median SDS length was 
higher than at HTx, -0.9 [IQR -1.6 to 0.9] versus -1.2 [IQR -2.5 to 0.6] at HTx, (p=0.007), 
indicating catch-up growth after HTx, Figure 5.
Figure 5. SDS score of length, at HTx and at last follow-up visit, (n=47, p=0.007)
HTx, heart transplantation 
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COMMENT
In this study we found that 68% of patients listed for HTx underwent transplantation, and 
mortality on the waiting list was 23%. Five- and 10-year survival was 95% and 88%. Causes 
of death after HTx were dominated by graft failure due to non-compliance. The most 
important transplantation related complications were PTLD and CAV. 
Characteristics of the Dutch Htx program
Seventy-four percent of listed children were diagnosed with DCM, while only a few 
had congenital heart disease. The characteristics of our program are in line with ISHLT 
reports demonstrating important differences between the case mix and the number of 
transplantations between North American and European pediatric HTx centers. In North 
America 2/3 of the centers perform more than 10 transplantations per year and more than 
40% of transplants are in (young) children with mostly failed palliation of univentricular 
hearts. In contrast, in Europe 60% of the centers perform less than 5 transplantations 
per year and congenital heart disease represents only 20% of the case mix (2,12). Recent 
reports indicate that in children with single ventricle physiology the transplantation 
rate is only around 1% and mainly confined to young children with (severe) systemic 
ventricular dysfunction (13). This is a group of children we have not typically evaluated 
for heart transplantation. In summary, ours would be a typical small- to medium sized 
European pediatric HTx program, the number of CHD transplants being at the low side of 
the spectrum. 
Waiting list outcome
We review our results against a background of a low HTx rate within one year of diagnosis. 
Our previous report on a low early HTx was derived from a nation-wide retrospective 
cohort study covering all children with DCM that presented between 2005 and the end 
of 2010 (5). In a recent analysis of children with DCM presenting between 2010 and 2017 
we found the same outcome (unpublished data), indicating that the low transplantation 
rate in the 1st year after diagnosis is consistent. The question is whether, compared to 
international literature, our low early HTx rate is associated with more severely ill patients 
on the waiting list, which could negatively affect waiting list outcome. The SCTR reports 
on a cohort of 3098 children and show that 56% of children with DCM are UNOS 1A at 
listing, indicating continuous mechanical ventilation and/or MCS. Overall 1-year waiting 
list mortality was 17% (14). The ISHLT database shows that 50% of children with DCM over 
1 year of age, are bridged to HTx on a VAD. Pietra et al report a waiting list mortality of 11% 
in children with DCM specifically (15). And lastly, Eurotransplant reported an overall 1-year 
waiting list mortality between 13% and 30% (12).
In this study, 74% of children were diagnosed with dilated cardiomyopathy and 41% of 
children were on MCS on the waiting list. We tend to reserve listing early after diagnosis 
to patients who require MCS or who cannot be weaned of inotropes as shown in Figure 
1a and b. The group of children who underwent transplantation or died while waiting 
within 1 year of diagnosis, was more often supported on MCS and waitlist mortality was 
higher as compared to the children who died or underwent HTx more than one year after 
diagnosis. However, overall percentage of MCS and waiting list mortality was within the 
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range of international literature. We therefore conclude that our listing strategy and a low 
early transplantation rate are not associated with an overall negative effect on waiting list 
outcome.
Survival after HTx
Given the low number of children with CHD in our cohort, the fairest approach would 
be to compare our results to conditional 1-year survival which leaves out early post-HTx 
mortality which is relatively high in CHD patients and infants (2). The ISHLT reports 5- and 
10-year conditional survival of 86% and 74% respectively, and up to 90% and 78% in the 
most recent era 2004-2016. Survival in our cohort was 95% (95% CI 88 to 100) after 5 
year and 88% (95% CI 76 to 100) after 10 years (2). This puts our results in a comparable 
range, although numbers are limited and median follow-up was only 5.3 years. Overall, we 
conclude that short- and intermediate term survival after HTx is favorable and comparable 
with international data.
Morbidity after HTx
We found rejection in 43% of patients in the first year after HTx which is in line with other 
single center studies who report rejection in a range of 34% to 76% (16,17). The ISHLT 
database reports treated rejection in only 15% of patients in the first year after discharge. 
However, the early in-hospital rejections are not taken into account, which may explain 
part of this difference (2).
PTLD is reported in approximately 10% of patients after 10 years (18,19). In our cohort, the 
incidence of PTLD was 13%, which is in the same range as the 4% - 12% reported in other 
single center studies (16,17,20-22).
CAV was present in 6% of our patients. The rate of CAV was low compared to international 
data, in which 33% of patients were affected 10 years after HTx (2). This is probably 
explained by our limited number of patients with follow-up > 10 years.
In our cohort, one patient died as a result of a pneumocystis jerovici pneumonia. No 
patients died of bacterial infections. One study reported bacterial infections in 164 HTx 
patients (60%) and mortality as a result of infection was 5% (23). Similar results were 
reported by the PHTS (24). Bacterial infection rate is low in our population, which may 
be related to the low number of children younger than 6 months who are predominantly 
affected by bacterial infections. Underreporting cannot be ruled out.
The proportion of patients who develop a psychiatric disorder is relatively high in our 
cohort. Literature on psychosocial outcome after HTx in children is scarce, but several 
studies indicate that this is an important issue. Whether psychiatric disorders predict post-
transplant non-compliance is not clear (25).
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Functional outcome
Functional outcome seems to be excellent, and in line with recent analysis of ISHLT 
data (9). Furthermore, length growth shows a significant trend to catch-up, which is an 
encouraging finding. Although only a subset of patients performed a CPET, median VO2 
max was 78% of predicted VO2 max.
Limitations
A limitation of our study is the relatively small size of the cohort and the limited number 
of patients who have a post-transplant follow-up longer than 10 years which precludes all 
too strong conclusions. Also, this is a retrospective study with inherent limitations.
Conclusion
Despite a low early transplantation rate, mortality on the waiting list is in line with 
international literature, and outcome after HTx is favorable. Heart transplantation is a viable 
option for a selected group of children with end-stage heart failure without alternative 
treatment options. Currently, donor shortage remains the critical limitation for HTx.
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In this thesis we aimed to obtain better insight into the etiology of childhood DCM; second, 
we evaluated the contribution of temporal evolution of risk factors in predicting adverse 
outcome, and third, we evaluated treatment of children across the clinical spectrum of 
DCM. Here we start with commenting on the CARS cohort as the basis of our study. We will 
than focus on insights we gained in understanding disease etiology and in particular the 
role of genetics and cell biology. Furthermore we will discuss the development of feasible 
prediction models and leading points for improving treatment.
CARS 
In the Cardiomyopathy Registry Study (CARS) we prospectively collected longitudinal 
data of children with DCM in different domains that reflect disease severity, and that 
are thought to be associated with outcome. During 7 years (2010-2017) we aimed to 
include all newly diagnosed children and prospectively gathered data of children who 
were already diagnosed before the start of the study. At the end of the study we had 
included 144 children, 103 children (72%) were newly diagnosed with DCM and 41 
children (28%) were diagnosed before 2010 (the large majority diagnosed between 2005 
and 2010). The inclusion rate of 93% was favorable, and loss to follow-up less than 5%. 
When we critically appraised the included patients, two possible issues arose that might 
have led to a selection of patients. First, we noticed that during the last years of CARS 
the yearly number of newly diagnosed children did not match the 20 we expected based 
on previous incidence rates. In seven years we expected to include 160 children in total, 
which are 16 more than we actually did include. This might have been caused by a failure 
to include patients that died within hours or days after presentation to the hospital in 
whom diagnosis may have been missed or not reported to the study team. We also may 
have missed patients who recovered quickly after initial presentation and have not been 
reported to the study team for that reason. Otherwise the incidence rate is truly lower 
than expected, for reasons not known to the study team. Secondly, the 41 children with 
a previous diagnosis are most certainly selected as they survived to study inclusion, thus 
leaving out the children who died early after presentation (approximately 20% in the first 
year after diagnosis). On the other hand, we cannot rule out the possibility that patients 
that already had (partly) recovered were not were not included in this group of children 
with a previous diagnosis as well. The net result of these opposing selection mechanisms 
is represented by the 41 children we included. At least we know that the survival rate and 
the HTx- free survival rate of the children that presented between 2005-2010 (which is 
cohort of all children with DCM we could retrospectively identify) is similar to the cohort of 
newly diagnosed children. In the 2005-2010 cohort, HTx-free survival was 82% 1 year after 
diagnosis and 72% 5 year after diagnosis, which is similar to 82% and 72% we found in the 
newly diagnosed children (1). Thus, the event rate in children with DCM seems consistent 
over the last 12 years and we concluded that the large majority of the 41 children with a 
prior diagnosis were obtained from a cohort with the same characteristics. Adding the 
children with a previous diagnosis provided a relative large number of children we were 
able to follow for many years (median follow-up was 3.8 years in the children who did not 
reach a study endpoint). In a rare pediatric disease as DCM, this approach is suboptimal 
but inevitable. We combined therefore the two cohorts in the analysis of association 
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between temporal evolution of risk factors and outcome, keeping in mind the limitations 
of this construction.
ETIOLOGY OF DCM
Why do we need to know the etiology of DCM in children? First of all, because we are asked 
by parents every time a child presents with DCM, what causes this disease. Also, doctors 
need to find a definite etiology as it is related to outcome and might have therapeutic 
consequences. For example DCM caused by myocarditis is known to have a more favorable 
course over time. When a genetic disease is found that renders the child prone to rhythm 
disturbances, an implantable cardioverter-defibrillator (ICD) should be considered. In this 
thesis we focused on 2 aspects of disease etiology that are closely related: genetic origin 
of DCM and cellular patho-mechanisms that underlie DCM.
Genetics of DCM
Starting point of the genetic study was to find out how many children with DCM underwent 
genetic testing, and if genetic etiology was related to outcome. First of all we found that 
only 74% of children were tested (Chapter 2). This is an outcome that we should not 
accept now that guidelines are available and genetic testing is easily accessible (2). Ways to 
improving the rate of genetic testing might be clear counseling of parents and explaining 
the pros and cons of genetic evaluation, supported by an interpreter when language 
barrier is an issue. Also, optimizing collaboration between pediatric cardiologists and 
clinical geneticists will most likely contribute to an increase in testing, but this will require 
continuous effort of both disciplines.
Secondly, the yield of testing was 36%, that is, in 39 of 107 children that were genetically 
evaluated we found a (likely) pathogenic variant. Although this is not a low yield 
compared to other pediatric DCM cohorts, it certainly leaves room for improvement (3-
8). As described by Herkert et al, when copy number variant analysis and whole exome 
sequencing would be performed in all children with DCM, the yield would potentially 
increase up to 54% (5).
Interestingly, we also found a pathogenic variant (LMNA) in a child that was initially 
diagnosed as DCM related to myocarditis. This finding fits in the mounting evidence 
that previously silent genetic defects might predispose to DCM early in life when an 
environmental factor (such as myocarditis or chemotherapy) acts as a second hit (9-12). 
In the CARS study, 7 of 23 children diagnosed with myocarditis, and 2 of 8 children with 
anthracycline related DCM, were genetically tested. It would be sensible to start with a 
genetic evaluation of those 22 children. 
Lastly, but perhaps most importantly, we demonstrated that children with DCM who carry 
a (likely) pathogenic variant were at a 2.8 times increased risk for death or HTx compared 
to children without a variant. 
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Up until now, the CARS cohort is the largest cohort of children with DCM that have been 
genetically tested and that showed this clear association. At this moment, the direct 
translation of a genetic variant into individual risk prediction is not possible as genetic 
DCM is a heterogeneous disease and penetrance is variable (3). However, the rationale 
for offering a genetic test to all children with DCM regardless of a presumed etiology is 
evident. When a (likely) pathogenic variant is found, children should be monitored with 
increased vigilance for disease progression, and devices to reduce the risk of sudden 
cardiac death should be considered when appropriate. Also, identification of at-risk 
relatives whether affected or clinically unaffected, may also have implications for genetic 
counseling and reproductive decision making. Most likely, large registries of children 
with DCM like the Pediatric Cardiomyopathy Registry (PCMR), will report on genetic 
testing and associations with outcome in the near future (13). Furthermore, improving 
the next generation sequencing techniques will broaden our knowledge on disease 
causing variants, but also on genetic modifiers that affect penetrance of DCM (14, 15). A 
step downstream in genetics, the field of gene expression and translational regulation, 
is increasingly recognized to play an important role in patho-mechanism of DCM (16). 
Interestingly, this might be uniquely regulated in children with DCM. Tatman et al recently 
showed a gene expression profile that affected cytokine signaling, signal transduction, 
and transcription that was not observed in adult DCM (17). This might be a leading point 
to develop targeted therapy in children with DCM and again underscores the importance 
of pediatric-focused investigations.
Hopefully, large cohorts of unselected children with DCM and novel genetic techniques 
as well as genetic knowledge will provide further insight into the relation between geno- 
and phenotype that will support personalized care.
Cellular patho-mechanisms of DCM in children
In this study we started with myocardial tissue of 11 hearts we obtained from children 
with DCM in end-stage heart failure at the time of heart transplantation. We found 
greatly reduced force generating capacity of single cardiomyocytes that was caused 
by a significant reduction in myofibril density (Chapter 3). Also, the ability to increase 
contractility upon stretch, which is the cellular basis of the Frank-Starling mechanism, was 
impaired. Furthermore, we did not find consistent upregulation of the compliant isoform 
of the giant elastic protein titin (N2BA). The compliance of titin, expressed as the ratio 
between N2BA/N2B, did not affect contractility. This implies that other factors underlie 
this impaired length-dependent contractility. 
The question that drove this study was whether pediatric DCM differs from adult DCM, 
which might explain a more aggressive course of the disease in children and no clear 
improvement on standard heart failure pharmacotherapy. Also, proven differences could 
be leading points for further research and patho-mechanism guided therapy. We found that 
pediatric DCM differed from adult DCM in several aspects. First, the decrease in myofibril 
density seems to be specific for pediatric DCM, at least it has not been found in adult iDCM 
yet(18). Whether reduced myofibril density is due to an inability to increase myofibril 
synthesis or is caused by an increased myofibril degradation needs to be investigated 
first. Second, we found no consistent upregulation of compliant titin (N2BA) as opposed 
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to adult DCM (18, 19). In the early stages of the disease, increasing compliance might a 
way of the myocardium to function under overstretched conditions. The observation that 
children do not seem to upregulate compliant titin could be explained by limited abilities 
for cardiac remodeling in general, as shown by Patel et al (20). If children with DCM display 
limited cardiac remodeling and differ from adult DCM in reduced myofibril density, than 
this might explain that standard therapy that is focused on treating adverse cardiac 
remodeling is not effective in children with DCM (21, 22). Rather, it would be worthwhile 
to focus on regeneration of myofibrils instead. However, it should be noted that the tissue 
that we studied was derived from end-stage DCM. It might also be possible that such 
compensating mechanisms might (no longer) function at this phase of the disease. 
Our study is a first step in elucidating cellular patho-mechanisms in children with DCM, 
but the road to patho-mechanism guided therapy is still long. It proofs to be complex 
to distinguish primary etiology-specific pathogenic effects like genetic mutations from 
secondary disease remodeling. However, in adult DCM, recent studies show that different 
causative genetic mutations lead to different cellular changes (18). If we can link specific 
genetic mutations to distinct patho-mechanisms than this would be a leading point 
for targeted therapy in genetic DCM patients. To study the pediatric counterpart is 
troublesome as the acquisition of cardiac tissue of children with DCM early in the disease 
is very difficult. The field of research in cardiomyocytes which are derived from patient 
fibroblasts can overcome the scarcity of pediatric DCM tissue. This principle has recently 
been demonstrated to work in ALPK3 -deficient cardiomyocytes generated from induced 
pluripotent stem cells obtained from patient skin tissue. Here abnormal calcium handling 
was shown (23). Studies like these are essential to understand patho-mechanisms related 
to genetic disease and to develop therapies that serve the pediatric DCM population.
HOW TO PREDICT OUTCOME – RISK FACTORS FOR ADVERSE OUTCOME
An important part of this thesis is the exploration of the use of serial measurements of 
known risk factors in the prediction of adverse outcome. In Chapter 4 and Chapter 5 the 
results of these efforts are shown. 
First of all, we conclude that modeling the serial measurements of the separate risk factors 
provides a clear picture of the average evolution over time in children with and without 
the study endpoint (death or HTx). The majority of the risk factors we studied show a 
clear association of the evolution over time with the study endpoint. The profile of 4 risk 
factors in children who reached the study endpoint was clearly distinct from those who 
did not: no decrease in NT-proBNP or LVIDd, a severe decrease in length Z-score and an 
increase in NYU PHFI. Furthermore, the temporal evolution of these 4 risk factors also 
distinguished the children who reached the study endpoint from those with ongoing 
disease. Most registry based studies compare children with the study endpoint to those 
without. However, in clinical practice it might be more useful to have tools to discern 3 
categories: children who reach the SE, those who remain ill but stable, and those who 
recover. Based on our own data and other registries we suspect that recovery in general 
takes place early, the majority within 1 year after diagnosis (1, 24). The clinical challenge 
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is to identify within the group of children who do not recover, who is at the highest risk 
for adverse outcome and should be considered for HTx. Ours is the first study to analyze 
this subgroup of children who remain ill but do not reach the SE. The finding that the 
abovementioned risk factors also discern these children from those who reached a SE 
supports outpatient management and the decision to suspend listing for HTx. 
Within the field of pediatric DCM, it is unique that we were able to collect prospective 
data in a relative large cohort which we believe is an adequate representation of the 
whole spectrum of children with DCM. The data we collected cover multiple relevant 
domains that are related to disease severity and linked to outcome: exercise tests (6MWD), 
biomarkers (NT-proBNP), heart failure score (NYUPHFI) and echocardiographic parameters 
of left ventricular function (LVIDd and GLS). However, a few critical remarks on the CARS 
study should be made, as these also indicate the possibilities for improvement.
The CARS study cohort consists of children with a diagnosis before inclusion in this study 
(before 2010), as well as children who are included directly after diagnosis. This may have 
induced a selection bias as we do not know which children we missed in the group with 
a prior diagnosis: how many recovered and how many died before 2010. We argued that, 
by and large, we are informed about the group of children that stems from the time frame 
2005 to 2010. This group was well described in a previous publication by den Boer et 
al (1). Although this covers the large majority of included patient we do not have the 
complete picture. A way to address this issue is to go back to the eight academic centers 
and retrospectively collect all DCM diagnoses in children as well as hard endpoints from 
the date of the diagnosis of the first patient we included. This would be a huge effort but 
most likely very rewarding.
Furthermore, in the multivariate analysis, NT-proBNP remained the only independent risk 
factor for adverse outcome. This might be due to an underpowering of the study. Den Boer 
et al previously calculated that, based on the Dutch population, we would need to collect 
data for 23 years to obtain enough data to include six risk factors in the analysis. This 
calculation was based on a ‘rule of thumb’ that at least 10 endpoints are needed to allow 
1 risk factor in the multivariate model. Alternative approaches to calculate sample size for 
multivariate analyses are conceivable to (25). Either way, we need large data sets to gain 
sufficient power, and a multi-center study design seems the only sensible way forward. 
In this way we might create a heart failure score, based on multiple variables, similar to 
the adult counterpart the Heart Failure Severity Score (26). Levy et al elegantly pointed 
out that heart failure risk models would improve if: 1) they were properly validated; 2) 
incremental value of adding new variables to the model would be assessed and 3) online 
calculators were made to allow for easy provider use (27). A pediatric heart failure score 
thus composed might be helpful in risk prediction in the global pediatric DCM population, 
and support counseling of patients and families. 
Also, we defined one hard study endpoint: death or HTx, but we also recorded the status 
of the surviving patients at the end of the study period: ongoing disease or recovered. In 
clinical practice it would be relevant if these three groups could be characterized and the 
temporal evolution of risk factors could be determined for all three groups. Because of 
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the limited number of endpoints we were not able to perform these analyses, but again 
a multicenter design would allow for such analyses. Than we could explore whether both 
children who reach an SE, children who have ongoing disease and children who recover 
display a distinctive profile over time.
For now, we should pursue to maintain this Dutch cohort in long-term follow- up and 
record data on endpoints of death, HTx and recovery, as well as the risk factors we identified 
to be most helpful in this thesis. We propose to obtain NT-proBNP, LVIDd, length Z-score 
and NYU PHFI two times per year in the first year after diagnosis and yearly thereafter. 
6MWD% was strongly related to outcome but stable over time, so 2 tests in the first year 
after diagnosis seem needed to reliably estimate 6MWD%. Thereafter repeating 6MWT 
seems of no added value. Questions that are to be answered are whether NT-proBNP 
is also a strong predictor in long term outcome. Long term follow-up is also needed to 
discern recovery from remission. Everitt et al demonstrated recurrence of heart failure in 
children with DCM who were recovered (28). In a recent study by Maher et al on children 
recovered from DCM, subtle cardiac dysfunction was found (measured by left ventricular 
layer-specific myocardial strain) in patients with recovered DCM. Long-term follow-up is 
therefore recommended in these patients (29). Also, recovery might take place later on in 
the disease as well, as shown by Fenton et al so which also argues in favor of long- term 
follow-up (30).
OPTIMIZING MEDICAL TREATMENT OF CHILDREN WITH DCM
Pharmacotherapy
In daily practice we are confronted with children with DCM who need medical treatment, 
a large part without a set etiology but all sharing a phenotype of systolic dysfunction 
and cardiac dilation. In optimizing pharmacotherapy three important issues arise. First, 
can we demonstrate effectiveness of standard therapy (ACEi and B-blockers). Second, 
how to optimize the treatment that is already available and third what possible new 
developments are in medical therapy, taken into consideration the characteristic patho-
mechanisms in pediatric DCM.
The first question is notoriously hard to answer. In this era where ACEi en B-blockers are 
already accepted as standard therapy, randomized placebo controlled trials are neither 
achievable nor ethical. This leaves the pediatric population with a treatment based on 
paradigms derived from adult heart failure and the question is whether this is good 
enough. Recently however, in the field of adult heart failure, a double blind trial compared 
standard therapy (enalapril) to the new heart failure drug LCZ696 (angiotensin receptor–
neprilysin inhibitor). The investigators convincingly showed that LCZ696 was superior to 
enalapril in reducing the risks of death and of hospitalization for adults with heart failure 
(31). Such a study design would also be suitable for the pediatric DCM population and 
currently a study on LCZ696 versus enalapril in children with systemic left ventricular 
systolic dysfunction is undertaken (32). This PANORAMA-HF study will determine if LCZ696 
improves clinical outcome and symptoms as compared to enalapril and will not focus on 
hard endpoint as death or HTx alone. Choosing such a study end-point allows meaningful 
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analyses with a substantial lower number of patients and is an important step in drug 
research in children with a relative rare disease as DCM. 
The second question on optimizing current treatment will focus on the ACEi enalapril, but 
the concept applies to other ACEi’s and B-blockers too. A way forward is linking adult data 
on pharmacokinetics of ACEi to the pediatric population. This approach can be motivated 
by assuming that, regardless what causes DCM, both adults and children share the same 
pathophysiology of heart failure. The decrease of systemic blood flow evokes a number 
of compensatory mechanisms through activation of the sympathetic nervous system 
and renin-angiotensin system (33). However, this activation is also maladaptive and 
contributes to myocardial damage, water and salt retention as well as worsening of heart 
failure. Medical treatment by means of ACEi is primarily based on blocking the effects of 
the renin-angiotensin system activation. Because efficacy has been demonstrated in adult 
with heart failure, pharmacokinetic bridging will be sufficient for extrapolation of efficacy 
of enalapril from the adult population to this pediatric population (34). In this thesis 
we reviewed available literature on the safety of ACEi in children with heart failure and 
concluded that ACEi are relatively safe, though low weight, young age and being prone 
to dehydration, were factors carrying an increased risk for adverse reactions (Chapter 6). 
This was the starting point of a larger research project to develop an age-appropriate 
pediatric enalapril formulation (EU FP7 LENA project). This study also obtained pediatric 
pharmacokinetic data to demonstrate the dose-exposure relationship in children with 
DCM in order to identify the doses that lead to an exposure equivalent to that achieved 
during the treatment of adults. We participated in this study and included 15 children 
with DCM. As we are (expectantly) awaiting the analyses at this moment, the results could 
not be described in this thesis. In the CARS cohort we also obtained pharmacokinetic data 
of both carvedilol and enalapril. These results too are expected in the near future and will 
provide further data to bridge the gap between adult and pediatric pharmacokinetic data.
The third issue on new mechanistic leading points for novel pharmacotherapy might be 
applicable in cases where DCM is diagnosed in a relatively early stage, for instance after 
screening of siblings of a child with the disease. Here, DCM has not progressed to an end-
stage and downstream phase that is no longer amendable to a mechanistic approach 
(35). An example of this strategy is to target the molecular consequences of a LMNA 
mutation. This has at first been studied in mice where in LMNA-mutated mice an increased 
cardiac activity of p38 MAP kinase was found (36). When the mice were treated with an 
inhibitor of p38 (ARRY-371797), LV dilation and deterioration of LV function were no longer 
found. Currently, a double-blind randomized placebo-controlled phase 3 trial is running 
which studies the benefit of ARRY-371797 on change in 6-minute-walking distance in 
symptomatic DCM patients caused by LMNA mutation (NCT03439514). Outcome of this 
study will stimulate further studies into the use of targeted therapy, hopefully also in the 
pediatric population.
Mechanical support of the circulation
After a careful evaluation of our mechanical support of the circulation (MCS ) program 
we concluded that ventricular assist devices (VAD) are an acceptable therapeutic tool to 
bridge children with end-stage heart failure to transplantation or recovery (Chapter 8). 
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In our hands, 61% of children with end-stage heart failure, supported on VAD, survived to 
heart transplantation or recovery, and mortality on the waiting list decreased from 44 to 
21%. However, improvement of outcome in these children is needed as still a significant 
number of children die on a VAD, or have lasting neurological disability due to VAD related 
complications. Here, a critical issue might be optimal timing of VAD implantation in children 
with acute decompensated heart failure (ADHF). Too early leads to an increase in VAD 
implantations and increases the risk of serious VAD related complications; too late on the 
other hand, results in low cardiac output and end-organ failure which is associated with 
increased mortality on the waiting list and after HTx (37-41). In adults, low systolic blood 
pressure, high urea and creatinin as well as elevated arterial lactate and hypothermia are 
strongly related to in-hospital mortality (42-44). Presence of these factors support clinicians 
in timing of VAD placement, but timing for the individual patient remains a weighed 
decision. The body of literature on risk factors for imminent death in children with ADHF 
is limited. Wong et al demonstrated that serial NTpro-BNP levels increased in 24 pediatric 
ADHF patients who went on to require mechanical support of the circulation (45). Medar 
et al described similar findings in 16 pediatric ADHF patients (46). Notably, the last two 
authors report that the trend, rather than the absolute value of NT-pro-BNP should be 
taken into account in predicting outcome in these patients, which again underscores the 
importance of repeating measurements. Maybe clinically most applicable is the finding 
of Singh et al that the hemodynamic profiles cold-dry and cold-wet were associated with 
mortality in children listed for HTx (40). In this study hemodynamic profile was assessed 
invasively by pulmonary capillary wedge pressure and cardiac index. In adults with 
ischemic cardiomyopathy it has been shown that hemodynamic profiles are concordant 
with clinical evaluation of cardiac output and congestion in 70% of cases (47). Whether 
clinical evaluation correlates with intracardiac hemodynamics in children with DCM and 
advanced heart failure, and whether hemodynamic congestion and hypoperfusion can be 
diagnosed clinically could be subject of future research. Until then, this approach hands 
on, during the rounds on the PICU, might be equally good. In addition to increase in NT-
proBNP, the children who are cold (and not the ones who are most congested (wet)) might 
be at the highest risk of dying and should be actively considered for VAD implantation. 
Furthermore, anti-coagulatory strategies sometimes appear more art than a science, and 
further refining evidence based-strategies is needed to prevent thrombo-embolic events. 
Heart transplantation
We aimed to evaluate our outcome after HTx against a background of a transplantation 
rate that is consistently low (3 to 6%) in the first year after DCM diagnosis as compared 
to other registries, with data now stemming from 2005 to 2017 (24, 48). Whether in our 
program we truly are more restrictive in listing children for HTx than other programs is 
hard to proof. We would need data of all children that were evaluated for HTx, including 
the ones that were not listed. In our study we only had access to data of the listed children 
which hampered elucidating this issue. However, we did show that the listed children 
were severely ill (the large majority of children with DCM were supported on a VAD 
or on inotropes) and otherwise most likely would have died, thus indirectly arguing a 
restrictive policy (Chapter 9). Future research may look into the data of all children that 
were evaluated for HTx and might find convincing evidence that we are truly restrictive in 
listing for HTx. The results of our HTx program are favorable. Mortality on the waiting list 
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and survival after HTx were well within international standards and complications after 
HTx were relatively low too. Of note, numbers were limited and median follow-up was 
only 5.3 years. 
There are several ways to further improve management of HTx patients and long-term 
outcome. In this respect, non-compliance is a significant issue, as it accounted for 2 of the 
3 deaths in our patient cohort. Non-compliance has been reported in 18% of adolescents 
and more than 2 episodes resulted in a mortality rate of 56% in the next 2 years(49). 
Similarly, smaller studies reported non-compliance in 43% up to 65% in teenage transplant 
recipients (50). Means to improve compliance in adolescents would be peer support 
groups, smartphone apps, group visits and improved transition to self-management 
and adult care (51). Whether such an approach would result in better compliance and 
reduction of post-transplant deaths could be subject of future research.
Also, donor shortage is a critical factor in waiting list mortality. Expanding the donor pool 
with ABO incompatible (ABOi) donors has been shown a sensible and safe strategy (52-
54). Eurotransplant reported that 17% of donor hearts <2 years were not used and that 
by expanding the ABOi program, a decrease in waiting list mortality can be achieved (55). 
Another option would be to include donation after circulatory death (DCD) transplants. 
Several studies showed the potential gain, including a four-fold increase of donor organs 
(56-59). Recent studies from Australia and the UK report outcomes in adults after DCD HTx 
that are comparable to that of recipients of donation after brain death (DBD) donors(60). 
The ISHLT reported DCD transplants in 21 pediatric patients (0.5%) only. DCD 1-year 
survival was significantly lower than DBD, but probably related to unfavorable acceptor 
characteristics (61). Potentially, the use of ex-vivo preservation to optimize graft function 
would enable DCD transplants (62). Recipient characteristics, as well as short- and long-
term patient outcome, would have to be monitored with utmost acuity.
Lastly, we should critically evaluate psychological problems and quality of life (QoL) in 
children after Htx. In a pilot study we performed in 11 children after HTx, we found that 
QoL only modestly improved after HTx and that parents seemed more content than their 
children. Also, we found a substantial number of patients who developed a psychiatric 
disorder (Chapter 9). Literature on psychosocial outcome after HTx in children is scarce. 
Multiple studies however indicate that psychological problems are more prevalent than 
in healthy children (63-65). Either way, psychosocial care should be standard and liberally 
available for children after HTx. 
FUTURE PERSPECTIVES 
The insights we gained in our study call for further research. Future studies in children 
with DCM should first aim to further elucidate disease etiology and understand 
pathophysiology. The fruitful collaboration with clinical geneticists and physiologists 
during this study would certainly allow for new studies. A study proposal is being prepared 
by a pediatric cardiologist (Dr. M. Dalinghaus, EMC Rotterdam) and a physiologist (Prof J 
.van der Velden, VUMC, Amsterdam). In this study, translational aspects of DCM will be 
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addressed by studying protein profiles in blood samples of children with DCM. This will 
provide further insight into translational regulation which is increasingly recognized as 
a critical patho-physiological process (16). Furthermore, the future of genetic research 
might be in large cohorts of children with DCM that are well phenotyped in combination 
with extensive genotyping to determine geno-phenotype relations. Also, the path of 
research in cardiomyocytes which are derived from patient fibroblasts is promising. This 
might be the basis from which we can link specific genetic mutations to distinct patho-
mechanisms and this would be a leading point for targeted therapy. With regard to 
the development of risk prediction tools: multicenter studies are the only rational way 
forward. As we have seen in a multi-center multi-national drug study (LENA –results not in 
this thesis) it is possible to collaborate and merge databases of children with DCM. Similar 
to the PCMR, a registry of all European children with DCM could generate data that would 
allow for the development of more robust risk stratification than a single center study like 
ours. Partnerships that already exist (such as LENA) might be used for that end. And lastly, 
important steps need to be made to bring pharmacotherapy for children with DCM to 
a next level. A starting point might be to find dose-response relations of standard heart 
failure drugs for the different age categories. The CARS contributed in this respect by 
collecting samples of enalapril and carvedilol, the results are expected in the near future. 
Here also large cohorts of children with DCM in all age ranges are needed to allow for 
robust pharmacokinetic modeling.
What I would like to accentuate here at the end of the discussion is the importance of close 
co-operation. We have to pool existing knowledge and skills if we want to make progress 
in the treatment of children with DCM. This co-operation applies to the laboratory and 
clinic, centers sharing data, different academic disciplines, experienced senior clinicians 
and research nurses as well as young investigators. This will speed up progress, and, not 
unimportant, it makes life more fun.
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SUMMARY
Dilated cardiomyopathy (DCM) is defined as depressed function of the heart muscle and 
dilation of the left ventricle. Clinical symptoms of the disease vary widely; some children 
do well with no impairment in daily life, while others develop end-stage heart failure and 
die or need heart transplantation (HTx) as last resort therapy. Starting point of this thesis 
is the concept that if we want to improve outcome of children with DCM, we need to 
know which children are at the highest risk for adverse outcome. Essential in this process 
is that we need to understand the disease better and gain insight in what marks disease 
progression. Many questions remain to be answered, for instance, what is the role of 
genetics in DCM and how is a genetic cause related to outcome? What are the processes 
by which end-stage heart failure develop, and in what ways is DCM in children different 
from adult DCM? How can we recognize the children at the highest risk for adverse 
outcome? And how could this knowledge affect the way children with DCM are treated, 
either in terms of medical therapy, the institution of mechanical circulatory support or 
timely offering HTx? Here we provide a summary of the 8 studies included in this thesis, 
which are preceded by a general introduction and followed by a general discussion. 
Chapter 1 provides a general introduction into dilated cardiomyopathy in children. The 
global contours of current knowledge and leading points for new research that led to this 
thesis are described. 
The etiology of DCM in children is a strong predictor of long-term outcome. For instance, 
it is known that children with DCM related to myocarditis have a more favorable prognosis 
than those with idiopathic DCM. It is assumed that in many cases of idiopathic disease 
yet unrecognized genetic disease may underlie the cardiomyopathy. However, not much 
is known about the utility of genetic testing for risk stratification in children with DCM. 
Studies in adult DCM patients have reported a more severe phenotype and earlier onset 
in those with a pathogenic genetic variant than in variant-negative patients. Chapter 2 
describes the current practice and results of genetic evaluation in our national cohort of 
children with DCM, and reports the relation between the presence of (likely) pathogenic 
variants and clinical outcome. We found that 75% of children were tested and 36% of 
those had a genetic cause of DCM. We also found that the children with a genetic cause 
had a serious increased risk for death or HTx compared to children without. These findings 
highlight the importance of early genetic testing in all children with DCM. Determination 
of a genetic etiology can provide a valuable contribution to predict clinical outcome in 
children with DCM. 
In Chapter 3 we address the similarities and differences between pediatric DCM and adult 
DCM at a cellular level. Here, we describe how found differences might be a step towards 
understanding the more aggressive course of the disease in children, and maybe also a 
clue why no clear improvement on standard heart failure pharmacotherapy is observed. 
In this study we started with myocardial tissue of 11 hearts we obtained from children 
with DCM in end-stage heart failure at the time of heart transplantation. We found 
greatly reduced force generating capacity of single cardiomyocytes that was caused by 
a significant reduction in myofibril density. Combined with the observation that many 
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pediatric patients did not show an upregulation of compliant titin, this could imply that 
the cardiomyocytes do not undergo extensive remodeling and therefore cannot cope with 
the cardiac stress. The limited adverse remodeling in pediatric CM might have contributed 
to their early and progressive disease. In future research it might be worthwhile to explore 
therapies directed at regenerative capacity and myofibrillogenesis of cardiac muscle cells 
rather than reversal of cellular remodeling.
In Chapter 4 we evaluate the added value of repeated 6MWT in addition to a single 6MWT 
in predicting outcome in children with DCM. The 6-minute walk test (6MWT) is a safe, 
simple and accepted prognostic tool in adults with heart failure. In children, the 6MWT is 
also feasible and has been shown to be reproducible. The distance walked in a 6MWT can 
be expressed as a percentage of predicted, taken into account height, gender and age 
(6MWD%). We have shown that 6MWT is a useful tool to identify children with DCM at a 
high risk of death or heart transplantation. In children who are able to perform a 6MWT, 
6MWD% remains constant over time, early after diagnosis and in the years thereafter. In 
those reaching an endpoint, 6MWD% is significantly lower throughout time, than in those 
not reaching an endpoint. We propose that initially at least 2 6MWT are needed to reliably 
estimate 6MWD%, thereafter repeating 6 MWT has little added value.
In Chapter 5 we present our study on prospectively and repeatedly collected clinical and 
echocardiographic risk factors for death and transplantation in a national cohort of children 
with DCM. We explored the temporal evolution of these factors, as these potentially hold 
relevant information for clinical decision making. We found that the temporal evolution 
of 4 risk factors distinguished the children who died or underwent transplantation from 
those who have ongoing disease or recover: no decrease in NT-proBNP or left ventricular 
diastolic dimension, a severe decrease in length Z-score, and an increase a pediatric heart 
failure score. Similarly, when comparing children who reached an endpoint with children 
with ongoing disease solely, excluding those who recovered, we found comparable 
differences in the evolution of risk factors, although the effect size was smaller. In the 
multivariate analysis, NT-proBNP remained the only independent risk factor for adverse 
outcome. We conclude that in children with DCM, change over time in known risk factors 
for death or heart transplantation (HTx) is predictive for outcome. In children who do 
not recover, persistent high levels of NT-proBNP, no decrease in left ventricular diastolic 
dimension, severe stunting of growth and an increase in the heart failure score identifies 
those at the highest risk for death or HTx. In this study, with limited study endpoints, we 
identified NT-proBNP as the strongest independent predictor for adverse outcome. 
Chapter 6 reviews the safety of ACE-inhibitors for the treatment of heart failure in children 
based on an extensive search of all available literature. In adults, the most prevalent adverse 
events (AEs) related to the use of ACER-i are renal failure, hypotension, hyperkalemia, 
cough and angioedema. It is assumed that the safety profile of ACE-i differs from that for 
adults, but also for children of different ages, as growth and development contribute to 
variation in the disposition and effect of most drugs administered to children. In this study 
we concluded that first, ACE-i are considered relatively safe for children with heart failure, 
but renal impairment, hypotension and hyperkalemia are common adverse reactions. 
Second, low weight, young age, and being prone to dehydration, (e.g. an account of 
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gastroenteritis or high doses of diuretics) are factors carrying an increased risk for adverse 
reactions related to ACE-1 consumption. 
Considering the symptoms and prognosis of DCM, substantial effects on psychosocial 
wellbeing can be expected. The predictive value of depressive and anxiety symptoms 
in children with DCM has not been previously studied. Information on the predictive 
value of depressive and anxiety symptoms may be valuable for clinical management 
strategies. Depressive and anxiety problems may lead to poorer self-care and, in turn, 
to disease progression. In Chapter 7 we evaluate the level of emotional and behavioral 
problems and whether depressive and anxiety problems are associated with outcome. 
We found that, compared with normative data of same-aged peers, larger percentages of 
older children (6–18 years old) with DCM showed overall internalizing problems, anxiety 
problems, and depressive problems. These results are in line with meta-analyses in adult 
heart failure populations, which demonstrate an increased risk of anxiety and depression. 
We found that anxiety and depressive problems in children with DCM did not predict the 
risk of death and cardiac transplantation whilst controlling for heart failure severity. This 
is possibly explained by the fact that in children parents may compensate for children’s 
poorer self-care behaviors. Our findings however do demonstrate the importance of 
including routine screening for internalizing problems to the clinical management of 
children with DCM, and of providing psychosocial support attuned to the needs of these 
children.
Ventricular assist devices (VADs) are nowadays a well-accepted, long-term therapeutic 
option in adult end-stage heart failure. Implementation of VADs in the pediatric population 
has been troublesome due to technical problems and difficulties in medical management. 
However, in recent years, several centers have presented their experience with Berlin 
Heart EXCOR VAD as long-term support. They have shown that Berlin Heart EXCOR VAD 
is a reliable and relatively safe device in bridging children to heart transplantation or 
recovery. Since 2006, the Berlin Heart EXCOR Pediatric VAD has become available in our 
hospital. Chapter 8 describes the outcome of children supported with a VAD and the 
effect of the introduction of VAD on waiting list mortality is evaluated. We found that, 
in our hands, 61% of children with end-stage heart failure, supported on VAD, survive to 
heart transplantation or recovery. This modest survival rate most likely reflects a selection 
of a severely ill patient population. Although thrombo-embolic events on VAD lead to 
considerable mortality and morbidity, overall mortality in the children on the waiting 
list halved since the introduction of VADs. This supports the growing evidence that VADs 
are an acceptable therapeutic tool to bridge children with end-stage heart failure to 
transplantation or recovery.
Previously, we reported a low heart transplantation rate (3%) in children with dilated 
cardiomyopathy in the first year after diagnosis as compared to other registries (18%), 
without an increase in mortality. Our low early transplantation rate might reflect a policy 
that defers listing patients for HTx as long as possible, and that pursues stabilizing patients 
on oral heart failure therapy before listing. This listing strategy may, however, select children 
with more severe heart failure at listing, having an unfavorable risk profile that could affect 
outcome on the waiting list, and after HTx. In Chapter 9 we evaluate the outcome of 18 
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years of pediatric heart transplantation in the Netherlands against this background of a 
small- to medium- sized program mainly consisting of children with DCM, and a low early 
transplantation rate. In this study we found that 68% of patients listed for HTx underwent 
transplantation, and mortality on the waiting list was 23%. Five- and 10-year survival after 
transplantation was 95% and 88%, which is favorable compared to international data. 
Graft failure due to non-compliance was an important cause of death. The most important 
transplantation related complications were post-transplant lymphoproliferative disorders 
and cardiac allograft vasculopathy. We concluded that our listing strategy did not result 
in a selection of more severely ill patients and increased overall waiting list mortality as 
compared to large pediatric patient cohorts. Heart transplantation is a viable option for 
a selected group of children with end-stage heart failure without alternative treatment 
options.
In Chapter 10 the main findings of the studies in this thesis are discussed in detail and 
placed in a broader perspective. Furthermore, we made suggestions for future research.
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SAMENVATTING
Gedilateerde cardiomyopathie (DCM) is een ziekte van de hartspier die wordt gekenmerkt 
door een verminderde knijpkracht en een opvallende verwijding van het hart. De 
verschijnselen van de ziekte lopen sterk uiteen; sommige kinderen ervaren weinig 
beperkingen in het dagelijks leven, terwijl anderen eindstadium hartfalen ontwikkelen en 
overlijden of als laatste redmiddel een harttransplantatie nodig hebben.
Dit proefschrift gaat over de vraag, welke kinderen de grootste kans hebben op een 
slechte afloop van de ziekte. Met een slechte afloop, of uitkomst, bedoelen we dan 
overlijden of een harttransplantatie. Het is hierbij belangrijk dat we te weten komen wat 
de kenmerken zijn van een verergering van de ziekte. Er zijn veel vragen die nog moeten 
worden beantwoord, bijvoorbeeld:
• Wat is de rol van erfelijkheidsonderzoek in DCM en hoe is een erfelijke oorzaak 
gerelateerd aan een slechte uitkomst?
• Wat zijn de processen waardoor eindstadium hartfalen zich ontwikkelt, en op welke 
manieren verschilt DCM bij kinderen van DCM bij volwassenen?
• Hoe kunnen we tijdig de kinderen herkennen die het grootste risico lopen op een 
slechte uitkomst?
• En hoe kan deze kennis van invloed zijn op de manier waarop kinderen met DCM 
worden behandeld, hetzij door middel van medicijnen, mechanische ondersteuning 
van de bloedsomloop (steunhart) of het tijdig aanbieden van een harttransplantatie? 
In dit hoofdstuk geven we een samenvatting van de 8 studies die in dit proefschrift 
staan. Het proefschrift begint met een algemene inleiding en wordt afgesloten met een 
algemene discussie.
In Hoofdstuk 1 geven we een algemene inleiding op DCM bij kinderen. We schetsen een 
globaal overzicht van de huidige kennis van dit ziektebeeld. Daarnaast beschrijven we 
aanknopingspunten in verschillende onderzoeksgebieden van DCM die tot de studies in 
dit proefschrift hebben geleid.
DCM is eigenlijk een verzamelnaam voor een zieke en verwijde hartspier, maar er zijn 
vele oorzaken die kunnen leiden tot DCM. Je kunt hierbij denken aan virusinfecties 
(myocarditis), hoge doses chemotherapie, spierziektes (bv de ziekte van Duchenne) of 
een erfelijke vorm van DCM. Er is ook een groep kinderen met DCM waar we de oorzaak 
niet van weten (idiopathische DCM). Uit eerder onderzoek blijkt dat de oorzaak van DCM 
bij kinderen sterk samenhangt met de uitkomst van de ziekte. We weten bijvoorbeeld 
dat kinderen met DCM die wordt veroorzaakt door ontsteking van het hart (myocarditis), 
een veel betere uitkomst hebben dan kinderen met idiopathische DCM. Het is dus heel 
belangrijk om de oorzaak te weten, omdat dat iets zegt over het verwachte beloop van de 
ziekte. We weten nog niet zo goed hoe het hebben van een erfelijke/genetische oorzaak 
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van DCM, van invloed is op het beloop van de ziekte bij kinderen. Uit studies bij volwassen 
patiënten met DCM hebben we geleerd dat het hebben van een erfelijke oorzaak van 
DCM leidt tot een ernstiger beloop van de ziekte, en ook dat de ziekte op een jongere 
leeftijd begint. Hoofdstuk 2 beschrijft hoe we in Nederland op dit moment omgaan met 
genetische testen bij kinderen met DCM en wat de resultaten van deze genetische testen 
zijn. We beschrijven de relatie tussen de aanwezigheid van (waarschijnlijke) erfelijke 
ziekte en overlijden of harttransplantatie. We vonden dat 75% van de kinderen met DCM 
genetisch is getest, en dat 36% daarvan een genetische oorzaak van DCM had. We hebben 
ook vastgesteld dat de kinderen met een genetische oorzaak een sterk verhoogd risico 
op overlijden of harttransplantatie hadden, in vergelijking met kinderen zonder erfelijke 
ziekte. Deze bevindingen onderstrepen het belang van vroege erfelijkheidstesten bij alle 
kinderen met DCM. Het vaststellen van een erfelijke oorzaak van DCM kan een waardevolle 
bijdrage leveren om de uitkomst bij kinderen met DCM te voorspellen.
In Hoofdstuk 3 behandelen we de overeenkomsten en verschillen tussen de vorm en 
functie van hartspiercellen bij kinderen en volwassenen met DCM. In deze studie zijn we 
begonnen met hartspierweefsel van 11 harten die we hebben verkregen van kinderen 
met DCM in het eindstadium van de ziekte, op het moment van harttransplantatie. Dit 
weefsel hebben we onder de microscoop onderzocht en ook hebben we gemeten hoe 
goed de spiercellen in staat zijn om samen te trekken. We vergeleken het hartspierweefsel 
van de kinderen met DCM, met hartspierweefsel van gezonde volwassenen. We vonden 
dat in de hartspiercellen er veel minder samentrekkende onderdelen aanwezig waren. 
Ook was het hartspierweefsel van de kinderen veel minder goed in staat om krachtig 
samen te trekken. Bij volwassenen met DCM kunnen de hartspiercellen zich aanpassen 
aan de verwijding en de stress van het zieke hart. Volwassen hartspiercellen kunnen wat 
meer mee rekken wat in het begin een gunstige aanpassing is. Later in het ziekte beloop 
slaat de balans door en leidt deze aanpassing alleen maar tot toename van de verwijding 
en afname van de pompkracht van het hart. Wij vonden dat kinderen veel minder goed 
in staat lijken te zijn om hun hartspiercellen op deze manier aan te passen. Dat zou een 
verklaring kunnen zijn hun snel voortschrijdende ziekte. Ook zou het kunnen verklaren 
waarom de medicijnen die bij volwassen werkzaam zijn niet zo goed lijken te werken bij 
kinderen. In toekomstig onderzoek lijkt het nuttig om ons te richten op behandelingen 
die het hart helpen om nieuwe hartspiercellen aan te maken.
De 6-minuten looptest (6MWT) is een veilig en eenvoudig middel om bij volwassenen 
met hartziekten de uitkomst van ziekte te voorspellen. Ook bij kinderen is de 6MWT goed 
uitvoerbaar. Bij andere ziektes, zoals kinderen met de ziekte van Duchenne, wordt de 
6MWT al gebruikt om het effect van medicatie te meten. De test meet de afstand die 
door het kind in 6 minuten gelopen wordt. Deze afstand wordt dan vergeleken dan met 
de afstand die een gezond kind van dezelfde leeftijd, geslacht en lengte zou lopen. De 
afstand die gelopen is wordt dan uitgedrukt als een percentage van voorspeld (6MWD%), 
en waarbij we dus rekening houden met lengte, geslacht en leeftijd. In eerder onderzoek 
in ons ziekenhuis hadden we al aangetoond, dat 1 enkele 6MWT een goed hulpmiddel 
is om bij kinderen met DCM diegenen op te sporen met een hoog risico op een slechte 
uitkomst. Het zou zo kunnen zijn dat niet alleen de uitslag van 1 test maar juist ook het 
verloop over de tijd van de test extra informatie geeft. Bijvoorbeeld, als er over het verloop 
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van de tijd een afname is van de gelopen afstand zou dat ook informatie kunnen opleveren. 
In Hoofdstuk 4 onderzoeken we of het herhalen van de 6MWT helpt bij het voorspellen 
van de uitkomst bij kinderen met DCM. We vonden dat bij de kinderen die een 6MWT 
kunnen uitvoeren, de 6MWD% constant blijft in het verloop van de tijd. Dat geldt voor de 
periode vroeg na de diagnose DCM, en ook voor de tijd daarna. Bij degenen die overleden 
of getransplanteerd werden was de 6MWD% wel aanzienlijk lager dan bij degenen die 
overleefden, maar veranderde dus niet over de tijd. Op basis van ons onderzoek stellen 
we voor dat er ten minste twee 6MWT worden gedaan om een betrouwbare inschatting 
te maken van de 6MWD%. Daarna heeft het herhalen van de 6MWT weinig toegevoegde 
waarde.
Er zijn bij kinderen met DCM risicofactoren bekend die een hogere kans geven op 
overlijden of transplantatie. Zo weten we bijvoorbeeld dat de grootte van de linkerkamer 
en het NT-proBNP (een stof die je in het bloed kunt meten en iets vertelt over de mate 
van oprekking van het hart) iets zeggen over de kans op een slechte uitkomst. De meeste 
studies die in het verleden zijn gedaan gaan over eenmalige metingen van risicofactoren. 
In Hoofdstuk 5 presenteren we onze studie die gaat over het nut van herhaalde 
metingen van risicofactoren, dus of het beloop over tijd extra informatie geeft. Dit zou 
ons kunnen helpen om de kinderen met de grootste kans op overlijden of transplantatie 
te onderscheiden. We vonden dat het beloop over de tijd van 4 risicofactoren de kinderen 
die stierven of transplantatie ondergingen, onderscheidde van degenen die ziek bleven of 
herstelden. De kinderen die overleden of een harttransplantatie ondergingen lieten geen 
afname van het NT-proBNP en de afmeting van de linker hartkamer zien, wel vertoonden 
ze ernstig achterblijvende lengte groei, en een score die de ernst van de hartspierziekte 
meet, liep op. Wanneer we naar al die risicofactoren tegelijk keken, bleek het NT-proBNP 
de enige risicofactor voor slechte uitkomst. We concluderen dat bij kinderen met DCM 
verandering van bekende risicofactoren voor overlijden of harttransplantatie voorspellend 
is voor de uitkomst. Aanhoudend hoge niveaus van NT-proBNP, geen afname van de linker 
hartkamer grootte, ernstige groeivertraging en een toename van de score voor falen van 
hart, kenmerken de kinderen met het hoogste risico op overlijden of transplantatie.
Hoofdstuk 6 bespreekt de veiligheid van een groep medicijnen, de zo genaamde ACE-
remmers, voor de behandeling van hartfalen bij kinderen. Dit hebben we gedaan op 
basis van alle literatuur die nu beschikbaar is. ACE-remmers worden bij volwassenen veel 
gebruikt bij onder andere DCM. De meest voorkomende bijwerkingen van ACE-remmers 
zijn nierfalen, lage bloeddruk, hoog kalium in het bloed, hoest en vasthouden van vocht. 
Het zou kunnen dat het veiligheidsprofiel van ACE-remmers voor kinderen verschilt van 
dat voor volwassenen. Dat heeft te maken met het feit dat groei en ontwikkeling bijdragen 
aan variatie in effect en bijwerkingen van de meeste geneesmiddelen. Op basis van alle 
beschikbare gegevens in de literatuur concluderen we als eerste dat ACE-remmers als 
relatief veilig kunnen worden beschouwd voor kinderen met hartfalen. Nierfalen, lage 
bloeddruk en een hoog kalium in het bloed zijn vaak voorkomende bijwerkingen. Ten 
tweede zijn een laag gewicht, een jonge leeftijd en kans op uitdroging (bijvoorbeeld bij 
een buikgriep of een hoge dosis plasmedicijnen) factoren die een verhoogd risico op 
bijwerkingen geven wanneer kinderen ACE-remmers gebruiken.
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DCM is een ernstige ziekte die veel lichamelijke klachten kan geven en waarbij kinderen 
ook eerder overlijden. Het is daarom heel goed voor te stellen dat er belangrijke gevolgen 
zijn voor het psychosociaal welzijn bij kinderen met DCM. Je kunt hierbij denken aan 
angstklachten en depressieve verschijnselen. Het was niet goed duidelijk hoe vaak dat 
voorkomt bij kinderen met DCM, en of het hebben van angstklachten en depressieve 
verschijnselen ook voorspelt wat de uitkomst van de ziekte is. Dat is namelijk bij 
volwassenen met DCM wel het geval, waarschijnlijk omdat angstklachten en depressieve 
verschijnselen kunnen leiden tot slechtere zelfzorg en daardoor tot verergering van de 
ziekte. In Hoofdstuk 7 bekeken we of de mate van emotionele en gedragsproblemen en 
of angstklachten en depressieve verschijnselen voorspellend zijn voor de uitkomst van 
de ziekte. We vonden dat, vergeleken met van leeftijdsgenoten, een hoger percentage 
oudere kinderen (6-18 jaar oud) met DCM angstklachten en depressieve verschijnselen 
vertoonden. De resultaten die we vonden komen overeen met grote studies bij 
volwassenen met hartfalen, die een verhoogd risico op angst en depressie aantoonden. 
We vonden dat angst en depressieve problemen bij kinderen met DCM het risico op 
overlijden en harttransplantatie niet voorspelden. Dit wordt mogelijk verklaard door het 
feit dat ouders bij kinderen de slechtere zelf zorg van kinderen kunnen compenseren. 
Onze bevindingen laten echter wel duidelijk zien dat het van belang is om kinderen 
met DCM routinematige te screenen op angstklachten en depressieve verschijnselen. 
Psychosociale ondersteuning afgestemd op de behoeften van deze kinderen is hierbij 
essentieel.
Een steun-hart (ventricular assist device: VAD) is tegenwoordig een algemeen 
geaccepteerde behandeling bij volwassenen met eindstadium hartfalen. Het gebruik 
van een VAD bij kinderen met DCM is ook mogelijk, maar was aanvankelijk lastig, 
vanwege de technische problemen en complicaties die kunnen optreden in een klein 
lichaam. De afgelopen jaren hebben verschillende ziekenhuizen hun ervaringen met 
de Berlin Heart EXCOR VAD gepresenteerd. Er is aangetoond dat de Berlin Heart EXCOR 
VAD een betrouwbaar en een relatief veilig kunsthart is dat het de tijd die kinderen 
moeten wachten op een harttransplantatie, kan helpen overbruggen. In een enkel geval 
overbrugt de VAD zelfs naar herstel. Sinds 2006 is de Berlin Heart EXCOR Pediatric VAD 
beschikbaar in ons ziekenhuis. Hoofdstuk 8 beschrijft hoe het gegaan is met de kinderen 
die een een kunsthart (VAD) kregen. Ook hebben we gekeken naar het effect van de 
introductie van de VAD op de sterfte op de wachtlijst voor harttransplantatie. We vonden 
dat 61% van de kinderen die een VAD moeten krijgen vanwege eindstadium hartfalen, 
overleeft tot harttransplantatie of herstel. Dat betekent dus ook dat bijna 40% van de 
kinderen overlijdt aan een VAD. Over het algemeen lijkt het zo te zijn dat hoe zieker het 
kind is wanneer het aan VAD gaat, des te groter de kans is om te overlijden. Dat in onze 
studie relatief veel kinderen aan een VAD overleden zegt waarschijnlijk dat de kinderen 
die op de wachtlijst stonden ernstig ziek waren. Aan de andere kant is het zo dat sinds de 
introductie van VADs in ons ziekenhuis, het sterftecijfer op de wachtlijst is gehalveerd. Dit 
ondersteunt het groeiende bewijs dat een VAD een acceptabele therapie is om kinderen 
met eindstadium hartfalen te overbruggen naar transplantatie of herstel. 
Wereldwijd is er redelijk veel verschil in het percentage kinderen dat in het eerste jaar 
na diagnose van DCM getransplanteerd word. Eerder rapporteerden we een relatief laag 
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harttransplantatiepercentage (3%) bij kinderen met DCM in het eerste jaar na de diagnose 
in vergelijking met andere grote studies (18%). Belangrijk was, dat we geen toename 
zagen van het aantal kinderen dat overleed. Het feit dat we zo weinig kinderen vroeg 
na diagnose transplanteren, zou kunnen komen doordat we harttransplantatie zo lang 
mogelijk uitstellen en herhaaldelijke pogingen doen om kinderen in een betere conditie 
te krijgen met medicijnen. Echter, het zou zo kunnen zijn dat deze aanpak leidt tot een 
selectie van kinderen die erg ziek zijn, tegen de tijd dat ze op de wachtlijst komen. Dit zou 
weer tot gevolg kunnen hebben dat er meer kinderen op de wachtlijst overlijden, en ook 
dat de uitkomst na harttransplantatie nadelig wordt beïnvloedt. In Hoofdstuk 9 bekijken 
we de uitkomst van 18 jaar harttransplantatie bij kinderen in Nederland. We houden 
er hierbij rekening mee dat we een klein - tot middelgroot transplantatie programma 
hebben, dat voornamelijk bestaat uit kinderen met DCM. In deze studie vonden we 
dat 68% van de kinderen die op de wachtlijst stonden een transplantatie ondergingen. 
Drieëntwintig procent van de kinderen overleed terwijl ze op de wachtlijst stonden. 
Vijf jaar na transplantatie was 95% van de getransplanteerde kinderen in leven, 10 jaar 
na transplantatie was dat nog 88%. Deze percentages zijn gunstig in vergelijking met 
internationale gegevens. De belangrijkste doodsoorzaak na transplantatie was afstoting, 
door het niet innemen van medicatie tegen afstoting. De belangrijkste complicaties na 
transplantatie waren een milde en goed behandelbare vorm van lymfeklier kanker, en ziekte 
aan de bloedvaten van het nieuwe hart. We concludeerden dat onze behandelstrategie 
niet resulteerde in een toegenomen sterfte op de wachtlijst. Harttransplantatie is een 
goed bruikbare behandeling voor een geselecteerde groep kinderen met eindstadium 
hartfalen.
In Hoofdstuk 10 worden de belangrijkste bevindingen van de studies in dit proefschrift 
in detail besproken en in een breder perspectief geplaatst. Verder hebben we suggesties 
gedaan voor toekomstig onderzoek.
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pediatric patients (oral presentation)
International Invitational Workshop on Coagulation and  
Extra corporeal assist devices, Rotterdam
Pediatric heart failure in the Netherlands, COEUR course Congenital Heart 
Disease, (oral presentation), Rotterdam
AEPC, Athene, Griekenland, 2 poster presentations 
AEPC, Sevilla, Spanje, 2 poster presentations
2014
2015
2015
2016
2016
2017
2018
2019
1.2
1.0
0.3 
1.2
0.5
0.5
1.2
1.2 
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International conferences
EACTS Milaan, Italie
ESDPPP Belgrado, Servië 
AEPC Psychosocial meeting, Rotterdam
2014
2015
2016
1.0
1.0 
0.5
Teaching activities 
Supervising Master’s theses
Outcome pediatric HTx, submitted article, Stefan Roest, 
Berlin Heart Excor in EMC, submitted article, Sofie Rohde
Other
Supervising MD students in writing a review on enalapril in heart failure in 
Fontan patients
2017
2018
2014
1.5
1.0
195
About the author
ABOUT THE AUTHOR
Marijke van der Meulen was born on 1st July 1978 
in Rotterdam, the Netherlands. She attended 
pre-university education at the Revius college in 
Rotterdam. Thereafter, Marijke started medical 
training at the Erasmus University of Rotterdam. 
During those 4 year, she worked in a medical students 
team on the ear-nose-throat ward of the Erasmus 
MC. She also participated in research in the liver 
transplantation team of the Erasmus MC, supervised 
by Prof. H.W. Tilanus. After her last senior internship 
in the Morgenster Mission Hospital in Kenya, she 
received her medical degree in 2003. She started 
working as a pediatric resident at the Reinier de 
Graaf Gasthuis in Delft under guidance of Dr. N. van 
der Lely. From 2005 to 2010 she started her formal 
training in pediatrics, supervised by Prof. M. de Hoog 
and Dr. A.A.P.H. Vaessen-Verberne. In her first years as a pediatrician she worked a year in 
general pediatrics and pediatric cardiology, and during 2 years in pediatric intensive care. 
In 2013 she applied for a research grant at the “Nederlandse Hartstichting” and “Stichting 
Hartedroom”, under supervision of dr. M. Dalinghaus, which was fortunately honored. In 
2014 she started the PhD project on dilated cardiomyopathy in children under supervision 
of Prof. Dr. W.A. Helbing, Prof. A.J.J.C. Bogers and Dr. M. Dalinghaus. She currently works 
in general pediatrics in the Beatrix ziekenhuis in Gorinchem. Marijke loves art, horses and 
sports climbing. She lives in Rotterdam with her three children Hannah, Tijn en Abel.

197
Dankwoord
DANKWOORD
Het laatste, misschien het belangrijkste, en in ieder geval het best gelezen … het 
dankwoord. Hoe recht te doen aan een ieders inspanningen, kritische begeleiding, 
steunende woorden, of warme vriendschap? Ik doe een oprechte poging.
Als eerste: heel veel dank aan alle kinderen en hun ouders die meewerkten aan de CARS 
studie. Als onderzoeker heb ik, misschien nog meer als dokter, een inkijkje gekregen in het 
leven met een ernstige ziekte als DCM. Van jullie leerde ik dat het ongelofelijk veel uitmaakt 
als een dagelijks medicijn de vorm heeft van een oplosbare minipil. Wat een opluchting 
wanneer het innemen geen problemen meer oplevert! Jullie bereidheid om vele malen 
voor de studie naar het ziekenhuis te komen was groot. Áls het maar wat opleverde, ook 
voor de kinderen die in de toekomst DCM krijgen. Aan het jeugdjournaal van 3 mei 2018, 
waar 1 van ‘onze’ kinderen hier over vertelt, bewaar ik de warmste herinneringen.
Oprichters van de stichting Hartedroom, beste Arno en Anne.  Hartelijk dank voor jullie 
steun, en wat was het mooi op de berg! Wens jullie nog vele mooie projecten op weg naar 
jullie droom: een wereld zonder DCM.
Mijn promotor, Prof. Dr. W.A. Helbing, beste Wim, dank voor je kritische blik en je vlotte 
commentaar op de manuscripten. Je nuchtere en resultaatgerichte aanpak in het laatste 
jaar hebben geleid tot een voorspoedige afronding van dit proefschrift. Dank je wel.
Mijn promotor, Prof. Dr. A.J.J.C Bogers, beste Ad. Jouw commentaar was altijd snel en ter 
zake. Je warme belangstelling voor de inhoud van het proefschrift, maar ook voor mijn 
persoonlijke reilen en zeilen heb ik heel erg gewaardeerd, dank daarvoor.
Mijn co-promotor, Dr. M. Dalinghaus, lieve Michiel. Als er 1 ding is waar ik je hier voor 
wil bedanken dan is het dat je er altijd voor me was. Op de toppen was het altijd goed 
met jou, geaccepteerde stukken, een mooi congres in Milaan, Mahler 5 als we dan toch 
in Londen moesten zijn voor studie overleg, DE top: op de Mont Ventoux, met ons hele 
team. We hebben het goed gehad, uitgebreid kunnen discussiëren over de inhoud van de 
zaak, en ook ontzettend veel gelachen. Minstens zo dierbaar voor mij is dat je er ook in de 
dalen altijd voor me was. Dank je wel, voor alles. Dat het boekje af is betekent een nieuw 
hoofdstuk, ik verheug me er op.
De leden van de kleine commissie, Prof. Dr. Ir. E. Boersma,  Prof. Dr. J. van de Velde, Prof. Dr. 
J.P. van Tintelen, dank voor het beoordelen van het manuscript. Prof. Dr. M. De Hoog en 
Prof. Dr. A.M.C. van Rossum, hartelijk dank voor het plaatsnemen in de oppositie.
Het uitvoeren van een studie in 8 universitaire centra was een enorme onderneming. Dat 
de studie zoveel waardevolle informatie heeft opgeleverd, en uiteindelijk geresulteerd 
heeft in dit proefschrift, is te danken aan de inspanningen van velen. Ik wil hier graag 
de kindercardiologen bedanken van alle centra: Prof. dr. Nico A. Blom, Drs. Gideon J. du 
Marchie Sarvaas, Dr. Arend D.J. ten Harkel, Dr. Hans M.P.J. Breur, Drs. Lukas A.J. Rammeloo en 
Dr. Ronald Tanke. Hartelijk dank voor jullie betrokkenheid bij het includeren van patiënten, 
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het eindeloos invullen van hartfalen scores en het motiveren van alle betrokkenen. Zonder 
jullie was het niet gelukt. Veel dank ook aan alle echografisten en polimedewerkers, het 
viel niet mee het CARS protocol steeds weer uit te voeren en alles in te plannen. Dank voor 
jullie flexibiliteit, hulp en gezelligheid.
Prof. Dr. Ir. H. Boersma, beste Eric. Je geduldige uitleg over toch behoorlijk onbegrijpelijke 
statische materie en je zorgvuldige analyses hebben zeer bijgedragen aan het tot stand 
komen van dit proefschrift. Daarbij was het overleggen met jou eigenlijk ook gewoon erg 
leuk, dank!
Prof. Dr. S.N. De Wildt, beste Saskia. Wat werk jij hard aan goede en veilige geneesmiddelen 
voor kinderen. Ik ben blij dat ik heb mogen mee werken aan de LENA studie, 
geneesmiddelen onderzoek bij kinderen was voor mij een totaal nieuwe wereld... Ik heb 
ongelofelijk veel geleerd: de regels en adminstratie duizelingwekkend, de protocollen 
talrijk, maar de resultaten die we verkregen staan als een huis. Samen de Mont Ventoux 
op fietsen en de gesprekken in ons huisje de dag erna, het was mooi, dank daarvoor.
Alle co-auteurs: dank voor jullie inbreng, hulp en fijne samenwerking. Ilse, ontzettend leuk 
en inspirerend om mee te mogen doen op jullie lab op de VU, jaloersmakend gewoon ;). 
Stefan, dank je wel voor je hulp bij het uitpluizen van de statussen van al onze HTx 
patienten, een monster klus! Anne, dank voor je kritische blik op de genetica data. Het 
was een heel proces, maar ik ben blij met het stuk dat we hebben geschreven. Malindi, 
dank voor je zorgvuldige analyse van de CBCL-lijsten.
Badies en Annelies, onderzoeksverpleegkundigen eersteklas, wat was ik blij met jullie 
komst en hulp! Badies, wat fijn dat jij een logboek in elkaar draaide dat ook daadwerkelijk 
werkte en overzichtelijk was, dank! Lieve Annelies, zo fijn en gezellig dat jij daarna aan 
boord kwam. Jij regelde de boel fantastisch, maar was er ook altijd voor een koffie en een 
peptalk wanneer nodig, thanks a million.
Lieve collega-kinderartsen Max, Carla, Yvonne, Roel, Marjolein, en Marjan, en lieve 
verpleegkundigen uit het Beatrix ziekenhuis. Tijdens het waarnemen in mijn jaren als 
onderzoeker ben ik gevallen voor jullie kundige en warme team. En nu alweer ruim een 
jaar bij jullie aan het werk als kinderarts. Dank voor jullie morele support, de oprechte 
belangstelling, en de 4 weken schrijfverlof, het heeft me enorm geholpen!
Ganggenoten van de Z-flat en collega-onderzoekers: Sjoerd, Nienke, Maarten, Dwight, 
Ester N en Esther M, Rosalie, Niina, Aniek, Marianne, Noortje, Lennart, Alexandra, Eva C, 
Wouter, Jelle en Linda: mooi om te zien hoe we allemaal onze weg zoeken en vinden. 
Tijdens de koffie of de lunch even volle bak emmeren over al het PhD gedoe en dan 
weer door: DANK! En Linda: ik zal een keer met de kinderen naar de Efteling gaan ;). Lieve 
Gertrude, dank voor je steun, vooral in het laatste jaar. Waar ik all over the place kan zijn, 
ben jij nuchter en praktisch. Dank voor de koppen thee, en je appjes en belletjes het 
afgelopen jaar. Je gaat een super goede huisarts worden! Lieve Eva, roomie van het laatste 
jaar. Nadat we hadden besloten waar de waterkoker moest komen en hoe de theezakjes 
dan weer ten opzichte van de waterkoker moesten staan, ging het heel goed samen ;). Ik 
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heb met bewondering gekeken hoe gedisciplineerd je werkt en hoe je in korte tijd een 
prachtig proefschrift bij elkaar hebt geschreven. We konden, bij de thee, alle ups en downs 
uitgebreid uitwisselen en dat was heel erg fijn. Binnenkort sta jij er ook (in een prachtige 
jurk-wat nou gedempte kleuren) en die opleidingsplek cardiologie komt er!
Rinze Neuteboom, collega van de kinderneurologie. Op de 1 of andere manier kwam ik je 
altijd op de goede momenten tegen in de gangen van het Sophia. Jouw advies: “we must 
try not to kill ourselves” heb ik maar ter harte genomen: een jaar later klaar dan ik had 
bedacht, maar ik ben er nog ;).
Lieve Edward: did it.
Lieve Marlies, voor deze keer ;) ..when you look back, everything is different.. Dank voor je 
deskundige hulp en ondersteuning in de afgelopen jaren.
Lieve buren van de Dopheide, dank voor jullie steun! Willemien en Martin: dank voor het 
bijspringen op momenten dat de ballen niet meer in de lucht waren. John: vanaf nu zal ik 
het gras weer zelf maaien ;).
Lieve Berber, gelukkig stond mijn buro naast het jouwe op de fellow kamer van de kinder-
IC, het begin van een mooie vriendschap.  Dank voor je hulp bij de laatste loodjes.
Lieve vrienden van al heel lang... dit boekje is er, ook dankzij jullie. Dank voor de 
vriendschap, het leven dat we met elkaar delen, en jullie steun in woelige jaren. Marije, 
wat is er veel veranderd en wat is er weinig veranderd sinds we 14 (!) waren. Blij dat we 
elkaar steeds weer vinden. Lieve Hester T, nu wat verder weg, maar dan smaken de kersen 
extra goed! Lieve Marcus, sinds het co-schap in Kenia vrienden voor het leven, jouw 
optimisme (later lachen we erom..) en plezier in het leven zijn aanstekelijk. LL 2019 was 
onvergetelijk, ik hoop op nog meer avonturen! Lieve Enneke, we pikken de draad altijd 
weer op, blij dat we vrienden zijn. Lieve Britt, dat jij je atelier voor me openstelde toen we 
elkaar nog maar nauwelijks kende.. dank je wel. Lieve Ester, wat kunnen we genieten van 
de dansers ;). Lieve Marlies, ik verheug me op het volgende rondje Londen (jij hebt de 
mapjes). Ulrike, liefste dokter die ik ken. Dank voor je hulp bij het schrijven, maar vooral 
voor de fijne avonden met mooie dingen. 
Lieve Hester, tijdens de jaren van het onderzoek, heb ik jou ontmoet en hebben we samen 
de film gemaakt. Dat ik je daar ongelofelijk dankbaar voor ben wil ik hier nog maar een 
keer zeggen, het was een lifesaver. In die zin hoor je ook zeker in dit dankwoord thuis ;). Ik 
ben blij met de vriendschap die is gegroeid en je huis wat voor me open staat (kom maar 
even eten vanavond..). Je hebt me ook aan het klimmen gekregen en dat heeft me veel 
gebracht en geleerd, al was het maar jouw klim-motto: ga nou eens op je poten staan! Het 
klimmen heeft me ook bij jou gebracht lieve Taco. Je bent m’n klimmaatje, altijd in voor 
nieuwe routes of een valoefening, maar je bent ook zoveel meer dan dat. De verhalen over 
je vader en zijn hydraulische systemen aan de TU, maar ook hoe je met je kinderen bent 
en hoe je voor de bewoners van de Hazenberglaan zorgt: jij staat met zoveel liefde en 
warmte in het leven en deelt dat ook met mij, dank je wel. Lieve Tineke, de laatste stelling 
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komt bij jou vandaan en je leeft m ook. Vallen hoort bij klimmen en vallen hoort bij het 
leven; als we dat omarmen is er alle ruimte voor groei. We oefenen en oefenen!
Lieve paranimfen van me, Suzanne en Barbara, wat ben ik blij dat jullie deze dag, 23 
september, naast mij willen staan. Suzanne, van jou mocht ik het CARS stokje overnemen, 
ik pakte de studie op terwijl jij schreef aan jouw proefschrift. En ondertussen maakte je 
me wegwijs in het wilde CARS woud. Zoals jij gebakken bent en in het leven staat, met 
zoveel goede zin en optimisme: ik kijk er met verbazing naar en ben blij dat ik er af en toe 
ook deel van mag uitmaken. Barbara, lieve en wijze oer-vriendin, bij jou is het altijd goed.. 
Lieve Annemiek, we bewandelen onze eigen weg, maar vinden elkaar steeds beter, ik 
ben daar ongelofelijk blij mee. Ik ben trots op wat je voor elkaar krijgt en hoe je je plek 
hebt gevonden als kinder-fysiotherapeut. Er liggen mooie jaren voor ons. Lieve Hans en 
Marian, wat fijn dat jullie altijd konden inspringen en dat de kinderen bij jullie terecht 
konden zodat ik m’n handen even vrij had, dank daarvoor. Lieve Wim en Ank, dank voor 
jullie warme belangstelling en hulp. Martin, dank je wel voor alle goede jaren, en voor 
onze prachtige kinderen. 
Hannah, lieve, slimme, eigenwijze en verstandige dochter van me. Jouw vele vragen: 
’wanneer is je boekje af ‘ hebben zeker geholpen om het tempo er in te houden ;). Tijn, 
lieve voetballer van me, ik ben gek op al je verhalen en vragen, en nog gekker op al je 
kroels en knuffels. Abel, lieve stoere klimmer en muzikant in de dop, met jou erbij is er 
altijd wat te beleven. Lieverds, ik hou van jullie, ben apetrots op jullie en verheug me op 
wat komen gaat. 
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